DDI-DrugBank.d0.s0.p0	The concomitant intake of @DRUG$ and @DRUG$ does not affect the pharmacokinetics of either alcohol or acamprosate.	0
DDI-DrugBank.d0.s0.p1	The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	0
DDI-DrugBank.d0.s0.p2	The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either alcohol or @DRUG$.	0
DDI-DrugBank.d0.s0.p3	The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	0
DDI-DrugBank.d0.s0.p4	The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either alcohol or @DRUG$.	0
DDI-DrugBank.d0.s0.p5	The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or @DRUG$.	0
DDI-DrugBank.d0.s2.p0	Co-administration of @DRUG$ with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.	0
DDI-DrugBank.d0.s2.p1	Co-administration of @DRUG$ with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	0
DDI-DrugBank.d0.s2.p2	Co-administration of naltrexone with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	0
DDI-DrugBank.d0.s4.p0	The pharmacokinetics of @DRUG$ and its major metabolite @DRUG$ were unaffected following co-administration with Acamprosate.	0
DDI-DrugBank.d0.s4.p1	The pharmacokinetics of @DRUG$ and its major metabolite 6-beta-naltrexol were unaffected following co-administration with @DRUG$.	3
DDI-DrugBank.d0.s4.p2	The pharmacokinetics of naltrexone and its major metabolite @DRUG$ were unaffected following co-administration with @DRUG$.	3
DDI-DrugBank.d0.s5.p0	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p1	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p2	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p3	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p4	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p5	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p6	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p7	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p8	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p9	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p10	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p11	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p12	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p13	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s5.p14	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	0
DDI-DrugBank.d0.s6.p0	Patients taking @DRUG$ concomitantly with @DRUG$ more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.	0
DDI-DrugBank.d10.s1.p0	Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.	0
DDI-DrugBank.d10.s1.p1	Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	0
DDI-DrugBank.d10.s1.p2	Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	0
DDI-DrugBank.d10.s2.p0	@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.	0
DDI-DrugBank.d10.s2.p1	@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	0
DDI-DrugBank.d10.s2.p2	Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	0
DDI-DrugBank.d100.s1.p0	Drug/Laboratory Test Interactions @DRUG$, including @DRUG$, are known to occasionally induce a positive direct Coombs test.	4
DDI-DrugBank.d103.s10.p0	It is important that patients understand how to use @DRUG$  (@DRUG$) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.	0
DDI-DrugBank.d103.s15.p0	Acute symptoms should be treated with a short-acting, inhaled  @DRUG$ such as @DRUG$ (the physician should provide the patient with such medication and instruct the patient in how it should be used).	0
DDI-DrugBank.d103.s2.p0	Concomitant administration of other @DRUG$ may potentiate the undesirable effects of @DRUG$.	4
DDI-DrugBank.d103.s20.p0	@DRUG$ should not be used as a substitute for oral or inhaled @DRUG$.	0
DDI-DrugBank.d103.s26.p0	Guardians of children who have been prescribed @DRUG$ should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of @DRUG$.	4
DDI-DrugBank.d103.s3.p0	@DRUG$ and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	3
DDI-DrugBank.d103.s3.p1	@DRUG$ and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	3
DDI-DrugBank.d103.s3.p2	@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	3
DDI-DrugBank.d103.s3.p3	@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	3
DDI-DrugBank.d103.s3.p4	@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	4
DDI-DrugBank.d103.s3.p5	Monoamine Oxidase Inhibitors and @DRUG$: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	4
DDI-DrugBank.d103.s3.p6	Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	3
DDI-DrugBank.d103.s3.p7	Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	4
DDI-DrugBank.d103.s3.p8	Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	4
DDI-DrugBank.d103.s3.p9	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	3
DDI-DrugBank.d103.s3.p10	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	4
DDI-DrugBank.d103.s3.p11	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	4
DDI-DrugBank.d103.s3.p12	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	3
DDI-DrugBank.d103.s3.p13	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	4
DDI-DrugBank.d103.s3.p14	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	4
DDI-DrugBank.d103.s4.p0	@DRUG$, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p1	@DRUG$, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p2	@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p3	@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p4	@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p5	@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	0
DDI-DrugBank.d103.s4.p6	Corticosteroids, @DRUG$ and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p7	Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p8	Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p9	Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p10	Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	0
DDI-DrugBank.d103.s4.p11	Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p12	Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p13	Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p14	Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	0
DDI-DrugBank.d103.s4.p15	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p16	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p17	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	0
DDI-DrugBank.d103.s4.p18	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	0
DDI-DrugBank.d103.s4.p19	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	0
DDI-DrugBank.d103.s4.p20	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  @DRUG$	0
DDI-DrugBank.d103.s8.p0	Other Drugs:Drugs such as @DRUG$, @DRUG$, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	4
DDI-DrugBank.d103.s8.p1	Other Drugs:Drugs such as @DRUG$, disopyramide, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	4
DDI-DrugBank.d103.s8.p2	Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	0
DDI-DrugBank.d103.s8.p3	Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	0
DDI-DrugBank.d103.s8.p4	Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	0
DDI-DrugBank.d103.s8.p5	Other Drugs:Drugs such as quinidine, @DRUG$, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	4
DDI-DrugBank.d103.s8.p6	Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	3
DDI-DrugBank.d103.s8.p7	Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	3
DDI-DrugBank.d103.s8.p8	Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	0
DDI-DrugBank.d103.s8.p9	Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	4
DDI-DrugBank.d103.s8.p10	Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	4
DDI-DrugBank.d103.s8.p11	Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	0
DDI-DrugBank.d103.s8.p12	Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	3
DDI-DrugBank.d103.s8.p13	Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	0
DDI-DrugBank.d103.s8.p14	Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, @DRUG$, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	0
DDI-DrugBank.d104.s0.p0	@DRUG$ may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, reserpine.	0
DDI-DrugBank.d104.s0.p1	@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, reserpine.	0
DDI-DrugBank.d104.s0.p2	@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, reserpine.	0
DDI-DrugBank.d104.s0.p3	@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, @DRUG$.	0
DDI-DrugBank.d104.s0.p4	Fenfluramine may increase slightly the effect of @DRUG$, e.g., @DRUG$, methyldopa, reserpine.	0
DDI-DrugBank.d104.s0.p5	Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, @DRUG$, reserpine.	0
DDI-DrugBank.d104.s0.p6	Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, @DRUG$.	0
DDI-DrugBank.d104.s0.p7	Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, @DRUG$, reserpine.	0
DDI-DrugBank.d104.s0.p8	Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, @DRUG$.	0
DDI-DrugBank.d104.s0.p9	Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, @DRUG$.	0
DDI-DrugBank.d105.s0.p0	@DRUG$ including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p1	@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p2	@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p3	@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p4	@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	0
DDI-DrugBank.d105.s0.p5	Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p6	Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p7	Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p8	Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	0
DDI-DrugBank.d105.s0.p9	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p10	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p11	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	0
DDI-DrugBank.d105.s0.p12	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	0
DDI-DrugBank.d105.s0.p13	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	0
DDI-DrugBank.d105.s0.p14	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with @DRUG$.	0
DDI-DrugBank.d106.s1.p0	@DRUG$ 150 mg twice daily did not interact significantly with @DRUG$ (AUC was decreased by 15-20 %).	0
DDI-DrugBank.d106.s11.p0	No significant interactions were found between @DRUG$ and @DRUG$ or digoxin.	0
DDI-DrugBank.d106.s11.p1	No significant interactions were found between @DRUG$ and warfarin or @DRUG$.	0
DDI-DrugBank.d106.s11.p2	No significant interactions were found between nisoldipine and @DRUG$ or @DRUG$.	0
DDI-DrugBank.d106.s3.p0	Coadministration of @DRUG$ with 40 mg @DRUG$ tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.	0
DDI-DrugBank.d106.s3.p1	Coadministration of @DRUG$ with 40 mg SULAR tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	0
DDI-DrugBank.d106.s3.p2	Coadministration of phenytoin with 40 mg @DRUG$ tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	0
DDI-DrugBank.d106.s7.p0	The blood pressure effect of @DRUG$ tended to be greater in patients on @DRUG$ than in patients on no other antihypertensive therapy.	0
DDI-DrugBank.d106.s7.p1	The blood pressure effect of @DRUG$ tended to be greater in patients on atenolol than in patients on no other @DRUG$ therapy.	0
DDI-DrugBank.d106.s7.p2	The blood pressure effect of SULAR tended to be greater in patients on @DRUG$ than in patients on no other @DRUG$ therapy.	0
DDI-DrugBank.d106.s9.p0	The immediate release, but not the coat-core formulation of @DRUG$ increased plasma @DRUG$ concentrations by about 20%.	0
DDI-DrugBank.d107.s0.p0	Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or enalaprilat.	0
DDI-DrugBank.d107.s0.p1	Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or @DRUG$.	0
DDI-DrugBank.d107.s0.p2	Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or @DRUG$.	0
DDI-DrugBank.d107.s1.p0	The possibility of hypotensive effects with @DRUG$ or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	0
DDI-DrugBank.d107.s1.p1	The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	0
DDI-DrugBank.d107.s1.p2	The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	0
DDI-DrugBank.d107.s1.p3	The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	0
DDI-DrugBank.d107.s1.p4	The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	0
DDI-DrugBank.d107.s1.p5	The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	0
DDI-DrugBank.d107.s1.p6	The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	0
DDI-DrugBank.d107.s1.p7	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	0
DDI-DrugBank.d107.s1.p8	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	0
DDI-DrugBank.d107.s1.p9	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or @DRUG$.	0
DDI-DrugBank.d107.s10.p0	Other Cardiovascular Agents: @DRUG$ and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p1	Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p2	Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p3	Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p4	Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p5	Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p6	Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p7	Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p8	Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p9	Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p10	Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p11	Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p12	Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p13	Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p14	Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p15	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p16	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p17	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p18	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p19	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p20	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p21	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p22	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p23	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p24	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p25	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p26	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p27	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p28	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p29	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p30	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p31	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p32	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p33	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p34	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s10.p35	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d107.s11.p0	@DRUG$ IV has been used concomitantly with @DRUG$ without evidence of clinically significant adverse reactions.	0
DDI-DrugBank.d107.s13.p0	@DRUG$ (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p1	@DRUG$ (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p2	@DRUG$ (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p3	@DRUG$ (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p4	@DRUG$ (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p5	Potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p6	Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p7	Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p8	Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p9	Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p10	Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p11	Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p12	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p13	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s13.p14	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	0
DDI-DrugBank.d107.s16.p0	@DRUG$: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	0
DDI-DrugBank.d107.s16.p1	@DRUG$: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	0
DDI-DrugBank.d107.s16.p2	@DRUG$: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	3
DDI-DrugBank.d107.s16.p3	Lithium: @DRUG$ toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	0
DDI-DrugBank.d107.s16.p4	Lithium: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	3
DDI-DrugBank.d107.s16.p5	Lithium: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including @DRUG$.	3
DDI-DrugBank.d107.s3.p0	Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).	0
DDI-DrugBank.d107.s3.p1	Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	0
DDI-DrugBank.d107.s3.p2	Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	0
DDI-DrugBank.d107.s3.p3	Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	0
DDI-DrugBank.d107.s3.p4	Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	0
DDI-DrugBank.d107.s3.p5	Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., @DRUG$).	0
DDI-DrugBank.d107.s4.p0	@DRUG$: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of enalapril may result in a further deterioration of renal function.	0
DDI-DrugBank.d107.s4.p1	@DRUG$: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of @DRUG$ may result in a further deterioration of renal function.	3
DDI-DrugBank.d107.s4.p2	Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of @DRUG$ may result in a further deterioration of renal function.	3
DDI-DrugBank.d107.s6.p0	In a clinical pharmacology study, @DRUG$ or @DRUG$ was administered to hypertensive patients receiving VASOTEC.	0
DDI-DrugBank.d107.s6.p1	In a clinical pharmacology study, @DRUG$ or sulindac was administered to hypertensive patients receiving @DRUG$.	0
DDI-DrugBank.d107.s6.p2	In a clinical pharmacology study, indomethacin or @DRUG$ was administered to hypertensive patients receiving @DRUG$.	0
DDI-DrugBank.d107.s8.p0	However, reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	0
DDI-DrugBank.d107.s9.p0	This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	4
DDI-DrugBank.d108.s0.p0	@DRUG$ should be administered with caution to patients receiving @DRUG$ (disulfiram, Wyeth-Ayerst Laboratories).	0
DDI-DrugBank.d108.s0.p1	@DRUG$ should be administered with caution to patients receiving Antabuse (@DRUG$, Wyeth-Ayerst Laboratories).	1
DDI-DrugBank.d108.s0.p2	Isocarboxazid should be administered with caution to patients receiving @DRUG$ (@DRUG$, Wyeth-Ayerst Laboratories).	4
DDI-DrugBank.d108.s5.p0	The monoamine oxidase inhibitory effects of @DRUG$ may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following @DRUG$.	4
DDI-DrugBank.d11.s1.p0	CYP2D6 inhibitors - @DRUG$ is primarily metabolized by the CYP2D6 pathway to @DRUG$.	0
DDI-DrugBank.d11.s3.p0	Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and quinidine.	0
DDI-DrugBank.d11.s3.p1	Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and quinidine.	0
DDI-DrugBank.d11.s3.p2	Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and @DRUG$.	0
DDI-DrugBank.d11.s3.p3	Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, @DRUG$, and quinidine.	0
DDI-DrugBank.d11.s3.p4	Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and @DRUG$.	0
DDI-DrugBank.d11.s3.p5	Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d11.s4.p0	In EM individuals treated with @DRUG$ or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	0
DDI-DrugBank.d11.s4.p1	In EM individuals treated with @DRUG$ or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	0
DDI-DrugBank.d11.s4.p2	In EM individuals treated with @DRUG$ or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	0
DDI-DrugBank.d11.s4.p3	In EM individuals treated with paroxetine or @DRUG$, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	0
DDI-DrugBank.d11.s4.p4	In EM individuals treated with paroxetine or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	0
DDI-DrugBank.d11.s4.p5	In EM individuals treated with paroxetine or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	0
DDI-DrugBank.d110.s0.p0	The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p1	The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p2	The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p3	The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p4	The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p5	The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p6	The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p7	The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p8	The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p9	The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p10	The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p11	The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p12	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p13	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s0.p14	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or @DRUG$ may produce severe, prolonged hypotension or hypertension.	4
DDI-DrugBank.d110.s3.p0	Concurrent administration of @DRUG$ (for the treatment of hypotension related to obstetric blocks) and @DRUG$ may cause severe, persistent hypertension or cerebrovascular accidents.	0
DDI-DrugBank.d111.s0.p0	@DRUG$ including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p1	@DRUG$ including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p2	@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p3	@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p4	@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	4
DDI-DrugBank.d111.s0.p5	Non-selective MAO inhibitors including @DRUG$, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p6	Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p7	Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p8	Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	4
DDI-DrugBank.d111.s0.p9	Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p10	Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p11	Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	4
DDI-DrugBank.d111.s0.p12	Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	4
DDI-DrugBank.d111.s0.p13	Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	4
DDI-DrugBank.d111.s0.p14	Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective @DRUG$ may cause hypertension.	4
DDI-DrugBank.d112.s0.p0	Concurrent use with @DRUG$ or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of @DRUG$.	0
DDI-DrugBank.d112.s1.p0	The conversion of @DRUG$ to @DRUG$ is catalyzed by aldehyde oxidase.	4
DDI-DrugBank.d113.s0.p0	@DRUG$: @DRUG$ enhances the effect of warfarin.	0
DDI-DrugBank.d113.s0.p1	@DRUG$: Meclofenamate sodium enhances the effect of @DRUG$.	4
DDI-DrugBank.d113.s0.p2	Warfarin: @DRUG$ enhances the effect of @DRUG$.	0
DDI-DrugBank.d113.s1.p0	Therefore, when @DRUG$ is given to a patient receiving @DRUG$, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.	0
DDI-DrugBank.d113.s1.p1	Therefore, when @DRUG$ is given to a patient receiving warfarin, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	0
DDI-DrugBank.d113.s1.p2	Therefore, when meclofenamate sodium is given to a patient receiving @DRUG$, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	0
DDI-DrugBank.d113.s2.p0	@DRUG$: Concurrent administration of @DRUG$ may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.	0
DDI-DrugBank.d113.s2.p1	@DRUG$: Concurrent administration of aspirin may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	0
DDI-DrugBank.d113.s2.p2	Aspirin: Concurrent administration of @DRUG$ may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	0
DDI-DrugBank.d113.s4.p0	@DRUG$ does not affect serum @DRUG$ levels.	0
DDI-DrugBank.d114.s1.p0	Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., @DRUG$, analgesics, antiemetics, sedatives, tranquilizers).	4
DDI-DrugBank.d114.s1.p1	Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, @DRUG$, antiemetics, sedatives, tranquilizers).	4
DDI-DrugBank.d114.s1.p2	Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, @DRUG$, sedatives, tranquilizers).	4
DDI-DrugBank.d114.s1.p3	Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, @DRUG$, tranquilizers).	4
DDI-DrugBank.d114.s1.p4	Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, sedatives, @DRUG$).	4
DDI-DrugBank.d114.s1.p5	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, @DRUG$, antiemetics, sedatives, tranquilizers).	4
DDI-DrugBank.d114.s1.p6	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, @DRUG$, sedatives, tranquilizers).	4
DDI-DrugBank.d114.s1.p7	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, @DRUG$, tranquilizers).	4
DDI-DrugBank.d114.s1.p8	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, sedatives, @DRUG$).	4
DDI-DrugBank.d114.s1.p9	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, @DRUG$, sedatives, tranquilizers).	4
DDI-DrugBank.d114.s1.p10	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, @DRUG$, tranquilizers).	4
DDI-DrugBank.d114.s1.p11	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, sedatives, @DRUG$).	4
DDI-DrugBank.d114.s1.p12	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, @DRUG$, tranquilizers).	4
DDI-DrugBank.d114.s1.p13	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, sedatives, @DRUG$).	4
DDI-DrugBank.d114.s1.p14	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, @DRUG$, @DRUG$).	4
DDI-DrugBank.d114.s10.p0	Although @DRUG$ have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p1	Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p2	Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p3	Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p4	Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p5	Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	3
DDI-DrugBank.d114.s10.p6	Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p7	Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p8	Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p9	Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p10	Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	3
DDI-DrugBank.d114.s10.p11	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p12	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p13	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p14	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	3
DDI-DrugBank.d114.s10.p15	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p16	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p17	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	3
DDI-DrugBank.d114.s10.p18	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	3
DDI-DrugBank.d114.s10.p19	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with @DRUG$.	3
DDI-DrugBank.d114.s10.p20	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with @DRUG$.	3
DDI-DrugBank.d114.s11.p0	Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.	0
DDI-DrugBank.d114.s11.p1	Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	2
DDI-DrugBank.d114.s11.p2	Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	0
DDI-DrugBank.d114.s2.p0	Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p1	Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p2	Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p3	Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p4	Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p5	Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p6	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p7	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p8	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p9	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p10	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p11	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p12	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p13	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p14	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p15	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p16	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p17	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	0
DDI-DrugBank.d114.s2.p18	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p19	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s2.p20	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with @DRUG$ may increase toxicity in these organ systems.	3
DDI-DrugBank.d114.s3.p0	The safety and efficacy of @DRUG$ in combination with any @DRUG$ have not been established.	4
DDI-DrugBank.d114.s5.p0	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.	0
DDI-DrugBank.d114.s5.p1	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	0
DDI-DrugBank.d114.s5.p2	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	0
DDI-DrugBank.d114.s5.p3	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	0
DDI-DrugBank.d114.s5.p4	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	0
DDI-DrugBank.d114.s5.p5	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	0
DDI-DrugBank.d114.s5.p6	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	0
DDI-DrugBank.d114.s5.p7	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	0
DDI-DrugBank.d114.s5.p8	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	0
DDI-DrugBank.d114.s5.p9	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, @DRUG$, tamoxifen and interferon-alfa.	0
DDI-DrugBank.d114.s5.p10	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, @DRUG$ and interferon-alfa.	0
DDI-DrugBank.d114.s5.p11	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and @DRUG$.	0
DDI-DrugBank.d114.s5.p12	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, @DRUG$ and interferon-alfa.	0
DDI-DrugBank.d114.s5.p13	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and @DRUG$.	0
DDI-DrugBank.d114.s5.p14	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and @DRUG$.	0
DDI-DrugBank.d114.s8.p0	Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving @DRUG$ and @DRUG$ concurrently.	0
DDI-DrugBank.d114.s9.p0	Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of @DRUG$ and @DRUG$, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.	0
DDI-DrugBank.d115.s0.p0	Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p1	Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p2	Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p3	Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p4	Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	0
DDI-DrugBank.d115.s0.p5	Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	0
DDI-DrugBank.d115.s0.p6	Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p7	Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p8	Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p9	Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	0
DDI-DrugBank.d115.s0.p10	Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	0
DDI-DrugBank.d115.s0.p11	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p12	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p13	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	0
DDI-DrugBank.d115.s0.p14	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	0
DDI-DrugBank.d115.s0.p15	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, @DRUG$, erythromycin, clarithromycin).	0
DDI-DrugBank.d115.s0.p16	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, @DRUG$, clarithromycin).	0
DDI-DrugBank.d115.s0.p17	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, @DRUG$).	0
DDI-DrugBank.d115.s0.p18	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, clarithromycin).	0
DDI-DrugBank.d115.s0.p19	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, @DRUG$).	0
DDI-DrugBank.d115.s0.p20	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$).	0
DDI-DrugBank.d115.s10.p0	@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).	0
DDI-DrugBank.d115.s10.p1	@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	0
DDI-DrugBank.d115.s10.p2	@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	0
DDI-DrugBank.d115.s10.p3	Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	0
DDI-DrugBank.d115.s10.p4	Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	0
DDI-DrugBank.d115.s10.p5	Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain @DRUG$, etc.).	0
DDI-DrugBank.d115.s11.p0	Because @DRUG$ is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard @DRUG$.	3
DDI-DrugBank.d115.s2.p0	There is a significant increase in exposure to @DRUG$ when @DRUG$ is coadministered with ketoconazole (CYP3A4 inhibitor).	0
DDI-DrugBank.d115.s2.p1	There is a significant increase in exposure to @DRUG$ when Gleevec is coadministered with @DRUG$ (CYP3A4 inhibitor).	0
DDI-DrugBank.d115.s2.p2	There is a significant increase in exposure to imatinib when @DRUG$ is coadministered with @DRUG$ (CYP3A4 inhibitor).	0
DDI-DrugBank.d115.s4.p0	Co-medications that induce CYP3A4 (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin, phenobarbital or St.	1
DDI-DrugBank.d115.s4.p1	Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, @DRUG$, rifampin, phenobarbital or St.	1
DDI-DrugBank.d115.s4.p2	Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$, phenobarbital or St.	1
DDI-DrugBank.d115.s4.p3	Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, @DRUG$ or St.	1
DDI-DrugBank.d115.s4.p4	Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, @DRUG$, rifampin, phenobarbital or St.	1
DDI-DrugBank.d115.s4.p5	Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, @DRUG$, phenobarbital or St.	1
DDI-DrugBank.d115.s4.p6	Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, @DRUG$ or St.	1
DDI-DrugBank.d115.s4.p7	Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, @DRUG$, phenobarbital or St.	1
DDI-DrugBank.d115.s4.p8	Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, @DRUG$ or St.	1
DDI-DrugBank.d115.s4.p9	Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$ or St.	1
DDI-DrugBank.d115.s6.p0	Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of @DRUG$, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	0
DDI-DrugBank.d115.s6.p1	Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of Gleevec, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	0
DDI-DrugBank.d115.s6.p2	Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of @DRUG$, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	0
DDI-DrugBank.d115.s9.p0	Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or pimozide).	0
DDI-DrugBank.d115.s9.p1	Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or @DRUG$).	0
DDI-DrugBank.d115.s9.p2	Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or @DRUG$).	0
DDI-DrugBank.d116.s0.p0	Careful observation is required when @DRUG$ is administered concurrently with @DRUG$.	4
DDI-DrugBank.d117.s0.p0	Concomitant use with @DRUG$s may result in the reduced absorption of @DRUG$.	4
DDI-DrugBank.d118.s0.p0	In vitro studies have shown that precipitation occurs when eye drops containing @DRUG$ are mixed with @DRUG$.	0
DDI-DrugBank.d119.s4.p0	@DRUG$    @DRUG$ antagonism	0
DDI-DrugBank.d119.s6.p0	@DRUG$     @DRUG$ antagonism	0
DDI-DrugBank.d12.s0.p0	Caution should be exercised when @DRUG$ are given in conjunction with @DRUG$.	0
DDI-DrugBank.d12.s3.p0	@DRUG$ may displace acidic drugs such as @DRUG$ or tolbutamide from their binding sites.	0
DDI-DrugBank.d12.s3.p1	@DRUG$ may displace acidic drugs such as phenytoin or @DRUG$ from their binding sites.	0
DDI-DrugBank.d12.s3.p2	Atromid-S may displace acidic drugs such as @DRUG$ or @DRUG$ from their binding sites.	0
DDI-DrugBank.d12.s5.p0	The hypoglycemic effect of @DRUG$ has been reported to increase when @DRUG$ is given concurrently.	0
DDI-DrugBank.d12.s6.p0	Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another @DRUG$ and @DRUG$ but may be seen after several months.	0
DDI-DrugBank.d12.s7.p0	For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with @DRUG$ and a @DRUG$ do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.	0
DDI-DrugBank.d12.s9.p0	Therefore, the combined use of @DRUG$ with @DRUG$ should generally be avoided.	0
DDI-DrugBank.d120.s1.p0	@DRUG$ or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$;	4
DDI-DrugBank.d120.s2.p0	@DRUG$ - prior ingestion of @DRUG$ may decrease the emetic response to apomorphine in the treatment of poisoning.	0
DDI-DrugBank.d120.s2.p1	@DRUG$ - prior ingestion of diphenidol may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	0
DDI-DrugBank.d120.s2.p2	@DRUG$ - prior ingestion of diphenidol may decrease the emetic response to @DRUG$ in the treatment of poisoning.	0
DDI-DrugBank.d120.s2.p3	apomorphine - prior ingestion of @DRUG$ may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	0
DDI-DrugBank.d120.s2.p4	apomorphine - prior ingestion of @DRUG$ may decrease the emetic response to @DRUG$ in the treatment of poisoning.	0
DDI-DrugBank.d120.s2.p5	apomorphine - prior ingestion of diphenidol may decrease the @DRUG$ response to @DRUG$ in the treatment of poisoning.	0
DDI-DrugBank.d121.s0.p0	Nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.	0
DDI-DrugBank.d121.s1.p0	Concomitant administration of @DRUG$ doubled the AUC for @DRUG$.	0
DDI-DrugBank.d121.s2.p0	The bioavailability of the capsule formulation of @DRUG$ was not affected when administered 5 minutes following an @DRUG$.	1
DDI-DrugBank.d122.s0.p0	Nephrotoxicity has been reported following concomitant administration of @DRUG$ with @DRUG$ or potent diuretics such as furosemide.	0
DDI-DrugBank.d122.s0.p1	Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent @DRUG$ such as furosemide.	0
DDI-DrugBank.d122.s0.p2	Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent diuretics such as @DRUG$.	0
DDI-DrugBank.d122.s0.p3	Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent @DRUG$ such as furosemide.	0
DDI-DrugBank.d122.s0.p4	Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent diuretics such as @DRUG$.	0
DDI-DrugBank.d122.s0.p5	Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent @DRUG$ such as @DRUG$.	0
DDI-DrugBank.d122.s3.p0	@DRUG$ has been shown to be antagonistic to @DRUG$, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	2
DDI-DrugBank.d122.s3.p1	@DRUG$ has been shown to be antagonistic to beta-lactam antibiotics, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	0
DDI-DrugBank.d122.s3.p2	Chloramphenicol has been shown to be antagonistic to @DRUG$, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	2
DDI-DrugBank.d123.s10.p0	This time window is different than for other oral formulations of @DRUG$, which are usually administered 2 hours before or 6 hours after @DRUG$.	0
DDI-DrugBank.d123.s11.p0	@DRUG$ (but not @DRUG$): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.	0
DDI-DrugBank.d123.s11.p1	@DRUG$ (but not aspirin): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	0
DDI-DrugBank.d123.s11.p2	Non-steroidal anti-inflammatory drugs (but not @DRUG$): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	0
DDI-DrugBank.d123.s12.p0	@DRUG$: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s12.p1	@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s12.p2	@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s12.p3	@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s12.p4	Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s12.p5	Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s12.p6	Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s12.p7	Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s12.p8	Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s12.p9	Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	4
DDI-DrugBank.d123.s13.p0	@DRUG$ should be taken as directed and @DRUG$ should be taken with a main meal of the day, preferably the evening meal..	0
DDI-DrugBank.d123.s14.p0	@DRUG$: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.	0
DDI-DrugBank.d123.s14.p1	@DRUG$: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	0
DDI-DrugBank.d123.s14.p2	Phenytoin: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	0
DDI-DrugBank.d123.s15.p0	@DRUG$: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.	0
DDI-DrugBank.d123.s15.p1	@DRUG$: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	0
DDI-DrugBank.d123.s15.p2	@DRUG$: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	0
DDI-DrugBank.d123.s15.p3	Probenecid: @DRUG$ interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	0
DDI-DrugBank.d123.s15.p4	Probenecid: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	0
DDI-DrugBank.d123.s15.p5	Probenecid: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of @DRUG$ in serum.	0
DDI-DrugBank.d123.s16.p0	@DRUG$: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s16.p1	@DRUG$: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s16.p2	@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s16.p3	@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s16.p4	Theophylline: As with some other @DRUG$, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s16.p5	Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s16.p6	Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s16.p7	Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s16.p8	Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s16.p9	Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	0
DDI-DrugBank.d123.s19.p0	@DRUG$: @DRUG$ have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.	4
DDI-DrugBank.d123.s19.p1	@DRUG$: Quinolones have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	4
DDI-DrugBank.d123.s19.p2	@DRUG$: Quinolones have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	4
DDI-DrugBank.d123.s19.p3	Warfarin: @DRUG$ have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	4
DDI-DrugBank.d123.s19.p4	Warfarin: @DRUG$ have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	4
DDI-DrugBank.d123.s19.p5	Warfarin: Quinolones have been reported to enhance the effects of the oral @DRUG$ @DRUG$ or its derivatives.	4
DDI-DrugBank.d123.s3.p0	@DRUG$: The concomitant administration of @DRUG$ with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.	0
DDI-DrugBank.d123.s3.p1	@DRUG$: The concomitant administration of ciprofloxacin with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	0
DDI-DrugBank.d123.s3.p2	@DRUG$: The concomitant administration of ciprofloxacin with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	0
DDI-DrugBank.d123.s3.p3	Glyburide: The concomitant administration of @DRUG$ with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	0
DDI-DrugBank.d123.s3.p4	Glyburide: The concomitant administration of @DRUG$ with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	0
DDI-DrugBank.d123.s3.p5	Glyburide: The concomitant administration of ciprofloxacin with the @DRUG$ @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	0
DDI-DrugBank.d123.s4.p0	@DRUG$: @DRUG$ appear to have no significant effect on the bioavailability of ciprofloxacin.	0
DDI-DrugBank.d123.s4.p1	@DRUG$: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of @DRUG$.	0
DDI-DrugBank.d123.s4.p2	Histamine H2-receptor antagonists: @DRUG$ appear to have no significant effect on the bioavailability of @DRUG$.	0
DDI-DrugBank.d123.s5.p0	@DRUG$ Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.	0
DDI-DrugBank.d123.s5.p1	@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	0
DDI-DrugBank.d123.s5.p2	@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	0
DDI-DrugBank.d123.s5.p3	Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	0
DDI-DrugBank.d123.s5.p4	Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	0
DDI-DrugBank.d123.s5.p5	Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of @DRUG$.	0
DDI-DrugBank.d123.s7.p0	Therefore, patients under @DRUG$ therapy should be carefully monitored when concomitant @DRUG$ therapy is indicated.	0
DDI-DrugBank.d123.s8.p0	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p1	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p2	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p3	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p4	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p5	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p6	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p7	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p8	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p9	Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p10	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p11	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p12	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p13	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p14	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p15	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p16	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p17	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p18	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p19	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p20	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p21	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p22	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p23	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p24	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p25	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p26	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p27	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p28	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p29	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p30	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p31	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p32	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p33	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p34	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p35	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p36	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p37	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p38	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p39	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p40	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p41	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p42	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p43	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p44	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p45	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p46	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p47	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p48	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p49	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p50	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p51	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p52	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p53	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d123.s8.p54	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	4
DDI-DrugBank.d124.s1.p0	Several drug interaction studies have been completed with both @DRUG$ and @DRUG$.	0
DDI-DrugBank.d124.s14.p0	@DRUG$: @DRUG$, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p1	@DRUG$: Amiodarone, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p2	@DRUG$: Amiodarone, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p3	@DRUG$: Amiodarone, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p4	@DRUG$: Amiodarone, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p5	Antiarrhythmics: @DRUG$, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p6	Antiarrhythmics: @DRUG$, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p7	Antiarrhythmics: @DRUG$, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p8	Antiarrhythmics: @DRUG$, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p9	Antiarrhythmics: Amiodarone, @DRUG$, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p10	Antiarrhythmics: Amiodarone, @DRUG$, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p11	Antiarrhythmics: Amiodarone, @DRUG$, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p12	Antiarrhythmics: Amiodarone, bepridil, @DRUG$, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p13	Antiarrhythmics: Amiodarone, bepridil, @DRUG$, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s14.p14	Antiarrhythmics: Amiodarone, bepridil, flecainide, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	0
DDI-DrugBank.d124.s15.p0	@DRUG$: @DRUG$*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	0
DDI-DrugBank.d124.s15.p1	@DRUG$: astemizole*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	0
DDI-DrugBank.d124.s15.p2	Antihistamines: @DRUG$*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	0
DDI-DrugBank.d124.s16.p0	@DRUG$: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p1	@DRUG$: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p2	@DRUG$: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p3	@DRUG$: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p4	@DRUG$: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p5	Ergot Derivatives: @DRUG$, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p6	Ergot Derivatives: @DRUG$, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p7	Ergot Derivatives: @DRUG$, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p8	Ergot Derivatives: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p9	Ergot Derivatives: Dihydroergotamine, @DRUG$, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p10	Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p11	Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p12	Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p13	Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s16.p14	Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	0
DDI-DrugBank.d124.s17.p0	@DRUG$: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	0
DDI-DrugBank.d124.s17.p1	@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	0
DDI-DrugBank.d124.s17.p2	@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	0
DDI-DrugBank.d124.s17.p3	@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	0
DDI-DrugBank.d124.s17.p4	Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	0
DDI-DrugBank.d124.s17.p5	Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	0
DDI-DrugBank.d124.s17.p6	Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	0
DDI-DrugBank.d124.s17.p7	Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	0
DDI-DrugBank.d124.s17.p8	Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	0
DDI-DrugBank.d124.s17.p9	Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of @DRUG$.	0
DDI-DrugBank.d124.s18.p0	Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (@DRUG$) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.	0
DDI-DrugBank.d124.s18.p1	Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	0
DDI-DrugBank.d124.s18.p2	Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	0
DDI-DrugBank.d124.s18.p3	Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	0
DDI-DrugBank.d124.s18.p4	Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	0
DDI-DrugBank.d124.s18.p5	Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole @DRUG$ due to the risk of decreased @DRUG$ plasma concentrations.	0
DDI-DrugBank.d124.s19.p0	No data are available for the coadministration of @DRUG$/@DRUG$ or FORTOVASE/ritonavir and garlic capsules.	0
DDI-DrugBank.d124.s19.p1	No data are available for the coadministration of @DRUG$/ritonavir or @DRUG$/ritonavir and garlic capsules.	0
DDI-DrugBank.d124.s19.p2	No data are available for the coadministration of @DRUG$/ritonavir or FORTOVASE/@DRUG$ and garlic capsules.	0
DDI-DrugBank.d124.s19.p3	No data are available for the coadministration of INVIRASE/@DRUG$ or @DRUG$/ritonavir and garlic capsules.	0
DDI-DrugBank.d124.s19.p4	No data are available for the coadministration of INVIRASE/@DRUG$ or FORTOVASE/@DRUG$ and garlic capsules.	0
DDI-DrugBank.d124.s19.p5	No data are available for the coadministration of INVIRASE/ritonavir or @DRUG$/@DRUG$ and garlic capsules.	0
DDI-DrugBank.d124.s2.p0	Observations from drug interaction studies with @DRUG$ may not be predictive for @DRUG$.	0
DDI-DrugBank.d124.s23.p0	@DRUG$/@DRUG$: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	0
DDI-DrugBank.d124.s23.p1	@DRUG$/Hypnotics: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	0
DDI-DrugBank.d124.s23.p2	@DRUG$/Hypnotics: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	0
DDI-DrugBank.d124.s23.p3	Sedatives/@DRUG$: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	0
DDI-DrugBank.d124.s23.p4	Sedatives/@DRUG$: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	0
DDI-DrugBank.d124.s23.p5	Sedatives/Hypnotics: @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	0
DDI-DrugBank.d124.s26.p0	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p1	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p2	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p3	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p4	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p5	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p6	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p7	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p8	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p9	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p10	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p11	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p12	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p13	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p14	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p15	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p16	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p17	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p18	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p19	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p20	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p21	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p22	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p23	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p24	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p25	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p26	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p27	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p28	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p29	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p30	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p31	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p32	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p33	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p34	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p35	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p36	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p37	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p38	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p39	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p40	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p41	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p42	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p43	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p44	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p45	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p46	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p47	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p48	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p49	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p50	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p51	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p52	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p53	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p54	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p55	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p56	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p57	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p58	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p59	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p60	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p61	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p62	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p63	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p64	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p65	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p66	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p67	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p68	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p69	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p70	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p71	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p72	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p73	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p74	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p75	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p76	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p77	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p78	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p79	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p80	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p81	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p82	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p83	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p84	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p85	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p86	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p87	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p88	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p89	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p90	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p91	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p92	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p93	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p94	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p95	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p96	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p97	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p98	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p99	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p100	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p101	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p102	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p103	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p104	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p105	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p106	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p107	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p108	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p109	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p110	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p111	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p112	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p113	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p114	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p115	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p116	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p117	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p118	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p119	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p120	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p121	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p122	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p123	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p124	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p125	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p126	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p127	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p128	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p129	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p130	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p131	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p132	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p133	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	0
DDI-DrugBank.d124.s26.p134	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s26.p135	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with @DRUG$;	0
DDI-DrugBank.d124.s30.p0	Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.	3
DDI-DrugBank.d124.s30.p1	Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	3
DDI-DrugBank.d124.s30.p2	Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	3
DDI-DrugBank.d124.s30.p3	Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	3
DDI-DrugBank.d124.s30.p4	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	3
DDI-DrugBank.d124.s30.p5	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	3
DDI-DrugBank.d124.s30.p6	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	3
DDI-DrugBank.d124.s30.p7	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, @DRUG$) may result in decreased plasma levels of saquinavir.	3
DDI-DrugBank.d124.s30.p8	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of @DRUG$.	3
DDI-DrugBank.d124.s30.p9	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of @DRUG$.	3
DDI-DrugBank.d124.s9.p0	Additional drugs that are not recommended for coadministration with @DRUG$ and @DRUG$ are included below.	0
DDI-DrugBank.d127.s2.p0	@DRUG$  may interact with drugs known to interact with the conventional formulation of @DRUG$.	0
DDI-DrugBank.d129.s2.p0	Concurrent administration of @DRUG$ and @DRUG$ may result in elevated serum levels of oxyphenbutazone.	0
DDI-DrugBank.d129.s2.p1	Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.	0
DDI-DrugBank.d129.s2.p2	Concurrent administration of oxyphenbutazone and @DRUG$ may result in elevated serum levels of @DRUG$.	0
DDI-DrugBank.d13.s0.p0	Drug Interactions: @DRUG$ may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p1	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p2	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p3	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p4	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p5	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p6	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p7	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p8	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p9	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p10	Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p11	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p12	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p13	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p14	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p15	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p16	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p17	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p18	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p19	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p20	Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p21	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p22	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p23	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p24	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p25	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p26	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p27	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p28	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p29	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p30	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p31	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p32	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p33	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p34	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p35	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p36	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p37	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p38	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p39	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p40	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p41	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p42	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p43	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p44	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p45	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p46	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p47	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p48	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p49	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p50	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p51	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p52	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p53	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p54	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p55	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p56	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p57	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p58	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p59	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p60	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p61	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p62	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p63	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: @DRUG$ increases the effect of Tricyclic antidepressants	4
DDI-DrugBank.d13.s0.p64	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of @DRUG$	4
DDI-DrugBank.d13.s0.p65	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of @DRUG$	4
DDI-DrugBank.d130.s0.p0	@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	3
DDI-DrugBank.d130.s2.p0	Antagonism between @DRUG$ and @DRUG$ in vitro has been demonstrated.	0
DDI-DrugBank.d131.s1.p0	The steady state plasma concentrations of @DRUG$ and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.	0
DDI-DrugBank.d131.s1.p1	The steady state plasma concentrations of @DRUG$ and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	0
DDI-DrugBank.d131.s1.p2	The steady state plasma concentrations of imipramine and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	0
DDI-DrugBank.d131.s10.p0	Data from in vitro studies of @DRUG$ other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p1	Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p2	Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p3	Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p4	Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	0
DDI-DrugBank.d131.s10.p5	Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	0
DDI-DrugBank.d131.s10.p6	Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p7	Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p8	Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p9	Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	0
DDI-DrugBank.d131.s10.p10	Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	0
DDI-DrugBank.d131.s10.p11	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, @DRUG$, amiodarone, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p12	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, @DRUG$, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p13	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, @DRUG$, and nifedipine.	0
DDI-DrugBank.d131.s10.p14	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and @DRUG$.	0
DDI-DrugBank.d131.s10.p15	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, @DRUG$, nicardipine, and nifedipine.	0
DDI-DrugBank.d131.s10.p16	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, @DRUG$, and nifedipine.	0
DDI-DrugBank.d131.s10.p17	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and @DRUG$.	0
DDI-DrugBank.d131.s10.p18	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, @DRUG$, and nifedipine.	0
DDI-DrugBank.d131.s10.p19	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and @DRUG$.	0
DDI-DrugBank.d131.s10.p20	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d131.s3.p0	Drugs That Inhibit @DRUG$ Metabolism Via Cytochrome P450 3A: The initial step in @DRUG$ metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).	3
DDI-DrugBank.d131.s5.p0	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s5.p1	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s5.p2	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s5.p3	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s5.p4	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s5.p5	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s5.p6	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s5.p7	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s5.p8	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s5.p9	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	0
DDI-DrugBank.d131.s6.p0	Coadministration of @DRUG$ decreased the maximum plasma concentration of @DRUG$ by 6%, decreased clearance by 38%, and increased half-life by 58%.	0
DDI-DrugBank.d131.s9.p0	Data from in vitro studies of @DRUG$ suggest a possible drug interaction with @DRUG$ for the following: sertraline and paroxetine.	0
DDI-DrugBank.d131.s9.p1	Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: @DRUG$ and paroxetine.	0
DDI-DrugBank.d131.s9.p2	Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: sertraline and @DRUG$.	0
DDI-DrugBank.d131.s9.p3	Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: @DRUG$ and paroxetine.	0
DDI-DrugBank.d131.s9.p4	Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: sertraline and @DRUG$.	0
DDI-DrugBank.d131.s9.p5	Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$ and @DRUG$.	0
DDI-DrugBank.d132.s1.p0	This may occur because @DRUG$ competitively displaces @DRUG$ from protein binding sites.	0
DDI-DrugBank.d132.s10.p0	This effect is small with occasional doses of @DRUG$, but may be clinically significant when @DRUG$ are used on a continuous schedule.	0
DDI-DrugBank.d132.s11.p0	@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.	0
DDI-DrugBank.d132.s11.p1	@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	0
DDI-DrugBank.d132.s11.p2	@DRUG$: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s11.p3	Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	0
DDI-DrugBank.d132.s11.p4	Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s11.p5	Acetaminophen: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s16.p0	@DRUG$: Caution should be used if @DRUG$ is administered concomitantly with methotrexate.	0
DDI-DrugBank.d132.s16.p1	@DRUG$: Caution should be used if diflunisal is administered concomitantly with @DRUG$.	0
DDI-DrugBank.d132.s16.p2	Methotrexate: Caution should be used if @DRUG$ is administered concomitantly with @DRUG$.	0
DDI-DrugBank.d132.s17.p0	@DRUG$ have been reported to decrease the tubular secretion of @DRUG$ and to potentiate its toxicity.	0
DDI-DrugBank.d132.s18.p0	@DRUG$: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	0
DDI-DrugBank.d132.s18.p1	@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	0
DDI-DrugBank.d132.s18.p2	@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	0
DDI-DrugBank.d132.s18.p3	Cyclosporine: Administration of @DRUG$ concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	0
DDI-DrugBank.d132.s18.p4	Cyclosporine: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	0
DDI-DrugBank.d132.s18.p5	Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	0
DDI-DrugBank.d132.s19.p0	@DRUG$ should be used with caution in patients taking @DRUG$, and renal function should be carefully monitored.	0
DDI-DrugBank.d132.s2.p0	Accordingly, when @DRUG$ is administered with oral @DRUG$, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.	0
DDI-DrugBank.d132.s20.p0	@DRUG$: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.	0
DDI-DrugBank.d132.s20.p1	@DRUG$: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	0
DDI-DrugBank.d132.s20.p2	@DRUG$: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s20.p3	Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	0
DDI-DrugBank.d132.s20.p4	Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s20.p5	Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s21.p0	In some patients the combined use of @DRUG$ and @DRUG$ has been associated with fatal gastrointestinal hemorrhage.	0
DDI-DrugBank.d132.s22.p0	Therefore, @DRUG$ and @DRUG$ should not be used concomitantly.	4
DDI-DrugBank.d132.s23.p0	The concomitant use of @DRUG$ tablets and other @DRUG$ is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.	0
DDI-DrugBank.d132.s25.p0	@DRUG$: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.	0
DDI-DrugBank.d132.s25.p1	@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	0
DDI-DrugBank.d132.s25.p2	@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	0
DDI-DrugBank.d132.s25.p3	Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	0
DDI-DrugBank.d132.s25.p4	Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	0
DDI-DrugBank.d132.s25.p5	Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and @DRUG$ were administered concomitantly.	0
DDI-DrugBank.d132.s26.p0	@DRUG$: The concomitant administration of @DRUG$ and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	0
DDI-DrugBank.d132.s26.p1	@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	0
DDI-DrugBank.d132.s26.p2	Sulindac: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	0
DDI-DrugBank.d132.s27.p0	@DRUG$: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	0
DDI-DrugBank.d132.s27.p1	@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	0
DDI-DrugBank.d132.s27.p2	@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	0
DDI-DrugBank.d132.s27.p3	@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	0
DDI-DrugBank.d132.s27.p4	Naproxen: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	0
DDI-DrugBank.d132.s27.p5	Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	0
DDI-DrugBank.d132.s27.p6	Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	0
DDI-DrugBank.d132.s27.p7	Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	0
DDI-DrugBank.d132.s27.p8	Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	0
DDI-DrugBank.d132.s27.p9	Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	0
DDI-DrugBank.d132.s28.p0	@DRUG$ had no effect on plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s4.p0	@DRUG$: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	0
DDI-DrugBank.d132.s4.p1	@DRUG$: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	0
DDI-DrugBank.d132.s4.p2	@DRUG$: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	0
DDI-DrugBank.d132.s4.p3	Tolbutamide: In diabetic patients receiving @DRUG$ and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	0
DDI-DrugBank.d132.s4.p4	Tolbutamide: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	0
DDI-DrugBank.d132.s4.p5	Tolbutamide: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	0
DDI-DrugBank.d132.s5.p0	@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.	0
DDI-DrugBank.d132.s5.p1	@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	0
DDI-DrugBank.d132.s5.p2	@DRUG$: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s5.p3	Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	0
DDI-DrugBank.d132.s5.p4	Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s5.p5	Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s6.p0	@DRUG$ decreased the hyperuricemic effect of @DRUG$.	0
DDI-DrugBank.d132.s8.p0	@DRUG$ decreased the hyperuricemic effect of @DRUG$.	0
DDI-DrugBank.d132.s9.p0	@DRUG$: Concomitant administration of @DRUG$ may reduce plasma levels of diflunisal.	0
DDI-DrugBank.d132.s9.p1	@DRUG$: Concomitant administration of antacids may reduce plasma levels of @DRUG$.	0
DDI-DrugBank.d132.s9.p2	Antacids: Concomitant administration of @DRUG$ may reduce plasma levels of @DRUG$.	0
DDI-DrugBank.d133.s0.p0	Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.	3
DDI-DrugBank.d133.s0.p1	Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	3
DDI-DrugBank.d133.s0.p2	Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	3
DDI-DrugBank.d133.s0.p3	Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	3
DDI-DrugBank.d133.s0.p4	Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	3
DDI-DrugBank.d133.s0.p5	Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	3
DDI-DrugBank.d135.s0.p0	Effects of @DRUG$ on Drug Metabolizing Enzymes and Drug Transport Systems @DRUG$ inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.	0
DDI-DrugBank.d135.s10.p0	If @DRUG$ is administered with drugs that inhibit Pgp, increased concentrations of @DRUG$ are likely, and caution should be exercised.	0
DDI-DrugBank.d135.s11.p0	Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).	0
DDI-DrugBank.d135.s11.p1	Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	0
DDI-DrugBank.d135.s11.p2	Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	0
DDI-DrugBank.d135.s5.p0	Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes @DRUG$ undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter @DRUG$ concentrations significantly.	0
DDI-DrugBank.d135.s7.p0	@DRUG$: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	0
DDI-DrugBank.d135.s7.p1	@DRUG$: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	0
DDI-DrugBank.d135.s7.p2	Ketoconazole: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	0
DDI-DrugBank.d135.s8.p0	@DRUG$: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.	0
DDI-DrugBank.d135.s8.p1	@DRUG$: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	0
DDI-DrugBank.d135.s8.p2	Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	0
DDI-DrugBank.d136.s0.p0	@DRUG$ (increases bioavailability by 50%), @DRUG$, and valproates.	0
DDI-DrugBank.d137.s0.p0	@DRUG$: The concomitant use of @DRUG$ with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.	0
DDI-DrugBank.d137.s0.p1	@DRUG$: The concomitant use of Bepridil with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	0
DDI-DrugBank.d137.s0.p2	Nitrates: The concomitant use of @DRUG$ with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	0
DDI-DrugBank.d137.s10.p0	@DRUG$ and @DRUG$ could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.	0
DDI-DrugBank.d137.s10.p1	@DRUG$ and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with @DRUG$.	4
DDI-DrugBank.d137.s10.p2	Anti-arrhythmics and @DRUG$ could exaggerate the prolongation of the QT interval observed with @DRUG$.	0
DDI-DrugBank.d137.s11.p0	@DRUG$ could exaggerate the depression of AV nodal conduction observed with @DRUG$.	0
DDI-DrugBank.d137.s2.p0	@DRUG$: The concomitant use of @DRUG$ and beta-blocking agents has been well tolerated in patients with stable angina.	0
DDI-DrugBank.d137.s2.p1	@DRUG$: The concomitant use of Bepridil and @DRUG$ has been well tolerated in patients with stable angina.	0
DDI-DrugBank.d137.s2.p2	Beta-blocking Agents: The concomitant use of @DRUG$ and @DRUG$ has been well tolerated in patients with stable angina.	0
DDI-DrugBank.d137.s4.p0	@DRUG$: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.	0
DDI-DrugBank.d137.s4.p1	@DRUG$: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	0
DDI-DrugBank.d137.s4.p2	Digoxin: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	0
DDI-DrugBank.d137.s5.p0	Limited clinical data in angina patients receiving concomitant @DRUG$ and @DRUG$ therapy indicate no discernible changes in serum digoxin levels.	0
DDI-DrugBank.d137.s9.p0	In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p1	In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p2	In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p3	In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p4	In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and @DRUG$.	3
DDI-DrugBank.d137.s9.p5	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p6	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p7	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p8	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and @DRUG$.	3
DDI-DrugBank.d137.s9.p9	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p10	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, @DRUG$ and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p11	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and @DRUG$.	3
DDI-DrugBank.d137.s9.p12	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, @DRUG$ and tricyclic anti-depressants.	3
DDI-DrugBank.d137.s9.p13	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and @DRUG$.	3
DDI-DrugBank.d137.s9.p14	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and @DRUG$.	3
DDI-DrugBank.d138.s3.p0	@DRUG$ have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.	0
DDI-DrugBank.d138.s3.p1	@DRUG$ have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	0
DDI-DrugBank.d138.s3.p2	Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	0
DDI-DrugBank.d139.s0.p0	@DRUG$-@DRUG$ may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.	0
DDI-DrugBank.d139.s0.p1	@DRUG$-Broad-spectrum antibiotics may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	0
DDI-DrugBank.d139.s0.p2	Broad-Spectrum Antibiotics-@DRUG$ may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	0
DDI-DrugBank.d139.s1.p0	@DRUG$-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p1	@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p2	@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p3	@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p4	@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p5	@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p6	@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p7	Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p8	Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p9	Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p10	Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p11	Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p12	Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p13	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p14	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p15	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p16	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p17	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p18	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p19	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p20	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p21	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p22	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p23	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p24	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p25	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p26	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s1.p27	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	4
DDI-DrugBank.d139.s3.p0	@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	4
DDI-DrugBank.d139.s3.p1	@DRUG$-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of vitamin K.	4
DDI-DrugBank.d139.s3.p2	@DRUG$-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of @DRUG$.	4
DDI-DrugBank.d139.s3.p3	Cholestyramine-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	4
DDI-DrugBank.d139.s3.p4	Cholestyramine-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	4
DDI-DrugBank.d139.s3.p5	Cholestyramine-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of @DRUG$.	4
DDI-DrugBank.d139.s4.p0	@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	4
DDI-DrugBank.d139.s4.p1	@DRUG$-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of vitamin K.	0
DDI-DrugBank.d139.s4.p2	@DRUG$-Concomitant intake of colestipol and vitamin K may reduce the absorption of @DRUG$.	0
DDI-DrugBank.d139.s4.p3	Colestipol-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	0
DDI-DrugBank.d139.s4.p4	Colestipol-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	0
DDI-DrugBank.d139.s4.p5	Colestipol-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of @DRUG$.	0
DDI-DrugBank.d139.s5.p0	@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	4
DDI-DrugBank.d139.s5.p1	@DRUG$-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of vitamin K.	4
DDI-DrugBank.d139.s5.p2	@DRUG$-Concomitant intake of mineral oil and vitamin K may reduce the absorption of @DRUG$.	4
DDI-DrugBank.d139.s5.p3	Mineral Oil-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	4
DDI-DrugBank.d139.s5.p4	Mineral Oil-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	4
DDI-DrugBank.d139.s5.p5	Mineral Oil-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of @DRUG$.	0
DDI-DrugBank.d139.s6.p0	@DRUG$-@DRUG$ may decrease the absorption of vitamin K.	4
DDI-DrugBank.d139.s6.p1	@DRUG$-Orlistat may decrease the absorption of @DRUG$.	4
DDI-DrugBank.d139.s6.p2	Orlistat-@DRUG$ may decrease the absorption of @DRUG$.	4
DDI-DrugBank.d139.s7.p0	@DRUG$-@DRUG$ in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.	0
DDI-DrugBank.d139.s8.p0	@DRUG$-@DRUG$ can antagonize the effect of warfarin	0
DDI-DrugBank.d139.s8.p1	@DRUG$-Vitamin K can antagonize the effect of @DRUG$	0
DDI-DrugBank.d139.s8.p2	Warfarin-@DRUG$ can antagonize the effect of @DRUG$	0
DDI-DrugBank.d140.s0.p0	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, @DRUG$, niacin (nicotinic acid), erythromycin, azole antifungals.	0
DDI-DrugBank.d140.s0.p1	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	0
DDI-DrugBank.d140.s0.p2	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (@DRUG$), erythromycin, azole antifungals.	0
DDI-DrugBank.d140.s0.p3	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, azole antifungals.	0
DDI-DrugBank.d140.s0.p4	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), erythromycin, @DRUG$.	0
DDI-DrugBank.d140.s0.p5	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	0
DDI-DrugBank.d140.s0.p6	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (@DRUG$), erythromycin, azole antifungals.	0
DDI-DrugBank.d140.s0.p7	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), @DRUG$, azole antifungals.	0
DDI-DrugBank.d140.s0.p8	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), erythromycin, @DRUG$.	0
DDI-DrugBank.d140.s0.p9	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (@DRUG$), erythromycin, azole antifungals.	0
DDI-DrugBank.d140.s0.p10	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), @DRUG$, azole antifungals.	0
DDI-DrugBank.d140.s0.p11	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, @DRUG$.	0
DDI-DrugBank.d140.s0.p12	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), @DRUG$, azole antifungals.	0
DDI-DrugBank.d140.s0.p13	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), erythromycin, @DRUG$.	0
DDI-DrugBank.d140.s0.p14	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, @DRUG$.	0
DDI-DrugBank.d140.s10.p0	Oral @DRUG$: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	0
DDI-DrugBank.d140.s10.p1	Oral @DRUG$: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	0
DDI-DrugBank.d140.s10.p2	Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	0
DDI-DrugBank.d140.s10.p3	Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	0
DDI-DrugBank.d140.s10.p4	Oral Contraceptives: Coadministration of @DRUG$ and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	0
DDI-DrugBank.d140.s10.p5	Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	0
DDI-DrugBank.d140.s10.p6	Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	0
DDI-DrugBank.d140.s10.p7	Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	0
DDI-DrugBank.d140.s10.p8	Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	0
DDI-DrugBank.d140.s10.p9	Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and @DRUG$ by approximately 30% and 20%.	0
DDI-DrugBank.d140.s11.p0	These increases should be considered when selecting an oral @DRUG$ for a woman taking @DRUG$.	0
DDI-DrugBank.d140.s12.p0	@DRUG$: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.	0
DDI-DrugBank.d140.s12.p1	@DRUG$: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	0
DDI-DrugBank.d140.s12.p2	Warfarin: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	0
DDI-DrugBank.d140.s17.p0	Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and cimetidine.	0
DDI-DrugBank.d140.s17.p1	Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and cimetidine.	0
DDI-DrugBank.d140.s17.p2	Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and @DRUG$.	0
DDI-DrugBank.d140.s17.p3	Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, @DRUG$, and cimetidine.	0
DDI-DrugBank.d140.s17.p4	Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and @DRUG$.	0
DDI-DrugBank.d140.s17.p5	Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d140.s3.p0	@DRUG$: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	0
DDI-DrugBank.d140.s3.p1	@DRUG$: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	0
DDI-DrugBank.d140.s3.p2	@DRUG$: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	0
DDI-DrugBank.d140.s3.p3	Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	0
DDI-DrugBank.d140.s3.p4	Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	0
DDI-DrugBank.d140.s3.p5	Antipyrine: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	0
DDI-DrugBank.d140.s4.p0	@DRUG$: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and atorvastatin were coadministered.	0
DDI-DrugBank.d140.s4.p1	@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	0
DDI-DrugBank.d140.s4.p2	@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and @DRUG$ were coadministered.	0
DDI-DrugBank.d140.s4.p3	Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	0
DDI-DrugBank.d140.s4.p4	Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and @DRUG$ were coadministered.	0
DDI-DrugBank.d140.s4.p5	Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and @DRUG$ were coadministered.	0
DDI-DrugBank.d140.s5.p0	However, LDL-C reduction was greater when @DRUG$ and @DRUG$ were coadministered than when either drug was given alone.	0
DDI-DrugBank.d140.s6.p0	@DRUG$: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.	0
DDI-DrugBank.d140.s6.p1	@DRUG$: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	0
DDI-DrugBank.d140.s6.p2	Cimetidine: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	0
DDI-DrugBank.d140.s7.p0	@DRUG$: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	0
DDI-DrugBank.d140.s7.p1	@DRUG$: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	0
DDI-DrugBank.d140.s7.p2	@DRUG$: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	0
DDI-DrugBank.d140.s7.p3	Digoxin: When multiple doses of @DRUG$ and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	0
DDI-DrugBank.d140.s7.p4	Digoxin: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	0
DDI-DrugBank.d140.s7.p5	Digoxin: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	0
DDI-DrugBank.d140.s9.p0	@DRUG$: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.	0
DDI-DrugBank.d140.s9.p1	@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	0
DDI-DrugBank.d140.s9.p2	@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	0
DDI-DrugBank.d140.s9.p3	Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	0
DDI-DrugBank.d140.s9.p4	Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	0
DDI-DrugBank.d140.s9.p5	Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and @DRUG$, a known inhibitor of cytochrome P450 3A4.	0
DDI-DrugBank.d141.s1.p0	@DRUG$ (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of antacid.	0
DDI-DrugBank.d141.s1.p1	@DRUG$ (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	0
DDI-DrugBank.d141.s1.p2	@DRUG$ (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	0
DDI-DrugBank.d141.s1.p3	ANTACID (@DRUG$): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	0
DDI-DrugBank.d141.s1.p4	ANTACID (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	0
DDI-DrugBank.d141.s1.p5	ANTACID (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of @DRUG$.	0
DDI-DrugBank.d141.s10.p0	The AUC and Cmax of both the (R) and (S) isomers of @DRUG$ were unaffected by concurrent dosing of 0.3 mg @DRUG$.	0
DDI-DrugBank.d141.s11.p0	Co-administration of @DRUG$ and @DRUG$ did not alter the pharmacokinetics of cerivastatin sodium.	0
DDI-DrugBank.d141.s11.p1	Co-administration of @DRUG$ and cerivastatin did not alter the pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d141.s11.p2	Co-administration of warfarin and @DRUG$ did not alter the pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d141.s12.p0	@DRUG$: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.	0
DDI-DrugBank.d141.s12.p1	@DRUG$: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	0
DDI-DrugBank.d141.s12.p2	ERYTHROMYCIN: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	0
DDI-DrugBank.d141.s13.p0	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p1	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p2	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p3	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p4	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p5	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p6	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p7	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p8	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p9	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p10	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p11	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p12	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p13	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p14	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p15	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p16	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p17	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p18	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p19	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s13.p20	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (@DRUG$) without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d141.s4.p0	In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.	0
DDI-DrugBank.d141.s4.p1	In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	0
DDI-DrugBank.d141.s4.p2	In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	0
DDI-DrugBank.d141.s5.p0	However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	0
DDI-DrugBank.d141.s5.p1	However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	0
DDI-DrugBank.d141.s5.p2	However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	0
DDI-DrugBank.d141.s5.p3	However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	0
DDI-DrugBank.d141.s5.p4	However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	0
DDI-DrugBank.d141.s5.p5	However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	0
DDI-DrugBank.d141.s6.p0	Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.	0
DDI-DrugBank.d141.s6.p1	Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	0
DDI-DrugBank.d141.s6.p2	Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	0
DDI-DrugBank.d141.s7.p0	@DRUG$: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	0
DDI-DrugBank.d141.s7.p1	@DRUG$: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	0
DDI-DrugBank.d141.s7.p2	@DRUG$: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	0
DDI-DrugBank.d141.s7.p3	DIGOXIN: Plasma @DRUG$ levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	0
DDI-DrugBank.d141.s7.p4	DIGOXIN: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	0
DDI-DrugBank.d141.s7.p5	DIGOXIN: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	0
DDI-DrugBank.d141.s9.p0	@DRUG$: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	0
DDI-DrugBank.d141.s9.p1	@DRUG$: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	0
DDI-DrugBank.d141.s9.p2	@DRUG$: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	0
DDI-DrugBank.d141.s9.p3	WARFARIN: Co- administration of @DRUG$ and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	0
DDI-DrugBank.d141.s9.p4	WARFARIN: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	0
DDI-DrugBank.d141.s9.p5	WARFARIN: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	0
DDI-DrugBank.d142.s0.p0	Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p1	Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p2	Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p3	Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p4	Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p5	Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	4
DDI-DrugBank.d142.s0.p6	Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	4
DDI-DrugBank.d142.s0.p7	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p8	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p9	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p10	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p11	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	4
DDI-DrugBank.d142.s0.p12	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	4
DDI-DrugBank.d142.s0.p13	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p14	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p15	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p16	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	4
DDI-DrugBank.d142.s0.p17	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	4
DDI-DrugBank.d142.s0.p18	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p19	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p20	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	4
DDI-DrugBank.d142.s0.p21	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	4
DDI-DrugBank.d142.s0.p22	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, @DRUG$, tricyclic antidepressants or some antihistamines.	4
DDI-DrugBank.d142.s0.p23	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	4
DDI-DrugBank.d142.s0.p24	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	4
DDI-DrugBank.d142.s0.p25	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, @DRUG$ or some antihistamines.	4
DDI-DrugBank.d142.s0.p26	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some @DRUG$.	4
DDI-DrugBank.d142.s0.p27	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some @DRUG$.	4
DDI-DrugBank.d142.s1.p0	@DRUG$ may interfere with the absorption of @DRUG$.	4
DDI-DrugBank.d143.s0.p0	@DRUG$ is metabolized to @DRUG$ by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.	3
DDI-DrugBank.d143.s13.p0	Monitoring for @DRUG$ toxicity and serial measurement of @DRUG$ serum concentration during concomitant protease inhibitor therapy should be considered.	0
DDI-DrugBank.d143.s13.p1	Monitoring for @DRUG$ toxicity and serial measurement of amiodarone serum concentration during concomitant @DRUG$ therapy should be considered.	0
DDI-DrugBank.d143.s13.p2	Monitoring for amiodarone toxicity and serial measurement of @DRUG$ serum concentration during concomitant @DRUG$ therapy should be considered.	0
DDI-DrugBank.d143.s15.p0	Other substances: Grapefruit juice given to healthy volunteers increased @DRUG$ AUC by 50% and Cmax by 84%, resulting in increased plasma levels of @DRUG$.	0
DDI-DrugBank.d143.s18.p0	@DRUG$ may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and CYP3A4.	1
DDI-DrugBank.d143.s18.p1	@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and CYP3A4.	1
DDI-DrugBank.d143.s18.p2	@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and CYP3A4.	1
DDI-DrugBank.d143.s18.p3	@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and @DRUG$.	1
DDI-DrugBank.d143.s18.p4	Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, @DRUG$, CYP2D6, and CYP3A4.	1
DDI-DrugBank.d143.s18.p5	Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, @DRUG$, and CYP3A4.	1
DDI-DrugBank.d143.s18.p6	Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and @DRUG$.	1
DDI-DrugBank.d143.s18.p7	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, @DRUG$, and CYP3A4.	1
DDI-DrugBank.d143.s18.p8	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and @DRUG$.	1
DDI-DrugBank.d143.s18.p9	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and @DRUG$.	1
DDI-DrugBank.d143.s21.p0	@DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	0
DDI-DrugBank.d143.s21.p1	@DRUG$: Simvastatin (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	0
DDI-DrugBank.d143.s21.p2	@DRUG$: Simvastatin (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	0
DDI-DrugBank.d143.s21.p3	HMG-CoA Reductase Inhibitors: @DRUG$ (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	0
DDI-DrugBank.d143.s21.p4	HMG-CoA Reductase Inhibitors: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	0
DDI-DrugBank.d143.s21.p5	HMG-CoA Reductase Inhibitors: Simvastatin (@DRUG$ substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	0
DDI-DrugBank.d143.s22.p0	Cardiovasculars: @DRUG$: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	0
DDI-DrugBank.d143.s22.p1	Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	0
DDI-DrugBank.d143.s22.p2	Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	0
DDI-DrugBank.d143.s22.p3	Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	0
DDI-DrugBank.d143.s22.p4	Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	0
DDI-DrugBank.d143.s22.p5	Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	0
DDI-DrugBank.d143.s24.p0	On administration of oral @DRUG$, the need for @DRUG$ therapy should be reviewed and the dose reduced by approximately 50% or discontinued.	0
DDI-DrugBank.d143.s27.p0	@DRUG$: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p1	@DRUG$: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p2	@DRUG$: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p3	@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p4	@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p5	@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	1
DDI-DrugBank.d143.s27.p6	Antiarrhythmics: Other @DRUG$ drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p7	Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p8	Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p9	Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p10	Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	1
DDI-DrugBank.d143.s27.p11	Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p12	Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p13	Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p14	Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	0
DDI-DrugBank.d143.s27.p15	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p16	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p17	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	1
DDI-DrugBank.d143.s27.p18	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and @DRUG$, have been used concurrently with amiodarone.	1
DDI-DrugBank.d143.s27.p19	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with @DRUG$.	0
DDI-DrugBank.d143.s27.p20	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with @DRUG$.	0
DDI-DrugBank.d143.s28.p0	There have been case reports of increased steady-state levels of @DRUG$, @DRUG$, and phenytoin during concomitant therapy with amiodarone.	0
DDI-DrugBank.d143.s28.p1	There have been case reports of increased steady-state levels of @DRUG$, procainamide, and @DRUG$ during concomitant therapy with amiodarone.	0
DDI-DrugBank.d143.s28.p2	There have been case reports of increased steady-state levels of @DRUG$, procainamide, and phenytoin during concomitant therapy with @DRUG$.	0
DDI-DrugBank.d143.s28.p3	There have been case reports of increased steady-state levels of quinidine, @DRUG$, and @DRUG$ during concomitant therapy with amiodarone.	0
DDI-DrugBank.d143.s28.p4	There have been case reports of increased steady-state levels of quinidine, @DRUG$, and phenytoin during concomitant therapy with @DRUG$.	0
DDI-DrugBank.d143.s28.p5	There have been case reports of increased steady-state levels of quinidine, procainamide, and @DRUG$ during concomitant therapy with @DRUG$.	0
DDI-DrugBank.d143.s30.p0	@DRUG$ taken concomitantly with @DRUG$ increases quinidine serum concentration by 33% after two days.	0
DDI-DrugBank.d143.s30.p1	@DRUG$ taken concomitantly with quinidine increases @DRUG$ serum concentration by 33% after two days.	0
DDI-DrugBank.d143.s30.p2	Amiodarone taken concomitantly with @DRUG$ increases @DRUG$ serum concentration by 33% after two days.	0
DDI-DrugBank.d143.s31.p0	@DRUG$ taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.	0
DDI-DrugBank.d143.s31.p1	@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	0
DDI-DrugBank.d143.s31.p2	@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	0
DDI-DrugBank.d143.s31.p3	Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	0
DDI-DrugBank.d143.s31.p4	Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	0
DDI-DrugBank.d143.s31.p5	Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl @DRUG$ by 55% and 33%, respectively.	0
DDI-DrugBank.d143.s32.p0	@DRUG$ and procainamide doses should be reduced by one-third when either is administered with @DRUG$.	0
DDI-DrugBank.d143.s33.p0	Plasma levels of @DRUG$ have been reported to increase in the presence of oral @DRUG$;	0
DDI-DrugBank.d143.s34.p0	because of this, the dosage of @DRUG$ should be adjusted when these @DRUG$ are administered concomitantly.	4
DDI-DrugBank.d143.s36.p0	Combination of @DRUG$ with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.	0
DDI-DrugBank.d143.s36.p1	Combination of @DRUG$ with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	0
DDI-DrugBank.d143.s36.p2	Combination of amiodarone with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	0
DDI-DrugBank.d143.s37.p0	During transfer to oral @DRUG$, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral @DRUG$.	0
DDI-DrugBank.d143.s38.p0	The continued need for the other @DRUG$ agent should be reviewed after the effects of @DRUG$ have been established, and discontinuation ordinarily should be attempted.	3
DDI-DrugBank.d143.s41.p0	@DRUG$: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p1	@DRUG$: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p2	@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p3	@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p4	@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p5	@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p6	@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p7	@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p8	@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p9	Antihypertensives: @DRUG$ should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p10	Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p11	Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p12	Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p13	Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p14	Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p15	Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p16	Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p17	Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p18	Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p19	Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p20	Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p21	Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p22	Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p23	Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p24	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p25	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p26	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p27	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p28	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p29	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p30	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p31	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p32	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p33	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p34	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p35	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p36	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p37	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p38	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p39	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p40	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p41	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p42	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p43	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s41.p44	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	1
DDI-DrugBank.d143.s43.p0	@DRUG$: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p1	@DRUG$: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p2	@DRUG$: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p3	@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p4	@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p5	Anticoagulants: Potentiation of @DRUG$-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p6	Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p7	Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p8	Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p9	Anticoagulants: Potentiation of warfarin-type (@DRUG$ and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p10	Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p11	Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p12	Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p13	Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s43.p14	Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	1
DDI-DrugBank.d143.s44.p0	Since the concomitant administration of @DRUG$ with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	0
DDI-DrugBank.d143.s44.p1	Since the concomitant administration of @DRUG$ with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	0
DDI-DrugBank.d143.s44.p2	Since the concomitant administration of warfarin with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	0
DDI-DrugBank.d143.s45.p0	Some @DRUG$/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of CYP3A4 (enzyme induction).	0
DDI-DrugBank.d143.s45.p1	Some @DRUG$/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of @DRUG$ (enzyme induction).	0
DDI-DrugBank.d143.s45.p2	Some drugs/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of @DRUG$ (enzyme induction).	0
DDI-DrugBank.d143.s48.p0	Administration of @DRUG$ concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.	0
DDI-DrugBank.d143.s48.p1	Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	0
DDI-DrugBank.d143.s48.p2	Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	0
DDI-DrugBank.d143.s48.p3	Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	0
DDI-DrugBank.d143.s48.p4	Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	0
DDI-DrugBank.d143.s48.p5	Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and @DRUG$.	0
DDI-DrugBank.d143.s50.p0	Since @DRUG$ is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.	0
DDI-DrugBank.d143.s50.p1	Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	0
DDI-DrugBank.d143.s50.p2	Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	0
DDI-DrugBank.d143.s50.p3	Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	0
DDI-DrugBank.d143.s50.p4	Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	0
DDI-DrugBank.d143.s50.p5	Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced @DRUG$ levels.	0
DDI-DrugBank.d143.s51.p0	Other reported interactions with @DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	0
DDI-DrugBank.d143.s51.p1	Other reported interactions with @DRUG$: Fentanyl (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	0
DDI-DrugBank.d143.s51.p2	Other reported interactions with @DRUG$: Fentanyl (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	0
DDI-DrugBank.d143.s51.p3	Other reported interactions with amiodarone: @DRUG$ (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	0
DDI-DrugBank.d143.s51.p4	Other reported interactions with amiodarone: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	0
DDI-DrugBank.d143.s51.p5	Other reported interactions with amiodarone: Fentanyl (@DRUG$ substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	0
DDI-DrugBank.d143.s52.p0	Sinus bradycardia has been reported with oral @DRUG$ in combination with @DRUG$ (CYP3A4 substrate) given for local anesthesia.	4
DDI-DrugBank.d143.s52.p1	Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (@DRUG$ substrate) given for local anesthesia.	4
DDI-DrugBank.d143.s52.p2	Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (CYP3A4 substrate) given for local @DRUG$.	4
DDI-DrugBank.d143.s52.p3	Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (@DRUG$ substrate) given for local anesthesia.	4
DDI-DrugBank.d143.s52.p4	Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (CYP3A4 substrate) given for local @DRUG$.	4
DDI-DrugBank.d143.s52.p5	Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (@DRUG$ substrate) given for local @DRUG$.	4
DDI-DrugBank.d143.s53.p0	Seizure, associated with increased @DRUG$ concentrations, has been reported with concomitant administration of intravenous @DRUG$.	0
DDI-DrugBank.d143.s54.p0	@DRUG$ is a substrate for both @DRUG$ and CYP3A4.	1
DDI-DrugBank.d143.s54.p1	@DRUG$ is a substrate for both CYP2D6 and @DRUG$.	1
DDI-DrugBank.d143.s54.p2	Dextromethorphan is a substrate for both @DRUG$ and @DRUG$.	1
DDI-DrugBank.d143.s55.p0	@DRUG$ inhibits @DRUG$.	0
DDI-DrugBank.d143.s56.p0	@DRUG$ increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and t1/2.	0
DDI-DrugBank.d143.s56.p1	@DRUG$ increases enterohepatic elimination of amiodarone and may reduce its serum levels and @DRUG$/2.	0
DDI-DrugBank.d143.s56.p2	Cholestyramine increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and @DRUG$/2.	0
DDI-DrugBank.d143.s58.p0	@DRUG$, @DRUG$, and azoles are known to cause QTc prolongation.	0
DDI-DrugBank.d143.s59.p0	There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when @DRUG$, macrolide antibiotics, or azoles were administered concomitantly.	0
DDI-DrugBank.d143.s59.p1	There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when fluoroquinolones, @DRUG$, or azoles were administered concomitantly.	0
DDI-DrugBank.d143.s59.p2	There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when @DRUG$, @DRUG$, or azoles were administered concomitantly.	0
DDI-DrugBank.d143.s60.p0	Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, @DRUG$, and verapamil.	0
DDI-DrugBank.d143.s60.p1	Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, diltiazem, and @DRUG$.	0
DDI-DrugBank.d143.s60.p2	Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d143.s62.p0	In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of @DRUG$, dextromethorphan, and methotrexate.	0
DDI-DrugBank.d143.s62.p1	In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, @DRUG$, and methotrexate.	0
DDI-DrugBank.d143.s62.p2	In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, dextromethorphan, and @DRUG$.	0
DDI-DrugBank.d143.s62.p3	In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, @DRUG$, and methotrexate.	0
DDI-DrugBank.d143.s62.p4	In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, dextromethorphan, and @DRUG$.	0
DDI-DrugBank.d143.s62.p5	In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d143.s7.p0	In view of the long and variable half-life of @DRUG$, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of @DRUG$.	0
DDI-DrugBank.d143.s8.p0	Since @DRUG$ is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of @DRUG$.	0
DDI-DrugBank.d143.s9.p0	Reported examples include the following: @DRUG$: @DRUG$ are known to inhibit CYP3A4 to varying degrees.	4
DDI-DrugBank.d144.s0.p0	Concomitant oral administration of @DRUG$ (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral @DRUG$.	0
DDI-DrugBank.d144.s1.p0	If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p1	If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p2	If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p3	If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p4	If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p5	If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	0
DDI-DrugBank.d144.s1.p6	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p7	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p8	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p9	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p10	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	0
DDI-DrugBank.d144.s1.p11	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p12	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p13	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p14	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	0
DDI-DrugBank.d144.s1.p15	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p16	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p17	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	0
DDI-DrugBank.d144.s1.p18	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	0
DDI-DrugBank.d144.s1.p19	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	0
DDI-DrugBank.d144.s1.p20	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	0
DDI-DrugBank.d145.s0.p0	Plasma levels of @DRUG$ may become subtherapeutic during @DRUG$ therapy.	0
DDI-DrugBank.d146.s0.p0	@DRUG$ is inhibited by @DRUG$.	0
DDI-DrugBank.d146.s2.p0	@DRUG$ may increase sensitivity to the @DRUG$.	4
DDI-DrugBank.d146.s3.p0	Response to @DRUG$ may be enhanced by @DRUG$.	3
DDI-DrugBank.d148.s1.p0	However, if @DRUG$ is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.	0
DDI-DrugBank.d148.s1.p1	However, if @DRUG$ is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	0
DDI-DrugBank.d148.s1.p2	However, if Argatroban is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	0
DDI-DrugBank.d148.s2.p0	@DRUG$/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p1	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p2	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p3	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p4	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p5	@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p6	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p7	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p8	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p9	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p10	Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p11	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p12	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p13	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p14	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p15	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p16	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p17	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p18	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p19	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s2.p20	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
DDI-DrugBank.d148.s3.p0	Oral @DRUG$: Pharmacokinetic drug-drug interactions between @DRUG$ and warfarin (7.5 mg single oral dose) have not been demonstrated.	0
DDI-DrugBank.d148.s3.p1	Oral @DRUG$: Pharmacokinetic drug-drug interactions between Argatroban and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	0
DDI-DrugBank.d148.s3.p2	Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between @DRUG$ and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	0
DDI-DrugBank.d148.s4.p0	However, the concomitant use of @DRUG$ and @DRUG$ (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).	0
DDI-DrugBank.d148.s6.p0	Co-administration: Concomitant use of @DRUG$ with @DRUG$, thrombolytics, and other anticoagulants may increase the risk of bleeding.	0
DDI-DrugBank.d148.s6.p1	Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, @DRUG$, and other anticoagulants may increase the risk of bleeding.	0
DDI-DrugBank.d148.s6.p2	Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	0
DDI-DrugBank.d148.s6.p3	Co-administration: Concomitant use of Argatroban with @DRUG$, @DRUG$, and other anticoagulants may increase the risk of bleeding.	0
DDI-DrugBank.d148.s6.p4	Co-administration: Concomitant use of Argatroban with @DRUG$, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	0
DDI-DrugBank.d148.s6.p5	Co-administration: Concomitant use of Argatroban with antiplatelet agents, @DRUG$, and other @DRUG$ may increase the risk of bleeding.	0
DDI-DrugBank.d148.s7.p0	Drug-drug interactions have not been observed between @DRUG$ and @DRUG$ or erythromycin.	0
DDI-DrugBank.d148.s7.p1	Drug-drug interactions have not been observed between @DRUG$ and digoxin or @DRUG$.	0
DDI-DrugBank.d148.s7.p2	Drug-drug interactions have not been observed between Argatroban and @DRUG$ or @DRUG$.	0
DDI-DrugBank.d149.s0.p0	Possible drug interactions of @DRUG$ with @DRUG$ or with other anticholinesterase agents.	0
DDI-DrugBank.d149.s0.p1	Possible drug interactions of @DRUG$ with succinylcholine or with other @DRUG$.	0
DDI-DrugBank.d149.s0.p2	Possible drug interactions of HUMORSOL with @DRUG$ or with other @DRUG$.	0
DDI-DrugBank.d15.s0.p0	In clinical studies performed with @DRUG$, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p1	In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p2	In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p3	In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p4	In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p5	In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p6	In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p7	In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	0
DDI-DrugBank.d15.s0.p8	In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p9	In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p10	In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p11	In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p12	In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p13	In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p14	In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	0
DDI-DrugBank.d15.s0.p15	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p16	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p17	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p18	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p19	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p20	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	0
DDI-DrugBank.d15.s0.p21	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p22	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p23	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p24	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p25	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	0
DDI-DrugBank.d15.s0.p26	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p27	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p28	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p29	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	0
DDI-DrugBank.d15.s0.p30	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p31	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p32	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	0
DDI-DrugBank.d15.s0.p33	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	0
DDI-DrugBank.d15.s0.p34	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	0
DDI-DrugBank.d15.s0.p35	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	0
DDI-DrugBank.d15.s1.p0	In addition, @DRUG$ neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p1	In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p2	In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p3	In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p4	In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	0
DDI-DrugBank.d15.s1.p5	In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p6	In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p7	In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p8	In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	0
DDI-DrugBank.d15.s1.p9	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p10	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p11	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	0
DDI-DrugBank.d15.s1.p12	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	0
DDI-DrugBank.d15.s1.p13	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	0
DDI-DrugBank.d15.s1.p14	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of @DRUG$ at steady state.	0
DDI-DrugBank.d15.s4.p0	In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of @DRUG$ by @DRUG$ (200 m m M i.e., 350 mg/L) was 17-28%.	3
DDI-DrugBank.d15.s6.p0	Since @DRUG$ does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, @DRUG$ is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.	0
DDI-DrugBank.d150.s1.p0	@DRUG$ may enhance the effects of @DRUG$, barbiturates, and other CNS depressants.	4
DDI-DrugBank.d150.s1.p1	@DRUG$ may enhance the effects of alcohol, @DRUG$, and other CNS depressants.	4
DDI-DrugBank.d150.s1.p2	@DRUG$ may enhance the effects of alcohol, barbiturates, and other @DRUG$.	4
DDI-DrugBank.d150.s1.p3	FLEXERIL may enhance the effects of @DRUG$, @DRUG$, and other CNS depressants.	4
DDI-DrugBank.d150.s1.p4	FLEXERIL may enhance the effects of @DRUG$, barbiturates, and other @DRUG$.	4
DDI-DrugBank.d150.s1.p5	FLEXERIL may enhance the effects of alcohol, @DRUG$, and other @DRUG$.	4
DDI-DrugBank.d150.s2.p0	@DRUG$ may block the antihypertensive action of @DRUG$ and similarly acting compounds.	3
DDI-DrugBank.d150.s3.p0	@DRUG$ may enhance the seizure risk in patients taking @DRUG$	0
DDI-DrugBank.d151.s0.p0	@DRUG$ in large amounts may counteract the antiepileptic effect of @DRUG$, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.	0
DDI-DrugBank.d151.s0.p1	@DRUG$ in large amounts may counteract the antiepileptic effect of phenobarbital, @DRUG$ and primidone, and increase the frequency of seizures in susceptible pediatric patients.	0
DDI-DrugBank.d151.s0.p2	@DRUG$ in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.	0
DDI-DrugBank.d151.s0.p3	Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$, @DRUG$ and primidone, and increase the frequency of seizures in susceptible pediatric patients.	0
DDI-DrugBank.d151.s0.p4	Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$, phenytoin and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.	0
DDI-DrugBank.d151.s0.p5	Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, @DRUG$ and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.	0
DDI-DrugBank.d151.s1.p0	Preliminary animal and human studies have shown that small quantities of systemically administered @DRUG$ enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual @DRUG$ concentrations following intrathecal administration.	4
DDI-DrugBank.d151.s2.p0	However, high doses of @DRUG$ may reduce the efficacy of intrathecally administered @DRUG$.	0
DDI-DrugBank.d152.s0.p0	Certain endocrine and liver function tests may be affected by @DRUG$-containing oral @DRUG$.	0
DDI-DrugBank.d153.s0.p0	The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s0.p1	The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s0.p2	The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s0.p3	The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s0.p4	The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s0.p5	The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s0.p6	The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s0.p7	The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s0.p8	The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s0.p9	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$ or @DRUG$ may produce severe, prolonged hypertension.	4
DDI-DrugBank.d153.s3.p0	Concurrent administration of @DRUG$ and of @DRUG$ may cause severe, persistent hypertension or cerebrovascular accidents.	0
DDI-DrugBank.d153.s4.p0	@DRUG$ and @DRUG$ may reduce or reverse the pressor effect of epinephrine.	4
DDI-DrugBank.d153.s4.p1	@DRUG$ and butyrophenones may reduce or reverse the pressor effect of @DRUG$.	4
DDI-DrugBank.d153.s4.p2	Phenothiazines and @DRUG$ may reduce or reverse the pressor effect of @DRUG$.	4
DDI-DrugBank.d154.s0.p0	The coadministration of @DRUG$ decreases the biologic half-life of @DRUG$ because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.	0
DDI-DrugBank.d154.s0.p1	The coadministration of @DRUG$ decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of @DRUG$ in the urine.	0
DDI-DrugBank.d154.s0.p2	The coadministration of aspirin decreases the biologic half-life of @DRUG$ because of an increase in metabolic clearance that results in a greater amount of @DRUG$ in the urine.	0
DDI-DrugBank.d154.s10.p0	Patients treated with @DRUG$ may be resistant to the effects of @DRUG$.	3
DDI-DrugBank.d154.s11.p0	In patients receiving @DRUG$ and a @DRUG$ concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.	0
DDI-DrugBank.d154.s11.p1	In patients receiving @DRUG$ and a steroid concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.	0
DDI-DrugBank.d154.s11.p2	In patients receiving @DRUG$ and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.	0
DDI-DrugBank.d154.s11.p3	In patients receiving Nalfon and a @DRUG$ concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.	0
DDI-DrugBank.d154.s11.p4	In patients receiving Nalfon and a @DRUG$ concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.	0
DDI-DrugBank.d154.s11.p5	In patients receiving Nalfon and a steroid concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.	0
DDI-DrugBank.d154.s2.p0	Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p1	Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p2	Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p3	Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p4	Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.	4
DDI-DrugBank.d154.s2.p5	Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p6	Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p7	Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p8	Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.	4
DDI-DrugBank.d154.s2.p9	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p10	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p11	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.	4
DDI-DrugBank.d154.s2.p12	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of @DRUG$ and salicylates is not recommended.	4
DDI-DrugBank.d154.s2.p13	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and @DRUG$ is not recommended.	4
DDI-DrugBank.d154.s2.p14	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and @DRUG$ is not recommended.	4
DDI-DrugBank.d154.s3.p0	Chronic administration of @DRUG$, a known enzyme inducer, may be associated with a decrease in the plasma half-life of @DRUG$.	0
DDI-DrugBank.d154.s4.p0	When @DRUG$ is added to or withdrawn from treatment, dosage adjustment of @DRUG$ may be required.	0
DDI-DrugBank.d154.s7.p0	Patients receiving @DRUG$, @DRUG$, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.	0
DDI-DrugBank.d154.s7.p1	Patients receiving @DRUG$, sulfonamides, or @DRUG$ should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.	0
DDI-DrugBank.d154.s7.p2	Patients receiving hydantoins, @DRUG$, or @DRUG$ should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.	0
DDI-DrugBank.d154.s8.p0	In patients receiving @DRUG$, the addition of @DRUG$ to therapy could prolong the prothrombin time.	0
DDI-DrugBank.d157.s0.p0	Clinical interaction studies with @DRUG$ and @DRUG$ indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.	0
DDI-DrugBank.d157.s0.p1	Clinical interaction studies with @DRUG$ and warfarin indicated that the coadministration of @DRUG$ with these drugs does not result in clinically- significant drug interactions.	0
DDI-DrugBank.d157.s0.p2	Clinical interaction studies with cimetidine and @DRUG$ indicated that the coadministration of @DRUG$ with these drugs does not result in clinically- significant drug interactions.	0
DDI-DrugBank.d158.s0.p0	Urinary acidifying agents These agents (@DRUG$, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	2
DDI-DrugBank.d158.s0.p1	Urinary acidifying agents These agents (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	2
DDI-DrugBank.d158.s0.p2	Urinary acidifying agents These agents (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	2
DDI-DrugBank.d158.s10.p0	@DRUG$: @DRUG$ may counteract the sedative effect of antihistamines.	4
DDI-DrugBank.d158.s10.p1	@DRUG$: Amphetamines may counteract the sedative effect of @DRUG$.	0
DDI-DrugBank.d158.s10.p2	Antihistamines: @DRUG$ may counteract the sedative effect of @DRUG$.	4
DDI-DrugBank.d158.s11.p0	@DRUG$: @DRUG$ may antagonize the hypotensive effects of antihypertensives.	0
DDI-DrugBank.d158.s11.p1	@DRUG$: Amphetamines may antagonize the hypotensive effects of @DRUG$.	0
DDI-DrugBank.d158.s11.p2	Antihypertensives: @DRUG$ may antagonize the hypotensive effects of @DRUG$.	0
DDI-DrugBank.d158.s12.p0	@DRUG$: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.	0
DDI-DrugBank.d158.s12.p1	@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	0
DDI-DrugBank.d158.s12.p2	@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	0
DDI-DrugBank.d158.s12.p3	Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	0
DDI-DrugBank.d158.s12.p4	Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	0
DDI-DrugBank.d158.s12.p5	Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat @DRUG$ poisoning.	0
DDI-DrugBank.d158.s13.p0	@DRUG$: @DRUG$ may delay intestinal absorption of ethosuximide.	0
DDI-DrugBank.d158.s13.p1	@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$.	0
DDI-DrugBank.d158.s13.p2	Ethosuximide: @DRUG$ may delay intestinal absorption of @DRUG$.	0
DDI-DrugBank.d158.s14.p0	@DRUG$: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.	0
DDI-DrugBank.d158.s14.p1	@DRUG$: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	0
DDI-DrugBank.d158.s14.p2	Haloperidol: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	0
DDI-DrugBank.d158.s15.p0	@DRUG$: The anorectic and stimulatory effects of @DRUG$ may be inhibited by lithium carbonate.	4
DDI-DrugBank.d158.s15.p1	@DRUG$: The anorectic and stimulatory effects of amphetamines may be inhibited by @DRUG$.	4
DDI-DrugBank.d158.s15.p2	Lithium carbonate: The anorectic and stimulatory effects of @DRUG$ may be inhibited by @DRUG$.	4
DDI-DrugBank.d158.s17.p0	@DRUG$ therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.	0
DDI-DrugBank.d158.s17.p1	@DRUG$ therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	0
DDI-DrugBank.d158.s17.p2	Methenamine therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	0
DDI-DrugBank.d158.s18.p0	@DRUG$: @DRUG$ enhance the adrenergic effect of norepinephrine.	0
DDI-DrugBank.d158.s18.p1	@DRUG$: Amphetamines enhance the adrenergic effect of @DRUG$.	0
DDI-DrugBank.d158.s18.p2	Norepinephrine: @DRUG$ enhance the adrenergic effect of @DRUG$.	0
DDI-DrugBank.d158.s2.p0	@DRUG$ @DRUG$ are inhibited by amphetamines.	0
DDI-DrugBank.d158.s2.p1	@DRUG$ Adrenergic blockers are inhibited by @DRUG$.	0
DDI-DrugBank.d158.s2.p2	Adrenergic blockers @DRUG$ are inhibited by @DRUG$.	0
DDI-DrugBank.d158.s21.p0	@DRUG$: @DRUG$ may delay intestinal absorption of phenytoin;	0
DDI-DrugBank.d158.s21.p1	@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	0
DDI-DrugBank.d158.s21.p2	Phenytoin: @DRUG$ may delay intestinal absorption of @DRUG$;	0
DDI-DrugBank.d158.s24.p0	@DRUG$: @DRUG$ inhibit the hypotensive effect of veratrum alkaloids.	0
DDI-DrugBank.d158.s24.p1	@DRUG$: Amphetamines inhibit the hypotensive effect of @DRUG$.	0
DDI-DrugBank.d158.s24.p2	Veratrum alkaloids: @DRUG$ inhibit the hypotensive effect of @DRUG$.	0
DDI-DrugBank.d158.s3.p0	@DRUG$, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	4
DDI-DrugBank.d158.s3.p1	@DRUG$, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	4
DDI-DrugBank.d158.s3.p2	@DRUG$, tricyclic Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	4
DDI-DrugBank.d158.s3.p3	@DRUG$, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	4
DDI-DrugBank.d158.s3.p4	Antidepressants, @DRUG$ @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	4
DDI-DrugBank.d158.s3.p5	Antidepressants, @DRUG$ Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	4
DDI-DrugBank.d158.s3.p6	Antidepressants, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	4
DDI-DrugBank.d158.s3.p7	Antidepressants, tricyclic @DRUG$ may enhance the activity of @DRUG$ or sympathomimetic agents;	4
DDI-DrugBank.d158.s3.p8	Antidepressants, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or @DRUG$;	4
DDI-DrugBank.d158.s3.p9	Antidepressants, tricyclic Amphetamines may enhance the activity of @DRUG$ or @DRUG$;	4
DDI-DrugBank.d158.s6.p0	@DRUG$ @DRUG$, as well as a metabolite of furazolidone, slow amphetamine metabolism.	0
DDI-DrugBank.d158.s6.p1	@DRUG$ MAOI antidepressants, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	0
DDI-DrugBank.d158.s6.p2	@DRUG$ MAOI antidepressants, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	0
DDI-DrugBank.d158.s6.p3	MAO inhibitors @DRUG$, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	0
DDI-DrugBank.d158.s6.p4	MAO inhibitors @DRUG$, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	0
DDI-DrugBank.d158.s6.p5	MAO inhibitors MAOI antidepressants, as well as a metabolite of @DRUG$, slow @DRUG$ metabolism.	0
DDI-DrugBank.d160.s1.p0	It is recommended to avoid concurrent administration of @DRUG$ with @DRUG$ containing antacids for at least 4 hours following ethambutol administration.	4
DDI-DrugBank.d160.s1.p1	It is recommended to avoid concurrent administration of @DRUG$ with aluminum hydroxide containing @DRUG$ for at least 4 hours following ethambutol administration.	4
DDI-DrugBank.d160.s1.p2	It is recommended to avoid concurrent administration of @DRUG$ with aluminum hydroxide containing antacids for at least 4 hours following @DRUG$ administration.	4
DDI-DrugBank.d160.s1.p3	It is recommended to avoid concurrent administration of ethambutol with @DRUG$ containing @DRUG$ for at least 4 hours following ethambutol administration.	4
DDI-DrugBank.d160.s1.p4	It is recommended to avoid concurrent administration of ethambutol with @DRUG$ containing antacids for at least 4 hours following @DRUG$ administration.	4
DDI-DrugBank.d160.s1.p5	It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing @DRUG$ for at least 4 hours following @DRUG$ administration.	4
DDI-DrugBank.d161.s1.p0	For information on the pharmacokinetics of @DRUG$ and @DRUG$ in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.	0
DDI-DrugBank.d162.s1.p0	@DRUG$, @DRUG$, or narcotics: potentiation of orthostatic hypotension may occur.	4
DDI-DrugBank.d162.s1.p1	@DRUG$, barbiturates, or @DRUG$: potentiation of orthostatic hypotension may occur.	4
DDI-DrugBank.d162.s1.p2	Alcohol, @DRUG$, or @DRUG$: potentiation of orthostatic hypotension may occur.	4
DDI-DrugBank.d162.s10.p0	@DRUG$ reduce the renal clearance of @DRUG$ and add a high risk of lithium toxicity.	0
DDI-DrugBank.d162.s10.p1	@DRUG$ reduce the renal clearance of lithium and add a high risk of @DRUG$ toxicity.	0
DDI-DrugBank.d162.s10.p2	Diuretic agents reduce the renal clearance of @DRUG$ and add a high risk of @DRUG$ toxicity.	0
DDI-DrugBank.d162.s11.p0	Refer to the package insert for @DRUG$ preparations before use of such preparations with @DRUG$.	0
DDI-DrugBank.d162.s12.p0	@DRUG$: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.	3
DDI-DrugBank.d162.s12.p1	@DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	3
DDI-DrugBank.d162.s12.p2	@DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	3
DDI-DrugBank.d162.s12.p3	@DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and @DRUG$.	3
DDI-DrugBank.d162.s12.p4	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	3
DDI-DrugBank.d162.s12.p5	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	3
DDI-DrugBank.d162.s12.p6	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and @DRUG$.	3
DDI-DrugBank.d162.s12.p7	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	3
DDI-DrugBank.d162.s12.p8	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	3
DDI-DrugBank.d162.s12.p9	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG-DRUG$.	3
DDI-DrugBank.d162.s13.p0	Therefore, when @DRUG$ and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.	4
DDI-DrugBank.d162.s13.p1	Therefore, when @DRUG$ and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	4
DDI-DrugBank.d162.s13.p2	Therefore, when Hydrochlorothiazide and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	4
DDI-DrugBank.d162.s2.p0	@DRUG$: (oral agents and @DRUG$) - dosage adjustment of the antidiabetic drug may be required.	0
DDI-DrugBank.d162.s2.p1	@DRUG$: (oral agents and insulin) - dosage adjustment of the @DRUG$ may be required.	0
DDI-DrugBank.d162.s2.p2	Antidiabetic drugs: (oral agents and @DRUG$) - dosage adjustment of the @DRUG$ may be required.	0
DDI-DrugBank.d162.s4.p0	@DRUG$ and @DRUG$ resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.	0
DDI-DrugBank.d162.s4.p1	@DRUG$ and colestipol @DRUG$: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.	0
DDI-DrugBank.d162.s4.p2	@DRUG$ and colestipol resins: Absorption of @DRUG$ is impaired in the presence of anionic exchange resins.	0
DDI-DrugBank.d162.s4.p3	@DRUG$ and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	0
DDI-DrugBank.d162.s4.p4	Cholestyramine and @DRUG$ @DRUG$: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.	0
DDI-DrugBank.d162.s4.p5	Cholestyramine and @DRUG$ resins: Absorption of @DRUG$ is impaired in the presence of anionic exchange resins.	0
DDI-DrugBank.d162.s4.p6	Cholestyramine and @DRUG$ resins: Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	0
DDI-DrugBank.d162.s4.p7	Cholestyramine and colestipol @DRUG$: Absorption of @DRUG$ is impaired in the presence of anionic exchange resins.	0
DDI-DrugBank.d162.s4.p8	Cholestyramine and colestipol @DRUG$: Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	0
DDI-DrugBank.d162.s4.p9	Cholestyramine and colestipol resins: Absorption of @DRUG$ is impaired in the presence of @DRUG$.	0
DDI-DrugBank.d162.s5.p0	Single doses of either @DRUG$ or @DRUG$ resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	0
DDI-DrugBank.d162.s5.p1	Single doses of either @DRUG$ or colestipol @DRUG$ bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	0
DDI-DrugBank.d162.s5.p2	Single doses of either @DRUG$ or colestipol resins bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	0
DDI-DrugBank.d162.s5.p3	Single doses of either cholestyramine or @DRUG$ @DRUG$ bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	0
DDI-DrugBank.d162.s5.p4	Single doses of either cholestyramine or @DRUG$ resins bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	0
DDI-DrugBank.d162.s5.p5	Single doses of either cholestyramine or colestipol @DRUG$ bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	0
DDI-DrugBank.d162.s8.p0	@DRUG$, nondepolarizing (e.g., @DRUG$): possible increased responsiveness to the muscle relaxant.	0
DDI-DrugBank.d162.s8.p1	@DRUG$, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the @DRUG$.	0
DDI-DrugBank.d162.s8.p2	Skeletal muscle relaxants, nondepolarizing (e.g., @DRUG$): possible increased responsiveness to the @DRUG$.	4
DDI-DrugBank.d162.s9.p0	@DRUG$: generally should not be given with @DRUG$.	0
DDI-DrugBank.d163.s0.p0	@DRUG$: Because of the relationship of @DRUG$ to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects	4
DDI-DrugBank.d163.s0.p1	@DRUG$: Because of the relationship of Accutane to @DRUG$, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects	4
DDI-DrugBank.d163.s0.p2	@DRUG$: Because of the relationship of Accutane to vitamin A, patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	4
DDI-DrugBank.d163.s0.p3	@DRUG$: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	4
DDI-DrugBank.d163.s0.p4	Vitamin A: Because of the relationship of @DRUG$ to @DRUG$, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects	4
DDI-DrugBank.d163.s0.p5	Vitamin A: Because of the relationship of @DRUG$ to vitamin A, patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	4
DDI-DrugBank.d163.s0.p6	Vitamin A: Because of the relationship of @DRUG$ to vitamin A, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	4
DDI-DrugBank.d163.s0.p7	Vitamin A: Because of the relationship of Accutane to @DRUG$, patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	4
DDI-DrugBank.d163.s0.p8	Vitamin A: Because of the relationship of Accutane to @DRUG$, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	4
DDI-DrugBank.d163.s0.p9	Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking @DRUG$ containing @DRUG$ to avoid additive toxic effects	4
DDI-DrugBank.d163.s13.p0	No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between @DRUG$ and @DRUG$.	0
DDI-DrugBank.d163.s16.p0	@DRUG$: @DRUG$ are known to cause osteoporosis.	0
DDI-DrugBank.d163.s17.p0	No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between @DRUG$ and @DRUG$.	0
DDI-DrugBank.d163.s2.p0	@DRUG$: Concomitant treatment with @DRUG$ and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	0
DDI-DrugBank.d163.s2.p1	@DRUG$: Concomitant treatment with Accutane and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	0
DDI-DrugBank.d163.s2.p2	@DRUG$: Concomitant treatment with Accutane and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	0
DDI-DrugBank.d163.s2.p3	@DRUG$: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	0
DDI-DrugBank.d163.s2.p4	Tetracyclines: Concomitant treatment with @DRUG$ and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	0
DDI-DrugBank.d163.s2.p5	Tetracyclines: Concomitant treatment with @DRUG$ and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	0
DDI-DrugBank.d163.s2.p6	Tetracyclines: Concomitant treatment with @DRUG$ and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	0
DDI-DrugBank.d163.s2.p7	Tetracyclines: Concomitant treatment with Accutane and @DRUG$ should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	0
DDI-DrugBank.d163.s2.p8	Tetracyclines: Concomitant treatment with Accutane and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	0
DDI-DrugBank.d163.s2.p9	Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	0
DDI-DrugBank.d163.s4.p0	Micro-dosed @DRUG$ Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.	0
DDI-DrugBank.d163.s4.p1	Micro-dosed @DRUG$ Preparations: Micro-dosed progesterone preparations (minipills that do not contain an @DRUG$) may be an inadequate method of contraception during Accutane therapy.	0
DDI-DrugBank.d163.s4.p2	Micro-dosed @DRUG$ Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during @DRUG$ therapy.	0
DDI-DrugBank.d163.s4.p3	Micro-dosed Progesterone Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an @DRUG$) may be an inadequate method of contraception during Accutane therapy.	0
DDI-DrugBank.d163.s4.p4	Micro-dosed Progesterone Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during @DRUG$ therapy.	0
DDI-DrugBank.d163.s4.p5	Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an @DRUG$) may be an inadequate method of contraception during @DRUG$ therapy.	0
DDI-DrugBank.d163.s5.p0	Although other @DRUG$ are highly effective, there have been reports of pregnancy from women who have used @DRUG$, as well as topical/injectable/implantable/insertable hormonal birth control products.	3
DDI-DrugBank.d163.s7.p0	It is not known if @DRUG$ differ in their effectiveness when used with @DRUG$.	0
DDI-DrugBank.d165.s0.p0	Both @DRUG$ and its major metabolite, @DRUG$, are inhibitors of the cytochrome P450 3A4 enzyme system.	3
DDI-DrugBank.d165.s10.p0	therefore concomitant administration of @DRUG$ with @DRUG$ is contraindicated.	0
DDI-DrugBank.d165.s15.p0	Coadministration of @DRUG$ and @DRUG$, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.	0
DDI-DrugBank.d165.s15.p1	Coadministration of @DRUG$ and cyclosporine, @DRUG$ or digoxin has led to increased plasma concentrations of the latter three drugs.	0
DDI-DrugBank.d165.s15.p2	Coadministration of @DRUG$ and cyclosporine, tacrolimus or @DRUG$ has led to increased plasma concentrations of the latter three drugs.	0
DDI-DrugBank.d165.s15.p3	Coadministration of Itraconazole and @DRUG$, @DRUG$ or digoxin has led to increased plasma concentrations of the latter three drugs.	0
DDI-DrugBank.d165.s15.p4	Coadministration of Itraconazole and @DRUG$, tacrolimus or @DRUG$ has led to increased plasma concentrations of the latter three drugs.	0
DDI-DrugBank.d165.s15.p5	Coadministration of Itraconazole and cyclosporine, @DRUG$ or @DRUG$ has led to increased plasma concentrations of the latter three drugs.	0
DDI-DrugBank.d165.s17.p0	Rhabdomyolysis has been observed in patients receiving @DRUG$ administered alone (at recommended dosages) or concomitantly with @DRUG$ including cyclosporine.	0
DDI-DrugBank.d165.s17.p1	Rhabdomyolysis has been observed in patients receiving @DRUG$ administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including @DRUG$.	0
DDI-DrugBank.d165.s17.p2	Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with @DRUG$ including @DRUG$.	0
DDI-DrugBank.d165.s18.p0	When @DRUG$ was coadministered with @DRUG$, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.	0
DDI-DrugBank.d165.s18.p1	When @DRUG$ was coadministered with phenytoin, @DRUG$, or H2antagonists, reduced plasma concentrations of itraconazole were reported.	0
DDI-DrugBank.d165.s18.p2	When @DRUG$ was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of @DRUG$ were reported.	0
DDI-DrugBank.d165.s18.p3	When Itraconazole was coadministered with @DRUG$, @DRUG$, or H2antagonists, reduced plasma concentrations of itraconazole were reported.	0
DDI-DrugBank.d165.s18.p4	When Itraconazole was coadministered with @DRUG$, rifampin, or H2antagonists, reduced plasma concentrations of @DRUG$ were reported.	0
DDI-DrugBank.d165.s18.p5	When Itraconazole was coadministered with phenytoin, @DRUG$, or H2antagonists, reduced plasma concentrations of @DRUG$ were reported.	0
DDI-DrugBank.d165.s19.p0	The physician is advised to monitor the plasma concentrations of @DRUG$ when any of these drugs is taken concurrently, and to increase the dose of @DRUG$ if necessary.	0
DDI-DrugBank.d165.s20.p0	Although no studies have been conducted, concomitant administration of @DRUG$ and @DRUG$ may alter the metabolism of phenytoin;	0
DDI-DrugBank.d165.s20.p1	Although no studies have been conducted, concomitant administration of @DRUG$ and phenytoin may alter the metabolism of @DRUG$;	0
DDI-DrugBank.d165.s20.p2	Although no studies have been conducted, concomitant administration of Itraconazole and @DRUG$ may alter the metabolism of @DRUG$;	0
DDI-DrugBank.d165.s22.p0	It has been reported that @DRUG$ enhances the anticoagulant effect of @DRUG$-like drugs.	0
DDI-DrugBank.d165.s23.p0	Therefore, prothrombin time should be carefully monitored in patients receiving @DRUG$ and @DRUG$-like drugs simultaneously.	0
DDI-DrugBank.d165.s24.p0	Plasma concentrations of @DRUG$ are reduced when given concurrently with @DRUG$.	0
DDI-DrugBank.d165.s26.p0	Severe hypoglycemia has been reported in patients concomitantly receiving @DRUG$ and oral @DRUG$.	0
DDI-DrugBank.d165.s27.p0	Blood glucose concentrations should be carefully monitored when @DRUG$ and oral @DRUG$ are coadministered.	0
DDI-DrugBank.d165.s28.p0	Tinnitus and decreased hearing have been reported in patients concomitantly receiving @DRUG$ and @DRUG$.	0
DDI-DrugBank.d165.s29.p0	Edema has been reported in patients concomitantly receiving @DRUG$ and @DRUG$.	0
DDI-DrugBank.d165.s3.p0	Coadministration of @DRUG$ with @DRUG$ has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.	0
DDI-DrugBank.d165.s3.p1	Coadministration of @DRUG$ with Itraconazole has led to elevated plasma concentrations of @DRUG$, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.	0
DDI-DrugBank.d165.s3.p2	Coadministration of terfenadine with @DRUG$ has led to elevated plasma concentrations of @DRUG$, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.	0
DDI-DrugBank.d165.s4.p0	Another oral @DRUG$, @DRUG$, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.	0
DDI-DrugBank.d165.s4.p1	Another oral @DRUG$, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.	0
DDI-DrugBank.d165.s4.p2	Another oral @DRUG$, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.	0
DDI-DrugBank.d165.s4.p3	Another oral @DRUG$, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.	0
DDI-DrugBank.d165.s4.p4	Another oral azole antifungal, @DRUG$, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.	0
DDI-DrugBank.d165.s4.p5	Another oral azole antifungal, @DRUG$, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.	0
DDI-DrugBank.d165.s4.p6	Another oral azole antifungal, @DRUG$, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.	0
DDI-DrugBank.d165.s4.p7	Another oral azole antifungal, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.	0
DDI-DrugBank.d165.s4.p8	Another oral azole antifungal, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.	0
DDI-DrugBank.d165.s4.p9	Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite @DRUG$ which may prolong QT intervals.	0
DDI-DrugBank.d165.s5.p0	In vitro data suggest that @DRUG$, when compared to @DRUG$, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.	3
DDI-DrugBank.d165.s5.p1	In vitro data suggest that @DRUG$, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of @DRUG$.	3
DDI-DrugBank.d165.s5.p2	In vitro data suggest that itraconazole, when compared to @DRUG$, has a less pronounced effect on the biotransformation system responsible for the metabolism of @DRUG$.	3
DDI-DrugBank.d165.s6.p0	Based on the chemical resemblance of @DRUG$ and @DRUG$, coadministration of astemizole with itraconazole is contraindicated.	0
DDI-DrugBank.d165.s6.p1	Based on the chemical resemblance of @DRUG$ and ketoconazole, coadministration of @DRUG$ with itraconazole is contraindicated.	0
DDI-DrugBank.d165.s6.p2	Based on the chemical resemblance of @DRUG$ and ketoconazole, coadministration of astemizole with @DRUG$ is contraindicated.	0
DDI-DrugBank.d165.s6.p3	Based on the chemical resemblance of itraconazole and @DRUG$, coadministration of @DRUG$ with itraconazole is contraindicated.	0
DDI-DrugBank.d165.s6.p4	Based on the chemical resemblance of itraconazole and @DRUG$, coadministration of astemizole with @DRUG$ is contraindicated.	0
DDI-DrugBank.d165.s6.p5	Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of @DRUG$ with @DRUG$ is contraindicated.	0
DDI-DrugBank.d165.s7.p0	Human pharmacokinetics data indicate that oral @DRUG$ potently inhibits the metabolism of @DRUG$ resulting in an eight-fold increase in the mean AUC of cisapride.	0
DDI-DrugBank.d165.s7.p1	Human pharmacokinetics data indicate that oral @DRUG$ potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of @DRUG$.	0
DDI-DrugBank.d165.s7.p2	Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of @DRUG$ resulting in an eight-fold increase in the mean AUC of @DRUG$.	0
DDI-DrugBank.d165.s8.p0	Data suggest that coadministration of oral @DRUG$ and @DRUG$ can result in prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d166.s1.p0	@DRUG$ may potentiate the adverse effects of other @DRUG$ administered concomitantly.	4
DDI-DrugBank.d166.s2.p0	In particular, convulsions have been reported when @DRUG$ is administered with @DRUG$ and special care should be taken when the treatment regimen includes both of these drugs.	4
DDI-DrugBank.d167.s1.p0	@DRUG$ (neostgmine, @DRUG$), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d167.s1.p1	@DRUG$ (neostgmine, physostigmine), @DRUG$, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d167.s1.p2	@DRUG$ (neostgmine, physostigmine), lignocaine, @DRUG$, procainamide can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d167.s1.p3	@DRUG$ (neostgmine, physostigmine), lignocaine, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d167.s1.p4	Anticholinesterases (neostgmine, @DRUG$), @DRUG$, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d167.s1.p5	Anticholinesterases (neostgmine, @DRUG$), lignocaine, @DRUG$, procainamide can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d167.s1.p6	Anticholinesterases (neostgmine, @DRUG$), lignocaine, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d167.s1.p7	Anticholinesterases (neostgmine, physostigmine), @DRUG$, @DRUG$, procainamide can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d167.s1.p8	Anticholinesterases (neostgmine, physostigmine), @DRUG$, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d167.s1.p9	Anticholinesterases (neostgmine, physostigmine), lignocaine, @DRUG$, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	4
DDI-DrugBank.d168.s0.p0	This drug may interact with @DRUG$ or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p1	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p2	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p3	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p4	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p5	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p6	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	4
DDI-DrugBank.d168.s0.p7	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p8	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p9	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p10	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p11	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p12	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	4
DDI-DrugBank.d168.s0.p13	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p14	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p15	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p16	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p17	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	4
DDI-DrugBank.d168.s0.p18	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p19	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p20	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p21	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	4
DDI-DrugBank.d168.s0.p22	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p23	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p24	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	4
DDI-DrugBank.d168.s0.p25	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	4
DDI-DrugBank.d168.s0.p26	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	4
DDI-DrugBank.d168.s0.p27	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	4
DDI-DrugBank.d169.s2.p0	Co-administration of single 25-mg dose @DRUG$ had no effect on the pharmacokinetics of total @DRUG$.	0
DDI-DrugBank.d169.s3.p0	Expected changes in laboratory assessments of PT and INR were observed after @DRUG$ administration, but these changes were not affected by concomitant @DRUG$ administration.	0
DDI-DrugBank.d17.s12.p0	(Concurrent use with @DRUG$ may enhance the possibility of @DRUG$ toxicity associated with hypokalemia.)	4
DDI-DrugBank.d17.s18.p0	for adult-onset diabetics, dosage adjustment of @DRUG$ may be necessary during and after @DRUG$ therapy;	0
DDI-DrugBank.d17.s25.p0	(In some patients, the @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	3
DDI-DrugBank.d17.s25.p1	(In some patients, the @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	3
DDI-DrugBank.d17.s25.p2	(In some patients, the @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and @DRUG$.	3
DDI-DrugBank.d17.s25.p3	(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	3
DDI-DrugBank.d17.s25.p4	(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	3
DDI-DrugBank.d17.s25.p5	(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG-DRUG$.	3
DDI-DrugBank.d17.s26.p0	Therefore, when @DRUG$ and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)	4
DDI-DrugBank.d17.s26.p1	Therefore, when @DRUG$ and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.)	4
DDI-DrugBank.d17.s26.p2	Therefore, when hydroflumethiazide and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.)	4
DDI-DrugBank.d17.s31.p0	(@DRUG$ may increase the responsiveness to @DRUG$.)	0
DDI-DrugBank.d17.s6.p0	@DRUG$, other, especially @DRUG$, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery	4
DDI-DrugBank.d17.s6.p1	@DRUG$, other, especially diazoxide, or pre@DRUG$ and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery	4
DDI-DrugBank.d17.s6.p2	@DRUG$, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery	4
DDI-DrugBank.d17.s6.p3	Antihypertensive medications, other, especially @DRUG$, or pre@DRUG$ and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery	4
DDI-DrugBank.d17.s6.p4	Antihypertensive medications, other, especially @DRUG$, or preanesthetic and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery	4
DDI-DrugBank.d17.s6.p5	Antihypertensive medications, other, especially diazoxide, or pre@DRUG$ and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery	4
DDI-DrugBank.d170.s0.p0	Agents Affecting Cytochrome P450 3A4 Isoenzyme System @DRUG$ is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when @DRUG$  is given concurrently with agents that affect CYP3A4 activity.	3
DDI-DrugBank.d170.s3.p0	The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and @DRUG$ with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	0
DDI-DrugBank.d170.s3.p1	The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and erythromycin with transdermal @DRUG$ may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	0
DDI-DrugBank.d170.s3.p2	The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and erythromycin with transdermal fentanyl may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	0
DDI-DrugBank.d170.s3.p3	The concomitant use of other CYP3A4 inhibitors such as diltiazem and @DRUG$ with transdermal @DRUG$ may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	0
DDI-DrugBank.d170.s3.p4	The concomitant use of other CYP3A4 inhibitors such as diltiazem and @DRUG$ with transdermal fentanyl may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	0
DDI-DrugBank.d170.s3.p5	The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal @DRUG$ may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	0
DDI-DrugBank.d170.s5.p0	@DRUG$: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p1	@DRUG$: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p2	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p3	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p4	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p5	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p6	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p7	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p8	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p9	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p10	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p11	@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p12	Central Nervous System Depressants: The concomitant use of @DRUG$  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p13	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p14	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p15	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p16	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p17	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p18	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p19	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p20	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p21	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p22	Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p23	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p24	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p25	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p26	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p27	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p28	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p29	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p30	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p31	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p32	Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p33	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p34	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p35	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p36	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p37	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p38	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p39	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p40	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p41	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p42	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p43	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p44	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p45	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p46	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p47	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p48	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p49	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p50	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p51	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p52	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p53	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p54	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p55	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p56	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p57	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p58	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p59	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p60	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p61	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p62	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p63	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p64	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p65	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p66	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p67	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p68	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p69	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p70	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p71	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p72	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p73	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p74	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p75	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p76	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s5.p77	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	4
DDI-DrugBank.d170.s7.p0	@DRUG$: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	0
DDI-DrugBank.d170.s7.p1	@DRUG$: DURAGESIC  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	0
DDI-DrugBank.d170.s7.p2	@DRUG$: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	0
DDI-DrugBank.d170.s7.p3	@DRUG$: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	0
DDI-DrugBank.d170.s7.p4	MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	0
DDI-DrugBank.d170.s7.p5	MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	0
DDI-DrugBank.d170.s7.p6	MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	0
DDI-DrugBank.d170.s7.p7	MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	0
DDI-DrugBank.d170.s7.p8	MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	0
DDI-DrugBank.d170.s7.p9	MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with @DRUG$	0
DDI-DrugBank.d171.s0.p0	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p1	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p2	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p3	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p4	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p5	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p6	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p7	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p8	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p9	@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p10	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p11	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p12	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p13	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p14	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p15	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p16	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p17	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p18	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p19	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p20	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p21	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p22	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p23	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p24	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p25	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p26	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p27	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p28	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p29	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p30	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p31	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p32	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p33	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p34	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p35	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p36	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p37	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p38	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p39	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p40	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p41	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p42	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p43	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p44	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p45	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p46	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p47	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p48	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p49	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p50	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p51	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p52	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p53	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s0.p54	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	3
DDI-DrugBank.d171.s2.p0	therefore, close monitoring of prothrombin time is recommended, and adjustment of the @DRUG$ dose may be necessary when @DRUG$ is administered concomitantly.	0
DDI-DrugBank.d171.s3.p0	Interaction with @DRUG$, @DRUG$ and theophylline has also been reported to produce adverse clinical effects.	0
DDI-DrugBank.d171.s3.p1	Interaction with @DRUG$, lidocaine and @DRUG$ has also been reported to produce adverse clinical effects.	0
DDI-DrugBank.d171.s3.p2	Interaction with phenytoin, @DRUG$ and @DRUG$ has also been reported to produce adverse clinical effects.	0
DDI-DrugBank.d171.s4.p0	However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of @DRUG$ (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	0
DDI-DrugBank.d171.s4.p1	However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (@DRUG$ , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	0
DDI-DrugBank.d171.s4.p2	However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	0
DDI-DrugBank.d171.s4.p3	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of @DRUG$ (@DRUG$ , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	0
DDI-DrugBank.d171.s4.p4	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of @DRUG$ (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	0
DDI-DrugBank.d171.s4.p5	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (@DRUG$ , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	0
DDI-DrugBank.d172.s11.p0	@DRUG$: Clinical studies, as well as post marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.	1
DDI-DrugBank.d172.s11.p1	@DRUG$: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	1
DDI-DrugBank.d172.s11.p2	@DRUG$: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	1
DDI-DrugBank.d172.s11.p3	Furosemide: Clinical studies, as well as post marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	1
DDI-DrugBank.d172.s11.p4	Furosemide: Clinical studies, as well as post marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	1
DDI-DrugBank.d172.s11.p5	Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	1
DDI-DrugBank.d172.s14.p0	However, concomitant administration of @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.	4
DDI-DrugBank.d172.s14.p1	However, concomitant administration of @DRUG$ with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	4
DDI-DrugBank.d172.s14.p2	However, concomitant administration of aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	4
DDI-DrugBank.d172.s16.p0	@DRUG$: Concomitant administration of @DRUG$ at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.	0
DDI-DrugBank.d172.s16.p1	@DRUG$: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in @DRUG$ plasma concentration.	0
DDI-DrugBank.d172.s16.p2	Fluconazole: Concomitant administration of @DRUG$ at 200 mg QD resulted in a two-fold increase in @DRUG$ plasma concentration.	0
DDI-DrugBank.d172.s17.p0	This increase is due to the inhibition of @DRUG$ metabolism via P450 2C9 by @DRUG$ (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).	0
DDI-DrugBank.d172.s19.p0	@DRUG$: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.	0
DDI-DrugBank.d172.s19.p1	@DRUG$: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.	0
DDI-DrugBank.d172.s19.p2	@DRUG$: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone.	0
DDI-DrugBank.d172.s19.p3	@DRUG$: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone.	0
DDI-DrugBank.d172.s19.p4	Lithium: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.	0
DDI-DrugBank.d172.s19.p5	Lithium: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone.	0
DDI-DrugBank.d172.s19.p6	Lithium: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone.	0
DDI-DrugBank.d172.s19.p7	Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone.	0
DDI-DrugBank.d172.s19.p8	Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone.	0
DDI-DrugBank.d172.s19.p9	Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving @DRUG$ alone.	0
DDI-DrugBank.d172.s20.p0	Patients on @DRUG$ treatment should be closely monitored when @DRUG$ is introduced or withdrawn.	0
DDI-DrugBank.d172.s21.p0	@DRUG$: In an interaction study of rheumatoid arthritis patients taking @DRUG$, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate.	0
DDI-DrugBank.d172.s21.p1	@DRUG$: In an interaction study of rheumatoid arthritis patients taking methotrexate, @DRUG$ did not have a significant effect on the pharmacokinetics of methotrexate.	0
DDI-DrugBank.d172.s21.p2	@DRUG$: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d172.s21.p3	Methotrexate: In an interaction study of rheumatoid arthritis patients taking @DRUG$, @DRUG$ did not have a significant effect on the pharmacokinetics of methotrexate.	0
DDI-DrugBank.d172.s21.p4	Methotrexate: In an interaction study of rheumatoid arthritis patients taking @DRUG$, CELEBREX did not have a significant effect on the pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d172.s21.p5	Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, @DRUG$ did not have a significant effect on the pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d172.s22.p0	@DRUG$: The effect of @DRUG$ on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.	0
DDI-DrugBank.d172.s22.p1	@DRUG$: The effect of celecoxib on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.	0
DDI-DrugBank.d172.s22.p2	@DRUG$: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of @DRUG$.	0
DDI-DrugBank.d172.s22.p3	Warfarin: The effect of @DRUG$ on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.	0
DDI-DrugBank.d172.s22.p4	Warfarin: The effect of @DRUG$ on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of @DRUG$.	0
DDI-DrugBank.d172.s22.p5	Warfarin: The effect of celecoxib on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2-5 mg of @DRUG$.	0
DDI-DrugBank.d172.s23.p0	In these subjects, @DRUG$ did not alter the anticoagulant effect of @DRUG$ as determined by prothrombin time.	0
DDI-DrugBank.d172.s24.p0	However, caution should be used when administering @DRUG$ with @DRUG$ since these patients are at increased risk of bleeding complications.	0
DDI-DrugBank.d172.s6.p0	Clinical studies with @DRUG$ have identified potentially significant interactions with @DRUG$ and lithium.	0
DDI-DrugBank.d172.s6.p1	Clinical studies with @DRUG$ have identified potentially significant interactions with fluconazole and @DRUG$.	0
DDI-DrugBank.d172.s6.p2	Clinical studies with celecoxib have identified potentially significant interactions with @DRUG$ and @DRUG$.	0
DDI-DrugBank.d172.s9.p0	@DRUG$: Reports suggest that @DRUG$ may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.	0
DDI-DrugBank.d172.s9.p1	@DRUG$: Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	0
DDI-DrugBank.d172.s9.p2	ACE inhibitors: Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	0
DDI-DrugBank.d175.s0.p0	Hypotension   Patients on @DRUG$ Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.	0
DDI-DrugBank.d175.s0.p1	Hypotension   Patients on @DRUG$ Therapy: Patients on diuretics and especially those in whom @DRUG$ therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.	0
DDI-DrugBank.d175.s0.p2	Hypotension   Patients on @DRUG$ Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	0
DDI-DrugBank.d175.s0.p3	Hypotension   Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom @DRUG$ therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.	0
DDI-DrugBank.d175.s0.p4	Hypotension   Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	0
DDI-DrugBank.d175.s0.p5	Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom @DRUG$ therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	0
DDI-DrugBank.d175.s1.p0	The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	0
DDI-DrugBank.d175.s1.p1	The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	0
DDI-DrugBank.d175.s1.p2	The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (@DRUG$ tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	0
DDI-DrugBank.d175.s1.p3	The possibility of hypotensive effects with captopril can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	0
DDI-DrugBank.d175.s1.p4	The possibility of hypotensive effects with captopril can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with captopril (@DRUG$ tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	0
DDI-DrugBank.d175.s1.p5	The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (@DRUG$ tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	0
DDI-DrugBank.d175.s11.p0	Therefore, agents affecting sympathetic activity (e.g., @DRUG$ or @DRUG$) should be used with caution.	3
DDI-DrugBank.d175.s16.p0	Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that @DRUG$ may reduce the antihypertensive effect of @DRUG$, especially in cases of low renin hypertension.	0
DDI-DrugBank.d175.s17.p0	Other @DRUG$ (e.g., @DRUG$) may also have this effect.	0
DDI-DrugBank.d175.s18.p0	@DRUG$: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	0
DDI-DrugBank.d175.s18.p1	@DRUG$: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	0
DDI-DrugBank.d175.s18.p2	@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	0
DDI-DrugBank.d175.s18.p3	@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.	0
DDI-DrugBank.d175.s18.p4	Lithium: Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	0
DDI-DrugBank.d175.s18.p5	Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	0
DDI-DrugBank.d175.s18.p6	Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.	0
DDI-DrugBank.d175.s18.p7	Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	0
DDI-DrugBank.d175.s18.p8	Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.	0
DDI-DrugBank.d175.s18.p9	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and @DRUG$ therapy.	0
DDI-DrugBank.d175.s20.p0	If a @DRUG$ is also used, it may increase the risk of @DRUG$ toxicity.	0
DDI-DrugBank.d175.s21.p0	@DRUG$: In a study of young healthy male subjects no evidence of a direct pharmacokinetic @DRUG$-digoxin interaction could be found.	0
DDI-DrugBank.d175.s21.p1	@DRUG$: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-@DRUG$ interaction could be found.	0
DDI-DrugBank.d175.s21.p2	Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic @DRUG$-@DRUG$ interaction could be found.	0
DDI-DrugBank.d175.s23.p0	@DRUG$: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when @DRUG$ and allopurinol were administered concomitantly for 6 days.	0
DDI-DrugBank.d175.s23.p1	@DRUG$: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and @DRUG$ were administered concomitantly for 6 days.	0
DDI-DrugBank.d175.s23.p2	Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when @DRUG$ and @DRUG$ were administered concomitantly for 6 days.	0
DDI-DrugBank.d175.s5.p0	Agents Having Vasodilator Activity: Data on the effect of concomitant use of other @DRUG$ in patients receiving @DRUG$ for heart failure are not available;	0
DDI-DrugBank.d175.s6.p0	therefore, @DRUG$ or other @DRUG$ (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.	0
DDI-DrugBank.d175.s6.p1	therefore, @DRUG$ or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting @DRUG$.	0
DDI-DrugBank.d175.s6.p2	therefore, nitroglycerin or other @DRUG$ (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting @DRUG$.	0
DDI-DrugBank.d175.s9.p0	For example, @DRUG$ (e.g., @DRUG$) may activate the renin-angiotensin-aldosterone system.	0
DDI-DrugBank.d176.s0.p0	@DRUG$: Patients on @DRUG$, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.	0
DDI-DrugBank.d176.s0.p1	@DRUG$: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	0
DDI-DrugBank.d176.s0.p2	Diuretics: Patients on @DRUG$, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	0
DDI-DrugBank.d176.s1.p0	The possibility of hypotensive effects can be minimized by either discontinuing the @DRUG$ or increasing salt intake prior to initiation of treatment with @DRUG$.	0
DDI-DrugBank.d176.s14.p0	In a pharmacokinetic interaction study with @DRUG$, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of @DRUG$ were not significantly changed.	0
DDI-DrugBank.d176.s15.p0	Drug/Laboratory Test Interaction @DRUG$ may cause a false low measurement of serum @DRUG$ levels with the Digi- Tab  RIA Kit for Digoxin.	0
DDI-DrugBank.d176.s15.p1	Drug/Laboratory Test Interaction @DRUG$ may cause a false low measurement of serum digoxin levels with the Digi- Tab  RIA Kit for @DRUG$.	0
DDI-DrugBank.d176.s15.p2	Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum @DRUG$ levels with the Digi- Tab  RIA Kit for @DRUG$.	4
DDI-DrugBank.d176.s3.p0	@DRUG$ Supplements and @DRUG$: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.	1
DDI-DrugBank.d176.s3.p1	@DRUG$ Supplements and Potassium-Sparing Diuretics: @DRUG$ can attenuate potassium loss caused by thiazide diuretics.	0
DDI-DrugBank.d176.s3.p2	@DRUG$ Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by @DRUG$.	0
DDI-DrugBank.d176.s3.p3	Potassium Supplements and @DRUG$: @DRUG$ can attenuate potassium loss caused by thiazide diuretics.	0
DDI-DrugBank.d176.s3.p4	Potassium Supplements and @DRUG$: Fosinopril sodium can attenuate potassium loss caused by @DRUG$.	0
DDI-DrugBank.d176.s3.p5	Potassium Supplements and Potassium-Sparing Diuretics: @DRUG$ can attenuate potassium loss caused by @DRUG$.	0
DDI-DrugBank.d176.s9.p0	@DRUG$: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p1	@DRUG$: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p2	@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p3	@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p4	@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p5	@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p6	@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p7	@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p8	@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	4
DDI-DrugBank.d176.s9.p9	Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p10	Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p11	Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p12	Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p13	Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p14	Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p15	Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p16	Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	4
DDI-DrugBank.d176.s9.p17	Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p18	Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p19	Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p20	Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p21	Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p22	Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p23	Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	4
DDI-DrugBank.d176.s9.p24	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p25	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p26	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p27	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p28	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p29	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	4
DDI-DrugBank.d176.s9.p30	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p31	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p32	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p33	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	2
DDI-DrugBank.d176.s9.p34	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	4
DDI-DrugBank.d176.s9.p35	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p36	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p37	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p38	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	4
DDI-DrugBank.d176.s9.p39	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p40	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p41	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	4
DDI-DrugBank.d176.s9.p42	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	4
DDI-DrugBank.d176.s9.p43	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of @DRUG$.	4
DDI-DrugBank.d176.s9.p44	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of @DRUG$.	4
DDI-DrugBank.d177.s1.p0	Consequently, drugs with a low therapeutic margin, such as @DRUG$, @DRUG$, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level.	0
DDI-DrugBank.d177.s1.p1	Consequently, drugs with a low therapeutic margin, such as @DRUG$, phenytoin, and @DRUG$, could have a delayed elimination and increases in their serum half-life leading to a toxic level.	0
DDI-DrugBank.d177.s1.p2	Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, @DRUG$, and @DRUG$, could have a delayed elimination and increases in their serum half-life leading to a toxic level.	0
DDI-DrugBank.d177.s3.p0	For example, when @DRUG$ are administered concomitantly with @DRUG$, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.	0
DDI-DrugBank.d177.s3.p1	For example, when @DRUG$ are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of @DRUG$ should be reduced.	0
DDI-DrugBank.d177.s3.p2	For example, when vitamin K antagonists are administered concomitantly with @DRUG$, prothrombin time should be carefully monitored and if necessary, the dosage of @DRUG$ should be reduced.	0
DDI-DrugBank.d178.s0.p0	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p1	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p2	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p3	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p4	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p5	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p6	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p7	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d178.s0.p8	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p9	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p10	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p11	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p12	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p13	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p14	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d178.s0.p15	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p16	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p17	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p18	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p19	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p20	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d178.s0.p21	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p22	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p23	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p24	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p25	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d178.s0.p26	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p27	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p28	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p29	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d178.s0.p30	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p31	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p32	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d178.s0.p33	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d178.s0.p34	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d178.s0.p35	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.	3
DDI-DrugBank.d178.s11.p0	@DRUG$: In a single-dose interaction study in NIDDM subjects, decreases in @DRUG$ AUC and Cmax were observed, but were highly variable.	0
DDI-DrugBank.d178.s4.p0	These drugs include the @DRUG$ and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p1	These drugs include the @DRUG$ and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p2	These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p3	These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p4	These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p5	These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	2
DDI-DrugBank.d178.s4.p6	These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p7	These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	2
DDI-DrugBank.d178.s4.p8	These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d178.s4.p9	These drugs include the thiazides and other @DRUG$, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p10	These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p11	These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p12	These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p13	These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p14	These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p15	These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	2
DDI-DrugBank.d178.s4.p16	These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d178.s4.p17	These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p18	These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p19	These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p20	These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p21	These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p22	These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	2
DDI-DrugBank.d178.s4.p23	These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d178.s4.p24	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p25	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p26	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p27	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p28	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	2
DDI-DrugBank.d178.s4.p29	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d178.s4.p30	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p31	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p32	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p33	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	2
DDI-DrugBank.d178.s4.p34	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d178.s4.p35	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p36	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p37	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	2
DDI-DrugBank.d178.s4.p38	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d178.s4.p39	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d178.s4.p40	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	2
DDI-DrugBank.d178.s4.p41	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d178.s4.p42	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, @DRUG$, and isoniazid.	2
DDI-DrugBank.d178.s4.p43	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d178.s4.p44	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and @DRUG$.	2
DDI-DrugBank.d178.s7.p0	A possible interaction between @DRUG$ and @DRUG$, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.	0
DDI-DrugBank.d178.s7.p1	A possible interaction between @DRUG$ and ciprofloxacin, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.	0
DDI-DrugBank.d178.s7.p2	A possible interaction between @DRUG$ and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of @DRUG$.	4
DDI-DrugBank.d178.s7.p3	A possible interaction between glyburide and @DRUG$, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.	0
DDI-DrugBank.d178.s7.p4	A possible interaction between glyburide and @DRUG$, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of @DRUG$.	0
DDI-DrugBank.d178.s7.p5	A possible interaction between glyburide and ciprofloxacin, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of @DRUG$.	0
DDI-DrugBank.d178.s9.p0	A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported.	0
DDI-DrugBank.d179.s1.p0	@DRUG$ may interact with any of the following: - @DRUG$ (e.g., Tylenol) (with long-term, high-dose use) or	0
DDI-DrugBank.d179.s1.p1	@DRUG$ may interact with any of the following: - Acetaminophen (e.g., @DRUG$) (with long-term, high-dose use) or	0
DDI-DrugBank.d179.s1.p2	Sulfapyridine may interact with any of the following: - @DRUG$ (e.g., @DRUG$) (with long-term, high-dose use) or	0
DDI-DrugBank.d179.s10.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s11.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s12.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s14.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s16.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s17.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s19.p0	- Oral @DRUG$ (birth control pills) containing @DRUG$ or	3
DDI-DrugBank.d179.s22.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s24.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s26.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s27.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s3.p0	- @DRUG$ (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p1	- @DRUG$ (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p2	- @DRUG$ (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p3	- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p4	- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p5	- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p6	- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p7	- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	2
DDI-DrugBank.d179.s3.p8	- Anabolic steroids (@DRUG$ [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p9	- Anabolic steroids (@DRUG$ [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p10	- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p11	- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p12	- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p13	- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p14	- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	2
DDI-DrugBank.d179.s3.p15	- Anabolic steroids (nandrolone [e.g., @DRUG$], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p16	- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p17	- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p18	- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p19	- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p20	- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	2
DDI-DrugBank.d179.s3.p21	- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p22	- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p23	- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p24	- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p25	- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	2
DDI-DrugBank.d179.s3.p26	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p27	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p28	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p29	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	2
DDI-DrugBank.d179.s3.p30	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p31	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p32	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	2
DDI-DrugBank.d179.s3.p33	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], @DRUG$ [e.g., Winstrol]) or	2
DDI-DrugBank.d179.s3.p34	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., @DRUG$]) or	2
DDI-DrugBank.d179.s3.p35	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., @DRUG$]) or	2
DDI-DrugBank.d179.s30.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s31.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s32.p0	- @DRUG$ (e.g., @DRUG$) or	4
DDI-DrugBank.d179.s33.p0	- @DRUG$ (e.g., @DRUG$, Synkayvite) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	4
DDI-DrugBank.d179.s33.p1	- @DRUG$ (e.g., AquaMEPHYTON, @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	4
DDI-DrugBank.d179.s33.p2	- @DRUG$ (e.g., AquaMEPHYTON, Synkayvite) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	4
DDI-DrugBank.d179.s33.p3	- Vitamin K (e.g., @DRUG$, @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	4
DDI-DrugBank.d179.s33.p4	- Vitamin K (e.g., @DRUG$, Synkayvite) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	4
DDI-DrugBank.d179.s33.p5	- Vitamin K (e.g., AquaMEPHYTON, @DRUG$) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	4
DDI-DrugBank.d179.s36.p0	- @DRUG$ (e.g., @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines	4
DDI-DrugBank.d179.s36.p1	- @DRUG$ (e.g., Mesantoin) Use of @DRUG$ with these medicines may increase the chance of side effects of these medicines	4
DDI-DrugBank.d179.s36.p2	- Mephenytoin (e.g., @DRUG$) Use of @DRUG$ with these medicines may increase the chance of side effects of these medicines	4
DDI-DrugBank.d179.s37.p0	- @DRUG$, oral (diabetes medicine you take by mouth) Use of oral @DRUG$ with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics	2
DDI-DrugBank.d179.s37.p1	- @DRUG$, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with @DRUG$ may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics	2
DDI-DrugBank.d179.s37.p2	- @DRUG$, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	2
DDI-DrugBank.d179.s37.p3	- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral @DRUG$ with @DRUG$ may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics	2
DDI-DrugBank.d179.s37.p4	- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral @DRUG$ with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	2
DDI-DrugBank.d179.s37.p5	- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with @DRUG$ may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	2
DDI-DrugBank.d179.s38.p0	- @DRUG$ (e.g., @DRUG$) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	4
DDI-DrugBank.d179.s38.p1	- @DRUG$ (e.g., Mexate) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	4
DDI-DrugBank.d179.s38.p2	- @DRUG$ (e.g., Mexate) Use of methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	4
DDI-DrugBank.d179.s38.p3	- @DRUG$ (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	4
DDI-DrugBank.d179.s38.p4	- Methotrexate (e.g., @DRUG$) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	4
DDI-DrugBank.d179.s38.p5	- Methotrexate (e.g., @DRUG$) Use of methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	4
DDI-DrugBank.d179.s38.p6	- Methotrexate (e.g., @DRUG$) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	4
DDI-DrugBank.d179.s38.p7	- Methotrexate (e.g., Mexate) Use of @DRUG$ with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	4
DDI-DrugBank.d179.s38.p8	- Methotrexate (e.g., Mexate) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	4
DDI-DrugBank.d179.s38.p9	- Methotrexate (e.g., Mexate) Use of methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	4
DDI-DrugBank.d179.s6.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s8.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d179.s9.p0	- @DRUG$ (e.g., @DRUG$) or	0
DDI-DrugBank.d18.s1.p0	Injection: @DRUG$ injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p1	Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p2	Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p3	Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p4	Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p5	Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p6	Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p7	Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p8	Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p9	Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p10	Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p11	Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p12	Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p13	Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p14	Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p15	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p16	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p17	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p18	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p19	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p20	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p21	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p22	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p23	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p24	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p25	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p26	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p27	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p28	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p29	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p30	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p31	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p32	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p33	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p34	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d18.s1.p35	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	4
DDI-DrugBank.d180.s0.p0	@DRUG$ toxicity may be aggravated by the initial release of norepinephrine caused by @DRUG$ Injection.	0
DDI-DrugBank.d180.s1.p0	The pressor effects of @DRUG$ such as @DRUG$ or norepinephrine are enhanced by Bretylium Tosylate.	4
DDI-DrugBank.d180.s1.p1	The pressor effects of @DRUG$ such as dopamine or @DRUG$ are enhanced by Bretylium Tosylate.	0
DDI-DrugBank.d180.s1.p2	The pressor effects of @DRUG$ such as dopamine or norepinephrine are enhanced by @DRUG$.	0
DDI-DrugBank.d180.s1.p3	The pressor effects of catecholamines such as @DRUG$ or @DRUG$ are enhanced by Bretylium Tosylate.	0
DDI-DrugBank.d180.s1.p4	The pressor effects of catecholamines such as @DRUG$ or norepinephrine are enhanced by @DRUG$.	0
DDI-DrugBank.d180.s1.p5	The pressor effects of catecholamines such as dopamine or @DRUG$ are enhanced by @DRUG$.	0
DDI-DrugBank.d180.s3.p0	Although there is little published information on concomitant administration of @DRUG$ and @DRUG$, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.	0
DDI-DrugBank.d183.s1.p0	@DRUG$ has been administered with @DRUG$, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p1	@DRUG$ has been administered with tolazoline, @DRUG$, dobutamine, steroids, surfactant, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p2	@DRUG$ has been administered with tolazoline, dopamine, @DRUG$, steroids, surfactant, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p3	@DRUG$ has been administered with tolazoline, dopamine, dobutamine, @DRUG$, surfactant, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p4	@DRUG$ has been administered with tolazoline, dopamine, dobutamine, steroids, @DRUG$, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p5	INOmax has been administered with @DRUG$, @DRUG$, dobutamine, steroids, surfactant, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p6	INOmax has been administered with @DRUG$, dopamine, @DRUG$, steroids, surfactant, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p7	INOmax has been administered with @DRUG$, dopamine, dobutamine, @DRUG$, surfactant, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p8	INOmax has been administered with @DRUG$, dopamine, dobutamine, steroids, @DRUG$, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p9	INOmax has been administered with tolazoline, @DRUG$, @DRUG$, steroids, surfactant, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p10	INOmax has been administered with tolazoline, @DRUG$, dobutamine, @DRUG$, surfactant, and high-frequency ventilation.	2
DDI-DrugBank.d183.s1.p11	INOmax has been administered with tolazoline, @DRUG$, dobutamine, steroids, @DRUG$, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p12	INOmax has been administered with tolazoline, dopamine, @DRUG$, @DRUG$, surfactant, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p13	INOmax has been administered with tolazoline, dopamine, @DRUG$, steroids, @DRUG$, and high-frequency ventilation.	0
DDI-DrugBank.d183.s1.p14	INOmax has been administered with tolazoline, dopamine, dobutamine, @DRUG$, @DRUG$, and high-frequency ventilation.	0
DDI-DrugBank.d183.s2.p0	Although there are no study data to evaluate the possibility, @DRUG$, including @DRUG$ and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.	0
DDI-DrugBank.d183.s2.p1	Although there are no study data to evaluate the possibility, @DRUG$, including sodium nitroprusside and @DRUG$, may have an additive effect with INOmax on the risk of developing methemoglobinemia.	0
DDI-DrugBank.d183.s2.p2	Although there are no study data to evaluate the possibility, @DRUG$, including sodium nitroprusside and nitroglycerin, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia.	0
DDI-DrugBank.d183.s2.p3	Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including @DRUG$ and @DRUG$, may have an additive effect with INOmax on the risk of developing methemoglobinemia.	0
DDI-DrugBank.d183.s2.p4	Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including @DRUG$ and nitroglycerin, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia.	0
DDI-DrugBank.d183.s2.p5	Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and @DRUG$, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia.	0
DDI-DrugBank.d185.s0.p0	A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/SMX).	2
DDI-DrugBank.d185.s0.p1	A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/SMX).	2
DDI-DrugBank.d185.s0.p2	A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/SMX).	2
DDI-DrugBank.d185.s0.p3	A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/@DRUG$).	2
DDI-DrugBank.d185.s0.p4	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/@DRUG$ (TMP/SMX).	2
DDI-DrugBank.d185.s0.p5	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (@DRUG$/SMX).	0
DDI-DrugBank.d185.s0.p6	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/@DRUG$).	0
DDI-DrugBank.d185.s0.p7	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (@DRUG$/SMX).	2
DDI-DrugBank.d185.s0.p8	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/@DRUG$).	2
DDI-DrugBank.d185.s0.p9	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/@DRUG$).	0
DDI-DrugBank.d185.s1.p0	During co-administration, systemic levels of @DRUG$ and @DRUG$ were essentially unchanged.	0
DDI-DrugBank.d185.s2.p0	Notably, systemic exposure (AUC0-12) of @DRUG$ (@DRUG$) was more than doubled in the presence of TMP/SMX.	0
DDI-DrugBank.d185.s2.p1	Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of @DRUG$/SMX.	0
DDI-DrugBank.d185.s2.p2	Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of TMP/@DRUG$.	0
DDI-DrugBank.d185.s2.p3	Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of @DRUG$/SMX.	0
DDI-DrugBank.d185.s2.p4	Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of TMP/@DRUG$.	0
DDI-DrugBank.d185.s2.p5	Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of @DRUG$/@DRUG$.	0
DDI-DrugBank.d185.s3.p0	Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with @DRUG$/@DRUG$.	0
DDI-DrugBank.d185.s5.p0	John s wort) may increase the formation of @DRUG$, a metabolite of @DRUG$ associated with hemolysis.	0
DDI-DrugBank.d186.s0.p0	An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with @DRUG$ plus @DRUG$.	2
DDI-DrugBank.d186.s3.p0	As with other @DRUG$, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.	4
DDI-DrugBank.d186.s3.p1	As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, opiates, and alcohol.	4
DDI-DrugBank.d186.s3.p2	As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, opiates, and alcohol.	4
DDI-DrugBank.d186.s3.p3	As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, @DRUG$, and alcohol.	4
DDI-DrugBank.d186.s3.p4	As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and @DRUG$.	4
DDI-DrugBank.d186.s3.p5	As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating @DRUG$ such as anesthetics, opiates, and alcohol.	4
DDI-DrugBank.d186.s3.p6	As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as @DRUG$, opiates, and alcohol.	4
DDI-DrugBank.d186.s3.p7	As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, @DRUG$, and alcohol.	4
DDI-DrugBank.d186.s3.p8	As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, opiates, and @DRUG$.	4
DDI-DrugBank.d186.s3.p9	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as @DRUG$, opiates, and alcohol.	4
DDI-DrugBank.d186.s3.p10	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, @DRUG$, and alcohol.	4
DDI-DrugBank.d186.s3.p11	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, opiates, and @DRUG$.	4
DDI-DrugBank.d186.s3.p12	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, @DRUG$, and alcohol.	4
DDI-DrugBank.d186.s3.p13	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, opiates, and @DRUG$.	4
DDI-DrugBank.d186.s3.p14	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, @DRUG$, and @DRUG$.	4
DDI-DrugBank.d187.s10.p0	To avoid @DRUG$ intoxication, appropriate adjustment of the @DRUG$ should be made.	0
DDI-DrugBank.d187.s11.p0	Therophylline: A recent study has shown that concomitan administration of @DRUG$ and @DRUG$ may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.	0
DDI-DrugBank.d187.s11.p1	Therophylline: A recent study has shown that concomitan administration of @DRUG$ and theophylline may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of isoniazid.	0
DDI-DrugBank.d187.s11.p2	Therophylline: A recent study has shown that concomitan administration of @DRUG$ and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of @DRUG$.	0
DDI-DrugBank.d187.s11.p3	Therophylline: A recent study has shown that concomitan administration of isoniazid and @DRUG$ may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of isoniazid.	0
DDI-DrugBank.d187.s11.p4	Therophylline: A recent study has shown that concomitan administration of isoniazid and @DRUG$ may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of @DRUG$.	0
DDI-DrugBank.d187.s11.p5	Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of @DRUG$.	0
DDI-DrugBank.d187.s12.p0	Since the therapeutic range of @DRUG$ is narrow @DRUG$ serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.	0
DDI-DrugBank.d187.s12.p1	Since the therapeutic range of @DRUG$ is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of @DRUG$ should be made.	0
DDI-DrugBank.d187.s12.p2	Since the therapeutic range of theophylline is narrow @DRUG$ serum levels should be monitored closely, and appropriate dosage adjustments of @DRUG$ should be made.	0
DDI-DrugBank.d187.s14.p0	Plasma @DRUG$ concentration should be monitored when @DRUG$ and valproate are co administered, and appropriate dosage adjustments of valproate should be made.	0
DDI-DrugBank.d187.s14.p1	Plasma @DRUG$ concentration should be monitored when isoniazid and @DRUG$ are co administered, and appropriate dosage adjustments of valproate should be made.	0
DDI-DrugBank.d187.s14.p2	Plasma @DRUG$ concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of @DRUG$ should be made.	0
DDI-DrugBank.d187.s14.p3	Plasma valproate concentration should be monitored when @DRUG$ and @DRUG$ are co administered, and appropriate dosage adjustments of valproate should be made.	0
DDI-DrugBank.d187.s14.p4	Plasma valproate concentration should be monitored when @DRUG$ and valproate are co administered, and appropriate dosage adjustments of @DRUG$ should be made.	0
DDI-DrugBank.d187.s14.p5	Plasma valproate concentration should be monitored when isoniazid and @DRUG$ are co administered, and appropriate dosage adjustments of @DRUG$ should be made.	0
DDI-DrugBank.d187.s2.p0	@DRUG$: A report of severe @DRUG$ toxicity was reported in a patient receiving Isoniazid.	0
DDI-DrugBank.d187.s2.p1	@DRUG$: A report of severe acetaminophen toxicity was reported in a patient receiving @DRUG$.	0
DDI-DrugBank.d187.s2.p2	Acetaminophen: A report of severe @DRUG$ toxicity was reported in a patient receiving @DRUG$.	0
DDI-DrugBank.d187.s3.p0	It is believed that the toxicity may have resulted from a previously unrecognized interaction between @DRUG$ and @DRUG$ and a molecular basis for this interaction has been proposed.	0
DDI-DrugBank.d187.s5.p0	Furthermore it has been proposed that @DRUG$ resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested @DRUG$ being converted to the toxic metabolites.	0
DDI-DrugBank.d187.s7.p0	@DRUG$: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p1	@DRUG$: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p2	@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p3	@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p4	@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p5	@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	0
DDI-DrugBank.d187.s7.p6	Carbamazepine: @DRUG$ is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p7	Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p8	Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p9	Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p10	Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	0
DDI-DrugBank.d187.s7.p11	Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p12	Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p13	Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p14	Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	0
DDI-DrugBank.d187.s7.p15	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p16	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p17	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	0
DDI-DrugBank.d187.s7.p18	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	0
DDI-DrugBank.d187.s7.p19	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	0
DDI-DrugBank.d187.s7.p20	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	0
DDI-DrugBank.d188.s0.p0	Concurrent administration of @DRUG$ and @DRUG$ may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.	0
DDI-DrugBank.d188.s0.p1	Concurrent administration of @DRUG$ and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.	0
DDI-DrugBank.d188.s0.p2	Concurrent administration of @DRUG$ and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.	0
DDI-DrugBank.d188.s0.p3	Concurrent administration of HEXALEN and @DRUG$ may cause severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.	0
DDI-DrugBank.d188.s0.p4	Concurrent administration of HEXALEN and @DRUG$ may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.	0
DDI-DrugBank.d188.s0.p5	Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.	0
DDI-DrugBank.d188.s2.p0	however, it adversely affected response duration suggesting that @DRUG$ should not be administered with @DRUG$ and/or cisplatin.1	2
DDI-DrugBank.d188.s2.p1	however, it adversely affected response duration suggesting that @DRUG$ should not be administered with HEXALEN and/or @DRUG$.1	2
DDI-DrugBank.d188.s2.p2	however, it adversely affected response duration suggesting that pyridoxine should not be administered with @DRUG$ and/or @DRUG$.1	2
DDI-DrugBank.d189.s0.p0	No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p1	No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p2	No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p3	No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p4	No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p5	No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p6	No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p7	No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	0
DDI-DrugBank.d189.s0.p8	No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	0
DDI-DrugBank.d189.s0.p9	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p10	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p11	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p12	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p13	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p14	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p15	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	0
DDI-DrugBank.d189.s0.p16	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	0
DDI-DrugBank.d189.s0.p17	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p18	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p19	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p20	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p21	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p22	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	0
DDI-DrugBank.d189.s0.p23	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	0
DDI-DrugBank.d189.s0.p24	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p25	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p26	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p27	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p28	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	0
DDI-DrugBank.d189.s0.p29	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	0
DDI-DrugBank.d189.s0.p30	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p31	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p32	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p33	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	0
DDI-DrugBank.d189.s0.p34	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	0
DDI-DrugBank.d189.s0.p35	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, @DRUG$, carvedilol, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p36	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p37	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	0
DDI-DrugBank.d189.s0.p38	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	0
DDI-DrugBank.d189.s0.p39	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, @DRUG$, ethanol or itraconazole.	0
DDI-DrugBank.d189.s0.p40	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, @DRUG$ or itraconazole.	0
DDI-DrugBank.d189.s0.p41	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or @DRUG$.	0
DDI-DrugBank.d189.s0.p42	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, @DRUG$ or itraconazole.	0
DDI-DrugBank.d189.s0.p43	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or @DRUG$.	0
DDI-DrugBank.d189.s0.p44	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or @DRUG$.	0
DDI-DrugBank.d19.s1.p0	@DRUG$ SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING @DRUG$ AND ITS CONGENERS.	1
DDI-DrugBank.d19.s2.p0	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION, PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.	0
DDI-DrugBank.d19.s2.p1	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON @DRUG$ THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.	0
DDI-DrugBank.d19.s2.p2	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.	0
DDI-DrugBank.d19.s2.p3	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON @DRUG$ THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.	0
DDI-DrugBank.d19.s2.p4	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.	0
DDI-DrugBank.d19.s2.p5	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON @DRUG$ THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.	0
DDI-DrugBank.d19.s6.p0	It may be necessary to adjust the dosage of oral @DRUG$ upon beginning or stopping @DRUG$. since disulfiram may prolong prothrombin time.	0
DDI-DrugBank.d19.s6.p1	It may be necessary to adjust the dosage of oral @DRUG$ upon beginning or stopping disulfiram. since @DRUG$ may prolong prothrombin time.	0
DDI-DrugBank.d19.s6.p2	It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping @DRUG$. since @DRUG$ may prolong prothrombin time.	0
DDI-DrugBank.d19.s9.p0	In rats, simultaneous ingestion of @DRUG$ and @DRUG$ in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.	2
DDI-DrugBank.d19.s9.p1	In rats, simultaneous ingestion of @DRUG$ and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that @DRUG$ may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.	2
DDI-DrugBank.d19.s9.p2	In rats, simultaneous ingestion of @DRUG$ and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with @DRUG$ in the rat stomach to form a nitrosamine, which is tumorigenic.	2
DDI-DrugBank.d19.s9.p3	In rats, simultaneous ingestion of disulfiram and @DRUG$ in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that @DRUG$ may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.	2
DDI-DrugBank.d19.s9.p4	In rats, simultaneous ingestion of disulfiram and @DRUG$ in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with @DRUG$ in the rat stomach to form a nitrosamine, which is tumorigenic.	2
DDI-DrugBank.d19.s9.p5	In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that @DRUG$ may react with @DRUG$ in the rat stomach to form a nitrosamine, which is tumorigenic.	2
DDI-DrugBank.d190.s1.p0	However, since there is an increased risk of bleeding with @DRUG$, caution should be employed when @DRUG$ is used with other drugs that affect hemostasis.	0
DDI-DrugBank.d190.s4.p0	Drug/Laboratory Test Interaction Because @DRUG$ may affect the APTT assay, @DRUG$ present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).	0
DDI-DrugBank.d193.s1.p0	There was no evidence of any pharmacokinetic interactions between @DRUG$ and @DRUG$.	0
DDI-DrugBank.d194.s0.p0	Caution should be exercised when administering @DRUG$ with drugs that are known to inhibit phosphatase activities (e.g., @DRUG$).	0
DDI-DrugBank.d194.s1.p0	High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.	0
DDI-DrugBank.d194.s1.p1	High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.	0
DDI-DrugBank.d194.s1.p2	High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.	0
DDI-DrugBank.d194.s1.p3	High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to @DRUG$ alone.	0
DDI-DrugBank.d194.s1.p4	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.	0
DDI-DrugBank.d194.s1.p5	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.	0
DDI-DrugBank.d194.s1.p6	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to @DRUG$ alone.	0
DDI-DrugBank.d194.s1.p7	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.	0
DDI-DrugBank.d194.s1.p8	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of etoposide compared to @DRUG$ alone.	0
DDI-DrugBank.d194.s1.p9	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of @DRUG$ compared to @DRUG$ alone.	0
DDI-DrugBank.d195.s2.p0	@DRUG$ did not alter the pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d195.s3.p0	Although there have been no formal interaction studies other than with @DRUG$, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of @DRUG$ with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.	0
DDI-DrugBank.d195.s4.p0	An interaction study with @DRUG$ showed no clinically significant effect of @DRUG$ on warfarin pharmacokinetics or anticoagulant activity.	0
DDI-DrugBank.d195.s4.p1	An interaction study with @DRUG$ showed no clinically significant effect of anastrozole on @DRUG$ pharmacokinetics or anticoagulant activity.	0
DDI-DrugBank.d195.s4.p2	An interaction study with warfarin showed no clinically significant effect of @DRUG$ on @DRUG$ pharmacokinetics or anticoagulant activity.	0
DDI-DrugBank.d195.s5.p0	At a median follow-up of 33 months, the combination of @DRUG$ and @DRUG$ did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.	0
DDI-DrugBank.d195.s5.p1	At a median follow-up of 33 months, the combination of @DRUG$ and tamoxifen did not demonstrate any efficacy benefit when compared with @DRUG$ in all patients as well as in the hormone receptor-positive subpopulation.	0
DDI-DrugBank.d195.s5.p2	At a median follow-up of 33 months, the combination of ARIMIDEX and @DRUG$ did not demonstrate any efficacy benefit when compared with @DRUG$ in all patients as well as in the hormone receptor-positive subpopulation.	2
DDI-DrugBank.d195.s9.p0	@DRUG$-containing therapies should not be used with @DRUG$ as they may diminish its pharmacologic action.	4
DDI-DrugBank.d196.s0.p0	Treatment with @DRUG$ once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in @DRUG$ AUC.	0
DDI-DrugBank.d196.s1.p0	@DRUG$ serum levels should be monitored and appropriate dose adjustments considered for patients given both @DRUG$ and PEGASYS.	0
DDI-DrugBank.d196.s1.p1	@DRUG$ serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and @DRUG$.	0
DDI-DrugBank.d196.s1.p2	Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both @DRUG$ and @DRUG$.	0
DDI-DrugBank.d196.s10.p0	Use With @DRUG$ @DRUG$ is genotoxic and mutagenic.	4
DDI-DrugBank.d196.s29.p0	Pregnancy: Category X: Use With @DRUG$ (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to @DRUG$.	0
DDI-DrugBank.d196.s3.p0	In patients with chronic hepatitis C treated with @DRUG$ in combination with @DRUG$, PEGASYS treatment did not affect ribavirin distribution or clearance.	0
DDI-DrugBank.d196.s3.p1	In patients with chronic hepatitis C treated with @DRUG$ in combination with COPEGUS, @DRUG$ treatment did not affect ribavirin distribution or clearance.	0
DDI-DrugBank.d196.s3.p2	In patients with chronic hepatitis C treated with @DRUG$ in combination with COPEGUS, PEGASYS treatment did not affect @DRUG$ distribution or clearance.	0
DDI-DrugBank.d196.s3.p3	In patients with chronic hepatitis C treated with PEGASYS in combination with @DRUG$, @DRUG$ treatment did not affect ribavirin distribution or clearance.	0
DDI-DrugBank.d196.s3.p4	In patients with chronic hepatitis C treated with PEGASYS in combination with @DRUG$, PEGASYS treatment did not affect @DRUG$ distribution or clearance.	0
DDI-DrugBank.d196.s3.p5	In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS, @DRUG$ treatment did not affect @DRUG$ distribution or clearance.	0
DDI-DrugBank.d196.s32.p0	Nursing Mothers It is not known whether @DRUG$ or @DRUG$ or its components are excreted in human milk.	2
DDI-DrugBank.d196.s33.p0	The effect of orally ingested @DRUG$ or @DRUG$ from breast milk on the nursing infant has not been evaluated.	2
DDI-DrugBank.d196.s34.p0	Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue @DRUG$ and @DRUG$ treatment.	2
DDI-DrugBank.d196.s35.p0	Pediatric Use The safety and effectiveness of @DRUG$, alone or in combination with @DRUG$ in patients below the age of 18 years have not been established.	4
DDI-DrugBank.d196.s39.p0	Clinical studies of @DRUG$ alone or in combination with @DRUG$ did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.	0
DDI-DrugBank.d196.s40.p0	Adverse reactions related to @DRUG$s, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of @DRUG$ in this population.	0
DDI-DrugBank.d196.s6.p0	@DRUG$ and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.	2
DDI-DrugBank.d196.s6.p1	@DRUG$ and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.	2
DDI-DrugBank.d196.s6.p2	@DRUG$ and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.	2
DDI-DrugBank.d196.s6.p3	@DRUG$ and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV.	2
DDI-DrugBank.d196.s6.p4	Stavudine and @DRUG$ @DRUG$ can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.	2
DDI-DrugBank.d196.s6.p5	Stavudine and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.	2
DDI-DrugBank.d196.s6.p6	Stavudine and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV.	2
DDI-DrugBank.d196.s6.p7	Stavudine and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.	2
DDI-DrugBank.d196.s6.p8	Stavudine and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV.	2
DDI-DrugBank.d196.s6.p9	Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and @DRUG$ against HIV.	2
DDI-DrugBank.d197.s2.p0	Specific studies have confirmed these effects with @DRUG$, @DRUG$, propofol, alfentanil, and midazolam.	2
DDI-DrugBank.d197.s2.p1	Specific studies have confirmed these effects with @DRUG$, isoflurane, @DRUG$, alfentanil, and midazolam.	2
DDI-DrugBank.d197.s2.p2	Specific studies have confirmed these effects with @DRUG$, isoflurane, propofol, @DRUG$, and midazolam.	2
DDI-DrugBank.d197.s2.p3	Specific studies have confirmed these effects with @DRUG$, isoflurane, propofol, alfentanil, and @DRUG$.	2
DDI-DrugBank.d197.s2.p4	Specific studies have confirmed these effects with sevoflurane, @DRUG$, @DRUG$, alfentanil, and midazolam.	0
DDI-DrugBank.d197.s2.p5	Specific studies have confirmed these effects with sevoflurane, @DRUG$, propofol, @DRUG$, and midazolam.	2
DDI-DrugBank.d197.s2.p6	Specific studies have confirmed these effects with sevoflurane, @DRUG$, propofol, alfentanil, and @DRUG$.	2
DDI-DrugBank.d197.s2.p7	Specific studies have confirmed these effects with sevoflurane, isoflurane, @DRUG$, @DRUG$, and midazolam.	2
DDI-DrugBank.d197.s2.p8	Specific studies have confirmed these effects with sevoflurane, isoflurane, @DRUG$, alfentanil, and @DRUG$.	2
DDI-DrugBank.d197.s2.p9	Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, @DRUG$, and @DRUG$.	2
DDI-DrugBank.d197.s3.p0	No pharmacokinetic interactions between @DRUG$ and @DRUG$, propofol, alfentanil, and midazolam have been demonstrated.	0
DDI-DrugBank.d197.s3.p1	No pharmacokinetic interactions between @DRUG$ and isoflurane, @DRUG$, alfentanil, and midazolam have been demonstrated.	0
DDI-DrugBank.d197.s3.p2	No pharmacokinetic interactions between @DRUG$ and isoflurane, propofol, @DRUG$, and midazolam have been demonstrated.	0
DDI-DrugBank.d197.s3.p3	No pharmacokinetic interactions between @DRUG$ and isoflurane, propofol, alfentanil, and @DRUG$ have been demonstrated.	0
DDI-DrugBank.d197.s3.p4	No pharmacokinetic interactions between dexmedetomidine and @DRUG$, @DRUG$, alfentanil, and midazolam have been demonstrated.	0
DDI-DrugBank.d197.s3.p5	No pharmacokinetic interactions between dexmedetomidine and @DRUG$, propofol, @DRUG$, and midazolam have been demonstrated.	0
DDI-DrugBank.d197.s3.p6	No pharmacokinetic interactions between dexmedetomidine and @DRUG$, propofol, alfentanil, and @DRUG$ have been demonstrated.	1
DDI-DrugBank.d197.s3.p7	No pharmacokinetic interactions between dexmedetomidine and isoflurane, @DRUG$, @DRUG$, and midazolam have been demonstrated.	0
DDI-DrugBank.d197.s3.p8	No pharmacokinetic interactions between dexmedetomidine and isoflurane, @DRUG$, alfentanil, and @DRUG$ have been demonstrated.	0
DDI-DrugBank.d197.s3.p9	No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, @DRUG$, and @DRUG$ have been demonstrated.	0
DDI-DrugBank.d198.s10.p0	@DRUG$: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p1	@DRUG$: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p2	@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p3	@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p4	@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	0
DDI-DrugBank.d198.s10.p5	HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p6	HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p7	HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p8	HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	0
DDI-DrugBank.d198.s10.p9	HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p10	HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p11	HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	0
DDI-DrugBank.d198.s10.p12	HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	0
DDI-DrugBank.d198.s10.p13	HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	0
DDI-DrugBank.d198.s10.p14	HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in @DRUG$ half-life.	0
DDI-DrugBank.d198.s11.p0	It is recommended not to exceed a single 2.5 mg @DRUG$ dose in a 24-hour period when used in combination with @DRUG$.	0
DDI-DrugBank.d198.s12.p0	@DRUG$ (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.	0
DDI-DrugBank.d198.s12.p1	@DRUG$ (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in vardenafil Cmax.	0
DDI-DrugBank.d198.s12.p2	@DRUG$ (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in @DRUG$ Cmax.	0
DDI-DrugBank.d198.s12.p3	Ritonavir (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in vardenafil Cmax.	0
DDI-DrugBank.d198.s12.p4	Ritonavir (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in @DRUG$ Cmax.	0
DDI-DrugBank.d198.s12.p5	Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in @DRUG$ Cmax.	0
DDI-DrugBank.d198.s13.p0	The interaction is a consequence of blocking hepatic metabolism of @DRUG$ by @DRUG$, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.	0
DDI-DrugBank.d198.s16.p0	Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: @DRUG$, warfarin, digoxin, Maalox, and ranitidine.	0
DDI-DrugBank.d198.s16.p1	Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, @DRUG$, digoxin, Maalox, and ranitidine.	0
DDI-DrugBank.d198.s16.p2	Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, warfarin, @DRUG$, Maalox, and ranitidine.	0
DDI-DrugBank.d198.s16.p3	Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, warfarin, digoxin, @DRUG$, and ranitidine.	0
DDI-DrugBank.d198.s16.p4	Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, warfarin, digoxin, Maalox, and @DRUG$.	0
DDI-DrugBank.d198.s16.p5	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, @DRUG$, digoxin, Maalox, and ranitidine.	0
DDI-DrugBank.d198.s16.p6	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, @DRUG$, Maalox, and ranitidine.	0
DDI-DrugBank.d198.s16.p7	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, digoxin, @DRUG$, and ranitidine.	0
DDI-DrugBank.d198.s16.p8	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, digoxin, Maalox, and @DRUG$.	0
DDI-DrugBank.d198.s16.p9	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, @DRUG$, @DRUG$, Maalox, and ranitidine.	0
DDI-DrugBank.d198.s16.p10	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, @DRUG$, digoxin, @DRUG$, and ranitidine.	0
DDI-DrugBank.d198.s16.p11	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, @DRUG$, digoxin, Maalox, and @DRUG$.	0
DDI-DrugBank.d198.s16.p12	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, @DRUG$, @DRUG$, and ranitidine.	0
DDI-DrugBank.d198.s16.p13	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, @DRUG$, Maalox, and @DRUG$.	0
DDI-DrugBank.d198.s16.p14	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d198.s17.p0	In the @DRUG$ study, @DRUG$ had no effect on the prothrombin time or other pharmacodynamic parameters.	0
DDI-DrugBank.d198.s23.p0	These effects were not observed when @DRUG$ 20 mg was taken 24 hours before the @DRUG$.	4
DDI-DrugBank.d198.s25.p0	@DRUG$: @DRUG$ 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.	0
DDI-DrugBank.d198.s25.p1	@DRUG$: Vardenafil 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.	0
DDI-DrugBank.d198.s25.p2	@DRUG$: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.	0
DDI-DrugBank.d198.s25.p3	Nifedipine: @DRUG$ 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.	0
DDI-DrugBank.d198.s25.p4	Nifedipine: @DRUG$ 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.	0
DDI-DrugBank.d198.s25.p5	Nifedipine: Vardenafil 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.	0
DDI-DrugBank.d198.s26.p0	@DRUG$ did not alter the plasma levels of @DRUG$ when taken in combination.	0
DDI-DrugBank.d198.s27.p0	In these patients whose hypertension was controlled with @DRUG$, @DRUG$ 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.	0
DDI-DrugBank.d198.s28.p0	@DRUG$: When @DRUG$ 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.	0
DDI-DrugBank.d198.s28.p1	@DRUG$: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of @DRUG$, significant hypotension developed in a substantial number of subjects.	0
DDI-DrugBank.d198.s28.p2	Alpha-blockers: When @DRUG$ 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of @DRUG$, significant hypotension developed in a substantial number of subjects.	0
DDI-DrugBank.d198.s29.p0	With simultaneous dosing of @DRUG$ 10 mg and @DRUG$ 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.	2
DDI-DrugBank.d198.s30.p0	With simultaneous dosing of @DRUG$ 20 mg and @DRUG$ 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.	2
DDI-DrugBank.d198.s32.p0	In a similar study with @DRUG$ in healthy volunteers, 1 of 24 subjects dosed with @DRUG$ 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.	0
DDI-DrugBank.d198.s32.p1	In a similar study with @DRUG$ in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and @DRUG$ 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.	0
DDI-DrugBank.d198.s32.p2	In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with @DRUG$ 20 mg and @DRUG$ 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.	0
DDI-DrugBank.d198.s33.p0	Two of 16 subjects dosed simultaneously with @DRUG$ 10 mg and @DRUG$ 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.	0
DDI-DrugBank.d198.s35.p0	Based on these data, @DRUG$ should not be used in patients on @DRUG$ therapy.	0
DDI-DrugBank.d198.s36.p0	@DRUG$ and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.	0
DDI-DrugBank.d198.s36.p1	@DRUG$ and indinavir: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.	0
DDI-DrugBank.d198.s36.p2	@DRUG$ and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$, the Cmax and AUC of ritonavir were reduced by approximately 20%.	0
DDI-DrugBank.d198.s36.p3	@DRUG$ and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	0
DDI-DrugBank.d198.s36.p4	Ritonavir and @DRUG$: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.	0
DDI-DrugBank.d198.s36.p5	Ritonavir and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$, the Cmax and AUC of ritonavir were reduced by approximately 20%.	0
DDI-DrugBank.d198.s36.p6	Ritonavir and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	0
DDI-DrugBank.d198.s36.p7	Ritonavir and indinavir: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID @DRUG$, the Cmax and AUC of ritonavir were reduced by approximately 20%.	0
DDI-DrugBank.d198.s36.p8	Ritonavir and indinavir: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	0
DDI-DrugBank.d198.s36.p9	Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	0
DDI-DrugBank.d198.s38.p0	@DRUG$: @DRUG$ (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.	0
DDI-DrugBank.d198.s38.p1	@DRUG$: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and @DRUG$ plasma levels were not altered when dosed simultaneously.	0
DDI-DrugBank.d198.s38.p2	Alcohol: @DRUG$ (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and @DRUG$ plasma levels were not altered when dosed simultaneously.	0
DDI-DrugBank.d198.s39.p0	@DRUG$ (20 mg) did not potentiate the hypotensive effects of @DRUG$ during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).	0
DDI-DrugBank.d198.s39.p1	@DRUG$ (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with @DRUG$ (0.5 g/kg body weight).	0
DDI-DrugBank.d198.s39.p2	Vardenafil (20 mg) did not potentiate the hypotensive effects of @DRUG$ during the 4-hour observation period in healthy volunteers when administered with @DRUG$ (0.5 g/kg body weight).	0
DDI-DrugBank.d198.s4.p0	@DRUG$ (400 mg b.i.d.) had no effect on @DRUG$ bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.	0
DDI-DrugBank.d198.s4.p1	@DRUG$ (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg Vardenafil in healthy volunteers.	0
DDI-DrugBank.d198.s4.p2	@DRUG$ (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg @DRUG$ in healthy volunteers.	0
DDI-DrugBank.d198.s4.p3	Cimetidine (400 mg b.i.d.) had no effect on @DRUG$ bioavailability (AUC) and maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg Vardenafil in healthy volunteers.	0
DDI-DrugBank.d198.s4.p4	Cimetidine (400 mg b.i.d.) had no effect on @DRUG$ bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg @DRUG$ in healthy volunteers.	0
DDI-DrugBank.d198.s4.p5	Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg @DRUG$ in healthy volunteers.	0
DDI-DrugBank.d198.s40.p0	@DRUG$: @DRUG$ (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).	0
DDI-DrugBank.d198.s40.p1	@DRUG$: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by @DRUG$ (two 81 mg tablets).	0
DDI-DrugBank.d198.s40.p2	Aspirin: @DRUG$ (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by @DRUG$ (two 81 mg tablets).	0
DDI-DrugBank.d198.s41.p0	Other interactions: @DRUG$ had no effect on the pharmacodynamics of @DRUG$ (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).	0
DDI-DrugBank.d198.s41.p1	Other interactions: @DRUG$ had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and @DRUG$ (prothrombin time or other pharmacodynamic parameters).	0
DDI-DrugBank.d198.s41.p2	Other interactions: Vardenafil had no effect on the pharmacodynamics of @DRUG$ (glucose and insulin concentrations) and @DRUG$ (prothrombin time or other pharmacodynamic parameters).	0
DDI-DrugBank.d198.s6.p0	It is recommended not to exceed a single 5 mg dose of @DRUG$ in a 24-hour period when used in combination with @DRUG$.	0
DDI-DrugBank.d198.s7.p0	@DRUG$ (200 mg once daily) produced a 10-fold increase in @DRUG$ AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.	0
DDI-DrugBank.d198.s7.p1	@DRUG$ (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with @DRUG$ (5 mg) in healthy volunteers.	0
DDI-DrugBank.d198.s7.p2	Ketoconazole (200 mg once daily) produced a 10-fold increase in @DRUG$ AUC and a 4-fold increase in Cmax when co-administered with @DRUG$ (5 mg) in healthy volunteers.	0
DDI-DrugBank.d198.s8.p0	A 5-mg @DRUG$ dose should not be exceeded when used in combination with 200 mg once daily @DRUG$.	0
DDI-DrugBank.d198.s9.p0	Since higher doses of @DRUG$ (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of @DRUG$ should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.	0
DDI-DrugBank.d198.s9.p1	Since higher doses of @DRUG$ (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with @DRUG$ 400 mg daily.	0
DDI-DrugBank.d198.s9.p2	Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of @DRUG$ should not be exceeded in a 24-hour period when used in combination with @DRUG$ 400 mg daily.	0
DDI-DrugBank.d2.s0.p0	@DRUG$ may augment the activity of other @DRUG$.	3
DDI-DrugBank.d20.s10.p0	@DRUG$ (@DRUG$)-A drug interaction study of eplerenone with an NSAID has not been conducted.	0
DDI-DrugBank.d20.s10.p1	@DRUG$ (NSAIDs)-A drug interaction study of @DRUG$ with an NSAID has not been conducted.	0
DDI-DrugBank.d20.s10.p2	@DRUG$ (NSAIDs)-A drug interaction study of eplerenone with an @DRUG$ has not been conducted.	0
DDI-DrugBank.d20.s10.p3	Nonsteroidal Anti-Inflammatory Drugs (@DRUG$)-A drug interaction study of @DRUG$ with an NSAID has not been conducted.	3
DDI-DrugBank.d20.s10.p4	Nonsteroidal Anti-Inflammatory Drugs (@DRUG$)-A drug interaction study of eplerenone with an @DRUG$ has not been conducted.	3
DDI-DrugBank.d20.s10.p5	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of @DRUG$ with an @DRUG$ has not been conducted.	3
DDI-DrugBank.d20.s11.p0	The administration of other @DRUG$ with @DRUG$ has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.	0
DDI-DrugBank.d20.s4.p0	@DRUG$ and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).	2
DDI-DrugBank.d20.s4.p1	@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).	2
DDI-DrugBank.d20.s4.p2	@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).	2
DDI-DrugBank.d20.s4.p3	@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).	2
DDI-DrugBank.d20.s4.p4	@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).	2
DDI-DrugBank.d20.s4.p5	@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/@DRUG$).	2
DDI-DrugBank.d20.s4.p6	ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).	0
DDI-DrugBank.d20.s4.p7	ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).	2
DDI-DrugBank.d20.s4.p8	ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).	0
DDI-DrugBank.d20.s4.p9	ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).	0
DDI-DrugBank.d20.s4.p10	ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/@DRUG$).	0
DDI-DrugBank.d20.s4.p11	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).	2
DDI-DrugBank.d20.s4.p12	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).	0
DDI-DrugBank.d20.s4.p13	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).	0
DDI-DrugBank.d20.s4.p14	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/@DRUG$).	0
DDI-DrugBank.d20.s4.p15	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or @DRUG$ (ACEI/ARB).	2
DDI-DrugBank.d20.s4.p16	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (@DRUG$/ARB).	2
DDI-DrugBank.d20.s4.p17	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/@DRUG$).	2
DDI-DrugBank.d20.s4.p18	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (@DRUG$/ARB).	0
DDI-DrugBank.d20.s4.p19	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/@DRUG$).	0
DDI-DrugBank.d20.s4.p20	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/@DRUG$).	0
DDI-DrugBank.d20.s6.p0	@DRUG$ and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s6.p1	@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s6.p2	@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s6.p3	@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s6.p4	ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s6.p5	ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s6.p6	ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s6.p7	ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s6.p8	ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s6.p9	ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	0
DDI-DrugBank.d20.s8.p0	@DRUG$-A drug interaction study of @DRUG$ with lithium has not been conducted.	0
DDI-DrugBank.d20.s8.p1	@DRUG$-A drug interaction study of eplerenone with @DRUG$ has not been conducted.	0
DDI-DrugBank.d20.s8.p2	Lithium-A drug interaction study of @DRUG$ with @DRUG$ has not been conducted.	0
DDI-DrugBank.d20.s9.p0	Serum @DRUG$ levels should be monitored frequently if @DRUG$ is administered concomitantly with lithium.	0
DDI-DrugBank.d20.s9.p1	Serum @DRUG$ levels should be monitored frequently if INSPRA is administered concomitantly with @DRUG$.	0
DDI-DrugBank.d20.s9.p2	Serum lithium levels should be monitored frequently if @DRUG$ is administered concomitantly with @DRUG$.	0
DDI-DrugBank.d200.s0.p0	Co-administration of @DRUG$ with @DRUG$ has been shown to increase the mean half-life and the area under the concentration-time curve.	0
DDI-DrugBank.d202.s0.p0	Steady-state serum concentrations of @DRUG$ are reported to fluctuate significantly when @DRUG$ is either added or deleted from the drug regimen.	0
DDI-DrugBank.d202.s1.p0	Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of @DRUG$ when @DRUG$ is added to the drug regimen.	2
DDI-DrugBank.d202.s14.p0	In addition, certain drugs that are metabolized by this isoenzyme, including many @DRUG$ (@DRUG$, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.	3
DDI-DrugBank.d202.s14.p1	In addition, certain drugs that are metabolized by this isoenzyme, including many @DRUG$ (tricyclic antidepressants, @DRUG$, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.	3
DDI-DrugBank.d202.s14.p2	In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (@DRUG$, @DRUG$, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.	3
DDI-DrugBank.d202.s2.p0	In addition, higher-than expected steady-state serum concentrations of @DRUG$ have been observed when therapy is initiated in patients already taking @DRUG$.	0
DDI-DrugBank.d202.s3.p0	In well-controlled patients undergoing concurrent therapy with @DRUG$, a decrease in the steady-state serum concentrations of @DRUG$ may occur when cime-tidine therapy is discontinued.	0
DDI-DrugBank.d202.s6.p0	There have been greater than 2-fold increases in previously stable plasma levels of other @DRUG$, including @DRUG$, when fluoxetine hydrochloride has been administered in combination with these agents.	0
DDI-DrugBank.d202.s6.p1	There have been greater than 2-fold increases in previously stable plasma levels of other @DRUG$, including nortriptyline, when @DRUG$ has been administered in combination with these agents.	0
DDI-DrugBank.d202.s6.p2	There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including @DRUG$, when @DRUG$ has been administered in combination with these agents.	0
DDI-DrugBank.d202.s7.p0	@DRUG$ and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for @DRUG$), that may affect strategies during conversion from one drug to the other.	0
DDI-DrugBank.d202.s8.p0	Administration of @DRUG$ during therapy with a @DRUG$ has been shown to produce a  stimulating  effect in some depressed patients.	0
DDI-DrugBank.d202.s9.p0	Close supervision and careful adjustment of the dosage are required when @DRUG$ is used with other @DRUG$ or sympathomimetic drugs.	0
DDI-DrugBank.d202.s9.p1	Close supervision and careful adjustment of the dosage are required when @DRUG$ is used with other anticholinergic drugs or @DRUG$.	0
DDI-DrugBank.d202.s9.p2	Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other @DRUG$ or @DRUG$.	4
DDI-DrugBank.d203.s2.p0	Compounds tested in man include @DRUG$, @DRUG$, phenytoin, diazepam, aminopyrine and antipyrine.	3
DDI-DrugBank.d203.s2.p1	Compounds tested in man include @DRUG$, theophylline, @DRUG$, diazepam, aminopyrine and antipyrine.	3
DDI-DrugBank.d203.s2.p2	Compounds tested in man include @DRUG$, theophylline, phenytoin, @DRUG$, aminopyrine and antipyrine.	3
DDI-DrugBank.d203.s2.p3	Compounds tested in man include @DRUG$, theophylline, phenytoin, diazepam, @DRUG$ and antipyrine.	3
DDI-DrugBank.d203.s2.p4	Compounds tested in man include @DRUG$, theophylline, phenytoin, diazepam, aminopyrine and @DRUG$.	3
DDI-DrugBank.d203.s2.p5	Compounds tested in man include warfarin, @DRUG$, @DRUG$, diazepam, aminopyrine and antipyrine.	3
DDI-DrugBank.d203.s2.p6	Compounds tested in man include warfarin, @DRUG$, phenytoin, @DRUG$, aminopyrine and antipyrine.	3
DDI-DrugBank.d203.s2.p7	Compounds tested in man include warfarin, @DRUG$, phenytoin, diazepam, @DRUG$ and antipyrine.	3
DDI-DrugBank.d203.s2.p8	Compounds tested in man include warfarin, @DRUG$, phenytoin, diazepam, aminopyrine and @DRUG$.	3
DDI-DrugBank.d203.s2.p9	Compounds tested in man include warfarin, theophylline, @DRUG$, @DRUG$, aminopyrine and antipyrine.	3
DDI-DrugBank.d203.s2.p10	Compounds tested in man include warfarin, theophylline, @DRUG$, diazepam, @DRUG$ and antipyrine.	3
DDI-DrugBank.d203.s2.p11	Compounds tested in man include warfarin, theophylline, @DRUG$, diazepam, aminopyrine and @DRUG$.	3
DDI-DrugBank.d203.s2.p12	Compounds tested in man include warfarin, theophylline, phenytoin, @DRUG$, @DRUG$ and antipyrine.	3
DDI-DrugBank.d203.s2.p13	Compounds tested in man include warfarin, theophylline, phenytoin, @DRUG$, aminopyrine and @DRUG$.	3
DDI-DrugBank.d203.s2.p14	Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, @DRUG$ and @DRUG$.	3
DDI-DrugBank.d207.s2.p0	International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking @DRUG$ while on @DRUG$ therapy.	0
DDI-DrugBank.d207.s4.p0	Substances that are potent inhibitors of CYP3A4 activity (eg, @DRUG$ and @DRUG$) decrease gefitinib metabolism and increase gefitinib plasma concentrations.	0
DDI-DrugBank.d207.s4.p1	Substances that are potent inhibitors of CYP3A4 activity (eg, @DRUG$ and itraconazole) decrease @DRUG$ metabolism and increase gefitinib plasma concentrations.	0
DDI-DrugBank.d207.s4.p2	Substances that are potent inhibitors of CYP3A4 activity (eg, @DRUG$ and itraconazole) decrease gefitinib metabolism and increase @DRUG$ plasma concentrations.	0
DDI-DrugBank.d207.s4.p3	Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and @DRUG$) decrease @DRUG$ metabolism and increase gefitinib plasma concentrations.	0
DDI-DrugBank.d207.s4.p4	Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and @DRUG$) decrease gefitinib metabolism and increase @DRUG$ plasma concentrations.	0
DDI-DrugBank.d207.s4.p5	Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease @DRUG$ metabolism and increase @DRUG$ plasma concentrations.	0
DDI-DrugBank.d207.s7.p0	Drugs that cause significant sustained elevation in gastric pH (@DRUG$ such as @DRUG$ or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.	4
DDI-DrugBank.d207.s7.p1	Drugs that cause significant sustained elevation in gastric pH (@DRUG$ such as ranitidine or @DRUG$) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.	4
DDI-DrugBank.d207.s7.p2	Drugs that cause significant sustained elevation in gastric pH (@DRUG$ such as ranitidine or cimetidine) may reduce plasma concentrations of @DRUG$ and therefore potentially may reduce efficacy.	0
DDI-DrugBank.d207.s7.p3	Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as @DRUG$ or @DRUG$) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.	0
DDI-DrugBank.d207.s7.p4	Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as @DRUG$ or cimetidine) may reduce plasma concentrations of @DRUG$ and therefore potentially may reduce efficacy.	0
DDI-DrugBank.d207.s7.p5	Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or @DRUG$) may reduce plasma concentrations of @DRUG$ and therefore potentially may reduce efficacy.	0
DDI-DrugBank.d208.s0.p0	@DRUG$ may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p1	@DRUG$ may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p2	@DRUG$ may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p3	@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p4	@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p5	@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p6	@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	3
DDI-DrugBank.d208.s0.p7	@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	3
DDI-DrugBank.d208.s0.p8	Benzthiazide may interact with @DRUG$, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p9	Benzthiazide may interact with @DRUG$, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p10	Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p11	Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p12	Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p13	Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p14	Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p15	Benzthiazide may interact with alcohol, @DRUG$s, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p16	Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p17	Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p18	Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p19	Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p20	Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p21	Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p22	Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p23	Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p24	Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p25	Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p26	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p27	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p28	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p29	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p30	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p31	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p32	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	2
DDI-DrugBank.d208.s0.p33	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like @DRUG$ or Ibuprofen, and high blood pressure medications.	3
DDI-DrugBank.d208.s0.p34	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or @DRUG$, and high blood pressure medications.	3
DDI-DrugBank.d208.s0.p35	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or @DRUG$, and high blood pressure medications.	3
DDI-DrugBank.d209.s2.p0	Compounds that have been tested in man include @DRUG$, @DRUG$, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.	3
DDI-DrugBank.d209.s2.p1	Compounds that have been tested in man include @DRUG$, digoxin, @DRUG$, theophylline, and warfarin and no clinically meaningful interactions were found.	0
DDI-DrugBank.d209.s2.p2	Compounds that have been tested in man include @DRUG$, digoxin, propranolol, @DRUG$, and warfarin and no clinically meaningful interactions were found.	0
DDI-DrugBank.d209.s2.p3	Compounds that have been tested in man include @DRUG$, digoxin, propranolol, theophylline, and @DRUG$ and no clinically meaningful interactions were found.	3
DDI-DrugBank.d209.s2.p4	Compounds that have been tested in man include antipyrine, @DRUG$, @DRUG$, theophylline, and warfarin and no clinically meaningful interactions were found.	3
DDI-DrugBank.d209.s2.p5	Compounds that have been tested in man include antipyrine, @DRUG$, propranolol, @DRUG$, and warfarin and no clinically meaningful interactions were found.	3
DDI-DrugBank.d209.s2.p6	Compounds that have been tested in man include antipyrine, @DRUG$, propranolol, theophylline, and @DRUG$ and no clinically meaningful interactions were found.	3
DDI-DrugBank.d209.s2.p7	Compounds that have been tested in man include antipyrine, digoxin, @DRUG$, @DRUG$, and warfarin and no clinically meaningful interactions were found.	0
DDI-DrugBank.d209.s2.p8	Compounds that have been tested in man include antipyrine, digoxin, @DRUG$, theophylline, and @DRUG$ and no clinically meaningful interactions were found.	0
DDI-DrugBank.d209.s2.p9	Compounds that have been tested in man include antipyrine, digoxin, propranolol, @DRUG$, and @DRUG$ and no clinically meaningful interactions were found.	3
DDI-DrugBank.d209.s3.p0	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p1	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p2	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p3	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p4	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p5	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p6	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p7	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p8	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p9	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p10	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p11	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p12	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p13	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p14	Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p15	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p16	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p17	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p18	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p19	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p20	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p21	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p22	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p23	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p24	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p25	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p26	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p27	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p28	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p29	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p30	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p31	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p32	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p33	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p34	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p35	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p36	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p37	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p38	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p39	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p40	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p41	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p42	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p43	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p44	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p45	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p46	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p47	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p48	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p49	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p50	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p51	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p52	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p53	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p54	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p55	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p56	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p57	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p58	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p59	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p60	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p61	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p62	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p63	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p64	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p65	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p66	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p67	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p68	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p69	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p70	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p71	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p72	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p73	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p74	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p75	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p76	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p77	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p78	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p79	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p80	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p81	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p82	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p83	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p84	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p85	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p86	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p87	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p88	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p89	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p90	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p91	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p92	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p93	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p94	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p95	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p96	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p97	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p98	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p99	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p100	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p101	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p102	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p103	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p104	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p105	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p106	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p107	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p108	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p109	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p110	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p111	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p112	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p113	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p114	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p115	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p116	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p117	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p118	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s3.p119	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and @DRUG$ without evidence of clinically significant adverse interactions.	0
DDI-DrugBank.d209.s7.p0	In clinical studies with @DRUG$ (@DRUG$, 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.	2
DDI-DrugBank.d209.s8.p0	Further, in clinical studies with @DRUG$ (@DRUG$, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.	0
DDI-DrugBank.d21.s1.p0	These results would seem to dictate against the clinical use of @DRUG$ with @DRUG$, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.	0
DDI-DrugBank.d21.s1.p1	These results would seem to dictate against the clinical use of @DRUG$ with ELSPAR, or during the period following @DRUG$ therapy when plasma asparagine levels are below normal.	0
DDI-DrugBank.d21.s1.p2	These results would seem to dictate against the clinical use of methotrexate with @DRUG$, or during the period following @DRUG$ therapy when plasma asparagine levels are below normal.	0
DDI-DrugBank.d210.s0.p0	@DRUG$: Reports suggest that @DRUG$ may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.	0
DDI-DrugBank.d210.s0.p1	@DRUG$: Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	0
DDI-DrugBank.d210.s0.p2	ACE inhibitors: Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	0
DDI-DrugBank.d210.s1.p0	In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the @DRUG$ benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.	0
DDI-DrugBank.d210.s1.p1	In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the ACE inhibitor @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.	0
DDI-DrugBank.d210.s1.p2	In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.	0
DDI-DrugBank.d210.s1.p3	In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the @DRUG$ @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.	0
DDI-DrugBank.d210.s1.p4	In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the @DRUG$ benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.	0
DDI-DrugBank.d210.s1.p5	In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.	0
DDI-DrugBank.d210.s12.p0	@DRUG$: @DRUG$ 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.	0
DDI-DrugBank.d210.s12.p1	@DRUG$: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of @DRUG$ after a single 0.5 mg oral dose.	0
DDI-DrugBank.d210.s12.p2	Digoxin: @DRUG$ 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of @DRUG$ after a single 0.5 mg oral dose.	0
DDI-DrugBank.d210.s16.p0	@DRUG$: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	3
DDI-DrugBank.d210.s16.p1	@DRUG$: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	0
DDI-DrugBank.d210.s16.p2	@DRUG$: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	0
DDI-DrugBank.d210.s16.p3	Lithium: @DRUG$ have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	3
DDI-DrugBank.d210.s16.p4	Lithium: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	3
DDI-DrugBank.d210.s16.p5	Lithium: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance.	0
DDI-DrugBank.d210.s2.p0	This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	4
DDI-DrugBank.d210.s20.p0	At higher than recommended doses, @DRUG$ 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving @DRUG$ 7.5 to 15 mg/week for rheumatoid arthritis.	0
DDI-DrugBank.d210.s22.p0	Standard monitoring of @DRUG$-related toxicity should be continued if @DRUG$ and methotrexate are administered concomitantly.	0
DDI-DrugBank.d210.s22.p1	Standard monitoring of @DRUG$-related toxicity should be continued if VIOXX and @DRUG$ are administered concomitantly.	0
DDI-DrugBank.d210.s22.p2	Standard monitoring of methotrexate-related toxicity should be continued if @DRUG$ and @DRUG$ are administered concomitantly.	0
DDI-DrugBank.d210.s24.p0	@DRUG$/@DRUG$: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.	0
DDI-DrugBank.d210.s24.p1	@DRUG$/prednisolone: @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.	0
DDI-DrugBank.d210.s24.p2	@DRUG$/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.	0
DDI-DrugBank.d210.s24.p3	@DRUG$/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	0
DDI-DrugBank.d210.s24.p4	Prednisone/@DRUG$: @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.	0
DDI-DrugBank.d210.s24.p5	Prednisone/@DRUG$: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.	0
DDI-DrugBank.d210.s24.p6	Prednisone/@DRUG$: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	0
DDI-DrugBank.d210.s24.p7	Prednisone/prednisolone: @DRUG$ did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.	0
DDI-DrugBank.d210.s24.p8	Prednisone/prednisolone: @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	0
DDI-DrugBank.d210.s24.p9	Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or @DRUG$.	0
DDI-DrugBank.d210.s25.p0	@DRUG$: Co-administration of @DRUG$ with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.	0
DDI-DrugBank.d210.s25.p1	@DRUG$: Co-administration of VIOXX with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.	0
DDI-DrugBank.d210.s25.p2	@DRUG$: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in @DRUG$ plasma concentrations.	0
DDI-DrugBank.d210.s25.p3	Rifampin: Co-administration of @DRUG$ with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.	0
DDI-DrugBank.d210.s25.p4	Rifampin: Co-administration of @DRUG$ with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in @DRUG$ plasma concentrations.	0
DDI-DrugBank.d210.s25.p5	Rifampin: Co-administration of VIOXX with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in @DRUG$ plasma concentrations.	0
DDI-DrugBank.d210.s26.p0	Therefore, a starting daily dose of 25 mg of @DRUG$ should be considered for the treatment of osteoarthritis when @DRUG$ is co-administered with potent inducers of hepatic metabolism.	0
DDI-DrugBank.d210.s28.p0	Adequate monitoring of @DRUG$ plasma concentrations should be considered when therapy with @DRUG$ is initiated or changed in patients receiving theophylline.	0
DDI-DrugBank.d210.s28.p1	Adequate monitoring of @DRUG$ plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving @DRUG$.	0
DDI-DrugBank.d210.s28.p2	Adequate monitoring of theophylline plasma concentrations should be considered when therapy with @DRUG$ is initiated or changed in patients receiving @DRUG$.	0
DDI-DrugBank.d210.s3.p0	@DRUG$: Concomitant administration of low-dose @DRUG$ with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.	4
DDI-DrugBank.d210.s3.p1	@DRUG$: Concomitant administration of low-dose aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.	4
DDI-DrugBank.d210.s3.p2	@DRUG$: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	4
DDI-DrugBank.d210.s3.p3	Aspirin: Concomitant administration of low-dose @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.	4
DDI-DrugBank.d210.s3.p4	Aspirin: Concomitant administration of low-dose @DRUG$ with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	4
DDI-DrugBank.d210.s3.p5	Aspirin: Concomitant administration of low-dose aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	4
DDI-DrugBank.d210.s30.p0	Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., @DRUG$, @DRUG$, and zileuton).	0
DDI-DrugBank.d210.s30.p1	Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., @DRUG$, tacrine, and @DRUG$).	0
DDI-DrugBank.d210.s30.p2	Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, @DRUG$, and @DRUG$).	0
DDI-DrugBank.d210.s31.p0	@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.	0
DDI-DrugBank.d210.s31.p1	@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding complications.	0
DDI-DrugBank.d210.s31.p2	Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding complications.	0
DDI-DrugBank.d210.s32.p0	In single and multiple dose studies in healthy subjects receiving both @DRUG$ and @DRUG$, prothrombin time (measured as INR) was increased by approximately 8% to 11%.	0
DDI-DrugBank.d210.s33.p0	In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving @DRUG$ concurrently with @DRUG$.	0
DDI-DrugBank.d210.s4.p0	In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated @DRUG$ plus @DRUG$ 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.	2
DDI-DrugBank.d210.s4.p1	In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated @DRUG$ plus VIOXX 25 mg daily, as compared to those taking @DRUG$ 2400 mg daily alone.	2
DDI-DrugBank.d210.s4.p2	In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus @DRUG$ 25 mg daily, as compared to those taking @DRUG$ 2400 mg daily alone.	2
DDI-DrugBank.d210.s5.p0	Patients taking low-dose @DRUG$ plus @DRUG$ were not studied.	0
DDI-DrugBank.d210.s6.p0	At steady state, @DRUG$ 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) @DRUG$, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.	0
DDI-DrugBank.d210.s7.p0	Because of its lack of platelet effects, @DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis.	2
DDI-DrugBank.d211.s2.p0	@DRUG$: @DRUG$, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.	4
DDI-DrugBank.d211.s2.p1	@DRUG$: Chloramphenicol, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.	4
DDI-DrugBank.d211.s2.p2	@DRUG$: Chloramphenicol, erythromycins, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.	4
DDI-DrugBank.d211.s2.p3	@DRUG$: Chloramphenicol, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.	2
DDI-DrugBank.d211.s2.p4	@DRUG$: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	4
DDI-DrugBank.d211.s2.p5	Bacteriostatic Antibiotics: @DRUG$, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.	4
DDI-DrugBank.d211.s2.p6	Bacteriostatic Antibiotics: @DRUG$, erythromycins, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.	4
DDI-DrugBank.d211.s2.p7	Bacteriostatic Antibiotics: @DRUG$, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.	2
DDI-DrugBank.d211.s2.p8	Bacteriostatic Antibiotics: @DRUG$, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	4
DDI-DrugBank.d211.s2.p9	Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.	4
DDI-DrugBank.d211.s2.p10	Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.	2
DDI-DrugBank.d211.s2.p11	Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	4
DDI-DrugBank.d211.s2.p12	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, @DRUG$, or @DRUG$ may interfere with the bactericidal effect of penicillins.	2
DDI-DrugBank.d211.s2.p13	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, @DRUG$, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	4
DDI-DrugBank.d211.s2.p14	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of @DRUG$.	2
DDI-DrugBank.d211.s5.p0	@DRUG$: May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or ampicillin toxicity.	0
DDI-DrugBank.d211.s5.p1	@DRUG$: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or @DRUG$ toxicity.	0
DDI-DrugBank.d211.s5.p2	Probenecid: May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or @DRUG$ toxicity.	0
DDI-DrugBank.d211.s6.p0	Drug/Laboratory Test Interaction After treatment with @DRUG$, a false-positive reaction for glucose in the urine may occur with @DRUG$ tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.	4
DDI-DrugBank.d212.s11.p0	Potential drug interactions between @DRUG$  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p1	Potential drug interactions between @DRUG$  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p2	Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p3	Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p4	Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p5	Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p6	Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p7	Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p8	Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p9	Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p10	Potential drug interactions between Keppra  and other @DRUG$ (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p11	Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p12	Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p13	Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p14	Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p15	Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p16	Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p17	Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p18	Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p19	Potential drug interactions between Keppra  and other AEDs (@DRUG$, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p20	Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p21	Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p22	Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p23	Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p24	Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p25	Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p26	Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p27	Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p28	Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p29	Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p30	Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p31	Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p32	Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p33	Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p34	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p35	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p36	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p37	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p38	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p39	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p40	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p41	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p42	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p43	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p44	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p45	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p46	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p47	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p48	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p49	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p50	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p51	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p52	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p53	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s11.p54	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these @DRUG$ during placebo-controlled clinical studies.	0
DDI-DrugBank.d212.s12.p0	These data indicate that @DRUG$ does not influence the plasma concentration of other @DRUG$ and that these AEDs do not influence the pharmacokinetics of levetiracetam.	2
DDI-DrugBank.d212.s12.p1	These data indicate that @DRUG$ does not influence the plasma concentration of other AEDs and that these @DRUG$ do not influence the pharmacokinetics of levetiracetam.	2
DDI-DrugBank.d212.s12.p2	These data indicate that @DRUG$ does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of @DRUG$.	2
DDI-DrugBank.d212.s12.p3	These data indicate that levetiracetam does not influence the plasma concentration of other @DRUG$ and that these @DRUG$ do not influence the pharmacokinetics of levetiracetam.	2
DDI-DrugBank.d212.s12.p4	These data indicate that levetiracetam does not influence the plasma concentration of other @DRUG$ and that these AEDs do not influence the pharmacokinetics of @DRUG$.	2
DDI-DrugBank.d212.s12.p5	These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these @DRUG$ do not influence the pharmacokinetics of @DRUG$.	2
DDI-DrugBank.d212.s13.p0	Effect of @DRUG$ in Pediatric Patients There was about a 22% increase of apparent total body clearance of @DRUG$ when it was co-administered with enzyme-inducing AEDs.	0
DDI-DrugBank.d212.s13.p1	Effect of @DRUG$ in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing @DRUG$.	0
DDI-DrugBank.d212.s13.p2	Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of @DRUG$ when it was co-administered with enzyme-inducing @DRUG$.	0
DDI-DrugBank.d212.s14.p0	Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of @DRUG$, valproate, topiramate, or lamotrigine.	0
DDI-DrugBank.d212.s14.p1	Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine, @DRUG$, topiramate, or lamotrigine.	0
DDI-DrugBank.d212.s14.p2	Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine, valproate, @DRUG$, or lamotrigine.	0
DDI-DrugBank.d212.s14.p3	Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or @DRUG$.	0
DDI-DrugBank.d212.s14.p4	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of @DRUG$, @DRUG$, topiramate, or lamotrigine.	0
DDI-DrugBank.d212.s14.p5	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of @DRUG$, valproate, @DRUG$, or lamotrigine.	0
DDI-DrugBank.d212.s14.p6	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of @DRUG$, valproate, topiramate, or @DRUG$.	0
DDI-DrugBank.d212.s14.p7	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, @DRUG$, @DRUG$, or lamotrigine.	0
DDI-DrugBank.d212.s14.p8	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, @DRUG$, topiramate, or @DRUG$.	0
DDI-DrugBank.d212.s14.p9	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, @DRUG$, or @DRUG$.	0
DDI-DrugBank.d212.s15.p0	Other Drug Interactions Oral @DRUG$ @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s15.p1	Other Drug Interactions Oral @DRUG$ Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s15.p2	Other Drug Interactions Oral @DRUG$ Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s15.p3	Other Drug Interactions Oral @DRUG$ Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s15.p4	Other Drug Interactions Oral Contraceptives @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s15.p5	Other Drug Interactions Oral Contraceptives @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s15.p6	Other Drug Interactions Oral Contraceptives @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s15.p7	Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s15.p8	Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s15.p9	Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg @DRUG$ and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	0
DDI-DrugBank.d212.s16.p0	Coadministration of this oral @DRUG$ did not influence the pharmacokinetics of @DRUG$.	2
DDI-DrugBank.d212.s17.p0	@DRUG$ @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.	0
DDI-DrugBank.d212.s17.p1	@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of @DRUG$ given as a 0.25 mg dose every day.	0
DDI-DrugBank.d212.s17.p2	Digoxin @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of @DRUG$ given as a 0.25 mg dose every day.	0
DDI-DrugBank.d212.s18.p0	Coadministration of @DRUG$ did not influence the pharmacokinetics of @DRUG$.	2
DDI-DrugBank.d212.s19.p0	@DRUG$ @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.	0
DDI-DrugBank.d212.s19.p1	@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d212.s19.p2	@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and @DRUG$.	0
DDI-DrugBank.d212.s19.p3	Warfarin @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d212.s19.p4	Warfarin @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of R and @DRUG$.	0
DDI-DrugBank.d212.s19.p5	Warfarin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of @DRUG-DRUG$.	0
DDI-DrugBank.d212.s2.p0	In addition, @DRUG$ does not affect the in vitro glucuronidation of @DRUG$.	0
DDI-DrugBank.d212.s21.p0	Coadministration of @DRUG$ did not affect the pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d212.s22.p0	@DRUG$: @DRUG$, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.	0
DDI-DrugBank.d212.s22.p1	@DRUG$: Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of @DRUG$ 1000 mg twice daily.	0
DDI-DrugBank.d212.s22.p2	Probenecid: @DRUG$, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of @DRUG$ 1000 mg twice daily.	0
DDI-DrugBank.d212.s25.p0	The effect of @DRUG$  on @DRUG$ was not studied.	4
DDI-DrugBank.d212.s5.p0	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, @DRUG$, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p1	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral @DRUG$, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p2	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, @DRUG$, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p3	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, digoxin, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p4	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p5	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral @DRUG$, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p6	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral contraceptive, @DRUG$, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p7	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral contraceptive, digoxin, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p8	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral contraceptive, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p9	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral @DRUG$, @DRUG$, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p10	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral @DRUG$, digoxin, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p11	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral @DRUG$, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p12	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, @DRUG$, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p13	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, @DRUG$, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s5.p14	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, @DRUG$, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	0
DDI-DrugBank.d212.s6.p0	Drug-Drug Interactions Between @DRUG$  And Other @DRUG$ (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p1	Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p2	Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (AEDs) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p3	Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (AEDs) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p4	Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p5	Drug-Drug Interactions Between Keppra  And Other @DRUG$ (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p6	Drug-Drug Interactions Between Keppra  And Other @DRUG$ (AEDs) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p7	Drug-Drug Interactions Between Keppra  And Other @DRUG$ (AEDs) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p8	Drug-Drug Interactions Between Keppra  And Other @DRUG$ (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p9	Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p10	Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p11	Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p12	Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) @DRUG$ @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p13	Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s6.p14	Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	0
DDI-DrugBank.d212.s8.p0	@DRUG$ @DRUG$  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.	0
DDI-DrugBank.d212.s8.p1	@DRUG$ Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of @DRUG$ in healthy volunteers.	0
DDI-DrugBank.d212.s8.p2	Valproate @DRUG$  (1500 mg twice daily) did not alter the pharmacokinetics of @DRUG$ in healthy volunteers.	0
DDI-DrugBank.d212.s9.p0	@DRUG$ 500 mg twice daily did not modify the rate or extent of @DRUG$ absorption or its plasma clearance or urinary excretion.	0
DDI-DrugBank.d213.s0.p0	@DRUG$ or @DRUG$ excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.	4
DDI-DrugBank.d213.s0.p1	@DRUG$ or iodine excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of Carbimazole.	4
DDI-DrugBank.d213.s0.p2	@DRUG$ or iodine excess may decrease the effect of Carbimazole, and an @DRUG$ deficiency can increase the effect of Carbimazole.	4
DDI-DrugBank.d213.s0.p3	@DRUG$ or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of @DRUG$.	4
DDI-DrugBank.d213.s0.p4	Iodine or @DRUG$ excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of Carbimazole.	4
DDI-DrugBank.d213.s0.p5	Iodine or @DRUG$ excess may decrease the effect of Carbimazole, and an @DRUG$ deficiency can increase the effect of Carbimazole.	4
DDI-DrugBank.d213.s0.p6	Iodine or @DRUG$ excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of @DRUG$.	4
DDI-DrugBank.d213.s0.p7	Iodine or iodine excess may decrease the effect of @DRUG$, and an @DRUG$ deficiency can increase the effect of Carbimazole.	4
DDI-DrugBank.d213.s0.p8	Iodine or iodine excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of @DRUG$.	4
DDI-DrugBank.d213.s0.p9	Iodine or iodine excess may decrease the effect of Carbimazole, and an @DRUG$ deficiency can increase the effect of @DRUG$.	4
DDI-DrugBank.d216.s1.p0	@DRUG$: Coadministration of single doses of @DRUG$ 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.	0
DDI-DrugBank.d216.s1.p1	@DRUG$: Coadministration of single doses of eszopiclone 3 mg and @DRUG$ 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.	0
DDI-DrugBank.d216.s1.p2	Paroxetine: Coadministration of single doses of @DRUG$ 3 mg and @DRUG$ 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.	0
DDI-DrugBank.d216.s10.p0	Drugs That Induce CYP3A4 (@DRUG$) Racemic @DRUG$ exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.	0
DDI-DrugBank.d216.s10.p1	Drugs That Induce CYP3A4 (@DRUG$) Racemic zopiclone exposure was decreased 80% by concomitant useof @DRUG$, a potent inducer of CYP3A4.	0
DDI-DrugBank.d216.s10.p2	Drugs That Induce CYP3A4 (Rifampicin) Racemic @DRUG$ exposure was decreased 80% by concomitant useof @DRUG$, a potent inducer of CYP3A4.	0
DDI-DrugBank.d216.s15.p0	Drugs With A Narrow Therapeutic Index @DRUG$ A single dose of @DRUG$ 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	0
DDI-DrugBank.d216.s15.p1	Drugs With A Narrow Therapeutic Index @DRUG$ A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of @DRUG$ measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	0
DDI-DrugBank.d216.s15.p2	Drugs With A Narrow Therapeutic Index Digoxin A single dose of @DRUG$ 3 mg did not affect the pharmacokinetics of @DRUG$ measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	0
DDI-DrugBank.d216.s16.p0	@DRUG$: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	0
DDI-DrugBank.d216.s16.p1	@DRUG$: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	0
DDI-DrugBank.d216.s16.p2	@DRUG$: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	0
DDI-DrugBank.d216.s16.p3	@DRUG$: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	0
DDI-DrugBank.d216.s16.p4	Warfarin: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	0
DDI-DrugBank.d216.s16.p5	Warfarin: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	0
DDI-DrugBank.d216.s16.p6	Warfarin: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	0
DDI-DrugBank.d216.s16.p7	Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG-DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	0
DDI-DrugBank.d216.s16.p8	Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	0
DDI-DrugBank.d216.s16.p9	Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	0
DDI-DrugBank.d216.s2.p0	@DRUG$: Coadministration of single doses of @DRUG$ 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.	0
DDI-DrugBank.d216.s2.p1	@DRUG$: Coadministration of single doses of eszopiclone 3 mg and @DRUG$ 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.	0
DDI-DrugBank.d216.s2.p2	Lorazepam: Coadministration of single doses of @DRUG$ 3 mg and @DRUG$ 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.	0
DDI-DrugBank.d216.s3.p0	@DRUG$: Coadministration of @DRUG$ 3 mg and olanzapine 10 mg produced a decrease in DSST scores.	2
DDI-DrugBank.d216.s3.p1	@DRUG$: Coadministration of eszopiclone 3 mg and @DRUG$ 10 mg produced a decrease in DSST scores.	0
DDI-DrugBank.d216.s3.p2	Olanzapine: Coadministration of @DRUG$ 3 mg and @DRUG$ 10 mg produced a decrease in DSST scores.	2
DDI-DrugBank.d216.s6.p0	Drugs That Inhibit CYP3A4 (@DRUG$) CYP3A4 is a major metabolic pathway for elimination of @DRUG$.	0
DDI-DrugBank.d216.s7.p0	The AUC of @DRUG$ was increased 2.2-fold by coadministration of @DRUG$, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.	0
DDI-DrugBank.d216.s9.p0	Other strong inhibitors of CYP3A4 (e.g., @DRUG$, @DRUG$, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.	1
DDI-DrugBank.d216.s9.p1	Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, @DRUG$, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p2	Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, nefazodone, @DRUG$, ritonavir, nelfinavir) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p3	Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, nefazodone, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.	1
DDI-DrugBank.d216.s9.p4	Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, nefazodone, troleandomycin, ritonavir, @DRUG$) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p5	Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, @DRUG$, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p6	Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, @DRUG$, ritonavir, nelfinavir) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p7	Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.	1
DDI-DrugBank.d216.s9.p8	Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, troleandomycin, ritonavir, @DRUG$) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p9	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, @DRUG$, @DRUG$, ritonavir, nelfinavir) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p10	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, @DRUG$, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p11	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, @DRUG$, troleandomycin, ritonavir, @DRUG$) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p12	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, @DRUG$, @DRUG$, nelfinavir) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p13	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, @DRUG$, ritonavir, @DRUG$) would be expected to behave similarly.	0
DDI-DrugBank.d216.s9.p14	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, @DRUG$, @DRUG$) would be expected to behave similarly.	0
DDI-DrugBank.d217.s0.p0	Elevated plasma levels of @DRUG$ have been reported with concomitant @DRUG$ use.	0
DDI-DrugBank.d217.s1.p0	There have been reports of @DRUG$-related side effects in patients on concomitant therapy with @DRUG$ and theophylline.	0
DDI-DrugBank.d217.s1.p1	There have been reports of @DRUG$-related side effects in patients on concomitant therapy with norfloxacin and @DRUG$.	0
DDI-DrugBank.d217.s1.p2	There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.	0
DDI-DrugBank.d217.s10.p0	The concomitant use of @DRUG$ is not recommended since @DRUG$ may antagonize the antibacterial effect of Norfloxacin in the urinary tract.	0
DDI-DrugBank.d217.s10.p1	The concomitant use of @DRUG$ is not recommended since nitrofurantoin may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	0
DDI-DrugBank.d217.s10.p2	The concomitant use of nitrofurantoin is not recommended since @DRUG$ may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	0
DDI-DrugBank.d217.s11.p0	@DRUG$, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p1	@DRUG$, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p2	@DRUG$, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p3	@DRUG$, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p4	@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p5	@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	4
DDI-DrugBank.d217.s11.p6	Multivitamins, or other products containing @DRUG$ or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p7	Multivitamins, or other products containing @DRUG$ or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p8	Multivitamins, or other products containing @DRUG$ or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p9	Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p10	Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	4
DDI-DrugBank.d217.s11.p11	Multivitamins, or other products containing iron or @DRUG$, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p12	Multivitamins, or other products containing iron or @DRUG$, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p13	Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p14	Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	4
DDI-DrugBank.d217.s11.p15	Multivitamins, or other products containing iron or zinc, @DRUG$ or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p16	Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p17	Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	4
DDI-DrugBank.d217.s11.p18	Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	4
DDI-DrugBank.d217.s11.p19	Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	4
DDI-DrugBank.d217.s11.p20	Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	4
DDI-DrugBank.d217.s3.p0	Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with norfloxacin.	0
DDI-DrugBank.d217.s3.p1	Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with @DRUG$.	0
DDI-DrugBank.d217.s3.p2	Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with @DRUG$.	0
DDI-DrugBank.d217.s4.p0	Therefore, @DRUG$ serum levels should be monitored and appropriate @DRUG$ dosage adjustments made when these drugs are used concomitantly.	0
DDI-DrugBank.d217.s5.p0	@DRUG$, including @DRUG$, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.	4
DDI-DrugBank.d217.s5.p1	@DRUG$, including norfloxacin, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	4
DDI-DrugBank.d217.s5.p2	@DRUG$, including norfloxacin, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	4
DDI-DrugBank.d217.s5.p3	Quinolones, including @DRUG$, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	4
DDI-DrugBank.d217.s5.p4	Quinolones, including @DRUG$, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	4
DDI-DrugBank.d217.s5.p5	Quinolones, including norfloxacin, may enhance the effects of oral @DRUG$, including @DRUG$ or its derivatives or similar agents.	4
DDI-DrugBank.d219.s0.p0	@DRUG$ Reports suggest that @DRUG$ may diminish the antihypertensive effect of ACE-inhibitors.	0
DDI-DrugBank.d219.s0.p1	@DRUG$ Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	0
DDI-DrugBank.d219.s0.p2	ACE-inhibitors Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	0
DDI-DrugBank.d219.s1.p0	This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	4
DDI-DrugBank.d219.s10.p0	@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$ or hydrochlorothiazide.	0
DDI-DrugBank.d219.s10.p1	@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or @DRUG$.	0
DDI-DrugBank.d219.s10.p2	Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$ or @DRUG$.	0
DDI-DrugBank.d219.s11.p0	Nevertheless, clinical studies, as well as postmarketing observations have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	1
DDI-DrugBank.d219.s11.p1	Nevertheless, clinical studies, as well as postmarketing observations have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	1
DDI-DrugBank.d219.s11.p2	Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	1
DDI-DrugBank.d219.s14.p0	@DRUG$: @DRUG$ has no apparent pharmacokinetic interaction when administered with glyburide.	0
DDI-DrugBank.d219.s14.p1	@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$.	0
DDI-DrugBank.d219.s14.p2	Glyburide: @DRUG$ has no apparent pharmacokinetic interaction when administered with @DRUG$.	0
DDI-DrugBank.d219.s15.p0	@DRUG$: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	3
DDI-DrugBank.d219.s15.p1	@DRUG$: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	0
DDI-DrugBank.d219.s15.p2	@DRUG$: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	0
DDI-DrugBank.d219.s15.p3	Lithium: @DRUG$ have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	3
DDI-DrugBank.d219.s15.p4	Lithium: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	3
DDI-DrugBank.d219.s15.p5	Lithium: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance.	0
DDI-DrugBank.d219.s19.p0	@DRUG$: @DRUG$ causes increase (by about 80%) in the free fraction of etodolac.	2
DDI-DrugBank.d219.s19.p1	@DRUG$: Phenylbutazone causes increase (by about 80%) in the free fraction of @DRUG$.	2
DDI-DrugBank.d219.s19.p2	Phenylbutazone: @DRUG$ causes increase (by about 80%) in the free fraction of @DRUG$.	2
DDI-DrugBank.d219.s21.p0	@DRUG$: @DRUG$ has no apparent pharmacokinetic interaction when administered with phenytoin.	0
DDI-DrugBank.d219.s21.p1	@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$.	0
DDI-DrugBank.d219.s21.p2	Phenytoin: @DRUG$ has no apparent pharmacokinetic interaction when administered with @DRUG$.	0
DDI-DrugBank.d219.s22.p0	@DRUG$: The effects of @DRUG$ and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.	2
DDI-DrugBank.d219.s22.p1	@DRUG$: The effects of warfarin and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.	0
DDI-DrugBank.d219.s22.p2	Warfarin: The effects of @DRUG$ and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.	0
DDI-DrugBank.d219.s23.p0	Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and @DRUG$  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	0
DDI-DrugBank.d219.s23.p1	Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	0
DDI-DrugBank.d219.s23.p2	Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.	0
DDI-DrugBank.d219.s23.p3	Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	0
DDI-DrugBank.d219.s23.p4	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$  (@DRUG$ capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	0
DDI-DrugBank.d219.s23.p5	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.	0
DDI-DrugBank.d219.s23.p6	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	0
DDI-DrugBank.d219.s23.p7	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.	0
DDI-DrugBank.d219.s23.p8	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	0
DDI-DrugBank.d219.s23.p9	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free @DRUG$.	0
DDI-DrugBank.d219.s24.p0	There was no significant difference in the pharmacodynamic effect of @DRUG$ administered alone and @DRUG$ administered with Lodine as measured by prothrombin time.	0
DDI-DrugBank.d219.s24.p1	There was no significant difference in the pharmacodynamic effect of @DRUG$ administered alone and warfarin administered with @DRUG$ as measured by prothrombin time.	0
DDI-DrugBank.d219.s24.p2	There was no significant difference in the pharmacodynamic effect of warfarin administered alone and @DRUG$ administered with @DRUG$ as measured by prothrombin time.	0
DDI-DrugBank.d219.s25.p0	Thus, concomitant therapy with @DRUG$ and @DRUG$ should not require dosage adjustment of either drug.	0
DDI-DrugBank.d219.s27.p0	Drug/Laboratory Test Interactions The urine of patients who take @DRUG$ can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of @DRUG$.	2
DDI-DrugBank.d219.s4.p0	@DRUG$: When @DRUG$ is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.	0
DDI-DrugBank.d219.s4.p1	@DRUG$: When Lodine is administered with @DRUG$, its protein binding is reduced, although the clearance of free etodolac is not altered.	0
DDI-DrugBank.d219.s4.p2	@DRUG$: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free @DRUG$ is not altered.	0
DDI-DrugBank.d219.s4.p3	Aspirin: When @DRUG$ is administered with @DRUG$, its protein binding is reduced, although the clearance of free etodolac is not altered.	0
DDI-DrugBank.d219.s4.p4	Aspirin: When @DRUG$ is administered with aspirin, its protein binding is reduced, although the clearance of free @DRUG$ is not altered.	0
DDI-DrugBank.d219.s4.p5	Aspirin: When Lodine is administered with @DRUG$, its protein binding is reduced, although the clearance of free @DRUG$ is not altered.	0
DDI-DrugBank.d219.s7.p0	Cyclosporine, Digoxin, Methotrexate @DRUG$, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.	0
DDI-DrugBank.d219.s7.p1	Cyclosporine, Digoxin, Methotrexate @DRUG$, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, digoxin, methotrexate, and increased toxicity.	0
DDI-DrugBank.d219.s7.p2	Cyclosporine, Digoxin, Methotrexate @DRUG$, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, @DRUG$, methotrexate, and increased toxicity.	0
DDI-DrugBank.d219.s7.p3	Cyclosporine, Digoxin, Methotrexate @DRUG$, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, @DRUG$, and increased toxicity.	0
DDI-DrugBank.d219.s7.p4	Cyclosporine, Digoxin, Methotrexate Lodine, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, digoxin, methotrexate, and increased toxicity.	0
DDI-DrugBank.d219.s7.p5	Cyclosporine, Digoxin, Methotrexate Lodine, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, @DRUG$, methotrexate, and increased toxicity.	0
DDI-DrugBank.d219.s7.p6	Cyclosporine, Digoxin, Methotrexate Lodine, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, @DRUG$, and increased toxicity.	0
DDI-DrugBank.d219.s7.p7	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, @DRUG$, methotrexate, and increased toxicity.	0
DDI-DrugBank.d219.s7.p8	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, digoxin, @DRUG$, and increased toxicity.	0
DDI-DrugBank.d219.s7.p9	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, @DRUG$, @DRUG$, and increased toxicity.	0
DDI-DrugBank.d219.s9.p0	Patients receiving these drugs who are given @DRUG$, or any other @DRUG$, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs.	0
DDI-DrugBank.d22.s0.p0	@DRUG$ may decrease the amount of @DRUG$ (Lanoxin, Lanoxicaps) that gets absorbed into your body.	0
DDI-DrugBank.d22.s0.p1	@DRUG$ may decrease the amount of digoxin (@DRUG$, Lanoxicaps) that gets absorbed into your body.	0
DDI-DrugBank.d22.s0.p2	@DRUG$ may decrease the amount of digoxin (Lanoxin, @DRUG$) that gets absorbed into your body.	0
DDI-DrugBank.d22.s0.p3	Aminosalicylic acid may decrease the amount of @DRUG$ (@DRUG$, Lanoxicaps) that gets absorbed into your body.	0
DDI-DrugBank.d22.s0.p4	Aminosalicylic acid may decrease the amount of @DRUG$ (Lanoxin, @DRUG$) that gets absorbed into your body.	0
DDI-DrugBank.d22.s0.p5	Aminosalicylic acid may decrease the amount of digoxin (@DRUG$, @DRUG$) that gets absorbed into your body.	0
DDI-DrugBank.d22.s1.p0	In the case that you are taking @DRUG$ while taking @DRUG$, higher doses of digoxin may be needed.	0
DDI-DrugBank.d22.s1.p1	In the case that you are taking @DRUG$ while taking aminosalicylic acid, higher doses of @DRUG$ may be needed.	0
DDI-DrugBank.d22.s1.p2	In the case that you are taking digoxin while taking @DRUG$, higher doses of @DRUG$ may be needed.	0
DDI-DrugBank.d22.s2.p0	@DRUG$ may also decrease the absorption of @DRUG$, which can lead to a deficiency.	4
DDI-DrugBank.d22.s3.p0	Therefore you may need to take a @DRUG$ supplement while taking @DRUG$.	0
DDI-DrugBank.d220.s13.p0	When @DRUG$ is taken concurrently with oral @DRUG$, attenuation of immunization cannot be excluded.	0
DDI-DrugBank.d220.s16.p0	Nevertheless, the effects of @DRUG$ on travelers receiving comedication, particularly diabetics or patients using @DRUG$, should be checked before departure.	3
DDI-DrugBank.d220.s17.p0	In clinical trials, the concomitant administration of @DRUG$ and @DRUG$ did not alter the adverse reaction profile.	0
DDI-DrugBank.d220.s5.p0	Concomitant administration of @DRUG$ and other related compounds (eg, @DRUG$, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.	0
DDI-DrugBank.d220.s5.p1	Concomitant administration of @DRUG$ and other related compounds (eg, quinine, @DRUG$ and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.	0
DDI-DrugBank.d220.s5.p2	Concomitant administration of @DRUG$ and other related compounds (eg, quinine, quinidine and @DRUG$) may produce electrocardiographic abnormalities and increase the risk of convulsions.	0
DDI-DrugBank.d220.s5.p3	Concomitant administration of Mefloquine and other related compounds (eg, @DRUG$, @DRUG$ and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.	0
DDI-DrugBank.d220.s5.p4	Concomitant administration of Mefloquine and other related compounds (eg, @DRUG$, quinidine and @DRUG$) may produce electrocardiographic abnormalities and increase the risk of convulsions.	0
DDI-DrugBank.d220.s5.p5	Concomitant administration of Mefloquine and other related compounds (eg, quinine, @DRUG$ and @DRUG$) may produce electrocardiographic abnormalities and increase the risk of convulsions.	0
DDI-DrugBank.d220.s9.p0	This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p1	This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p2	This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	3
DDI-DrugBank.d220.s9.p3	This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	3
DDI-DrugBank.d220.s9.p4	This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p5	This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p6	This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p7	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p8	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p9	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p10	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p11	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p12	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p13	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p14	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p15	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p16	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p17	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p18	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	3
DDI-DrugBank.d220.s9.p19	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p20	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p21	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p22	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p23	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p24	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p25	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p26	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d220.s9.p27	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and @DRUG$) might also contribute to a prolongation of the QTc interval.	0
DDI-DrugBank.d221.s0.p0	The risk of a potential interaction between @DRUG$ and @DRUG$ concentrates has not been adequately evaluated in preclinical or clinical studies.	0
DDI-DrugBank.d221.s2.p0	Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., @DRUG$, @DRUG$) and NovoSeven.	0
DDI-DrugBank.d221.s2.p1	Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., @DRUG$, aminocaproic acid) and @DRUG$.	0
DDI-DrugBank.d221.s2.p2	Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, @DRUG$) and @DRUG$.	0
DDI-DrugBank.d222.s1.p0	The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of @DRUG$ and @DRUG$.	0
DDI-DrugBank.d222.s2.p0	Since @DRUG$ are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions.	0
DDI-DrugBank.d223.s10.p0	Nevertheless, caution is indicated in the co-administration of @DRUG$ with any of the @DRUG$ and also in switching from one class to the other.	3
DDI-DrugBank.d223.s12.p0	Concomitant use of @DRUG$ with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	4
DDI-DrugBank.d223.s14.p0	It is desirable to monitor @DRUG$ plasma levels whenever a @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6.	0
DDI-DrugBank.d223.s19.p0	@DRUG$: Serious side effects and even death have been reported following the concomitant use of certain drugs with @DRUG$.	3
DDI-DrugBank.d223.s2.p0	Poor metabolizers have higher than expected plasma concentrations of @DRUG$ (@DRUG$) when given usual doses.	0
DDI-DrugBank.d223.s20.p0	Therefore, @DRUG$ should be discontinued at least two weeks prior to the cautious initiation of therapy with @DRUG$.	0
DDI-DrugBank.d223.s22.p0	@DRUG$: @DRUG$ has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.	0
DDI-DrugBank.d223.s22.p1	@DRUG$: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various @DRUG$.	0
DDI-DrugBank.d223.s22.p2	Cimetidine: @DRUG$ has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various @DRUG$.	0
DDI-DrugBank.d223.s23.p0	Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of @DRUG$ when @DRUG$ therapy is initiated.	0
DDI-DrugBank.d223.s24.p0	Additionally, higher than expected @DRUG$ levels have been observed when they are begun in patients already taking @DRUG$.	0
DDI-DrugBank.d223.s28.p0	@DRUG$: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on @DRUG$ (1 gm/day) 11 days after the addition of doxepin (75 mg/day).	0
DDI-DrugBank.d223.s28.p1	@DRUG$: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of @DRUG$ (75 mg/day).	0
DDI-DrugBank.d223.s28.p2	Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on @DRUG$ (1 gm/day) 11 days after the addition of @DRUG$ (75 mg/day).	0
DDI-DrugBank.d223.s8.p0	While all the @DRUG$ (@DRUG$), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p1	While all the @DRUG$ (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p2	While all the @DRUG$ (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p3	While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p4	While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p5	While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p6	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., @DRUG$, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p7	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p8	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p9	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p10	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, escitalopram, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p11	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p12	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p13	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p14	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p15	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p16	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p17	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p18	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, @DRUG$, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p19	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, @DRUG$, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s8.p20	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, @DRUG$, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d223.s9.p0	The extent to which @DRUG$-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.	2
DDI-DrugBank.d223.s9.p1	The extent to which @DRUG$-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	2
DDI-DrugBank.d223.s9.p2	The extent to which SSRI-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	2
DDI-DrugBank.d224.s0.p0	@DRUG$ should not be used in patients receiving @DRUG$..	1
DDI-DrugBank.d224.s1.p0	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.	0
DDI-DrugBank.d224.s1.p1	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, anesthetics) should be considered.	4
DDI-DrugBank.d224.s1.p2	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, anesthetics) should be considered.	4
DDI-DrugBank.d224.s1.p3	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, anesthetics) should be considered.	4
DDI-DrugBank.d224.s1.p4	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, anesthetics) should be considered.	4
DDI-DrugBank.d224.s1.p5	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, @DRUG$) should be considered.	4
DDI-DrugBank.d224.s1.p6	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (@DRUG$, barbiturates, opiates, sedatives, anesthetics) should be considered.	0
DDI-DrugBank.d224.s1.p7	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, @DRUG$, opiates, sedatives, anesthetics) should be considered.	0
DDI-DrugBank.d224.s1.p8	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, @DRUG$, sedatives, anesthetics) should be considered.	0
DDI-DrugBank.d224.s1.p9	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, @DRUG$, anesthetics) should be considered.	0
DDI-DrugBank.d224.s1.p10	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, @DRUG$) should be considered.	0
DDI-DrugBank.d224.s1.p11	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, @DRUG$, opiates, sedatives, anesthetics) should be considered.	4
DDI-DrugBank.d224.s1.p12	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, @DRUG$, sedatives, anesthetics) should be considered.	4
DDI-DrugBank.d224.s1.p13	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, @DRUG$, anesthetics) should be considered.	0
DDI-DrugBank.d224.s1.p14	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, @DRUG$) should be considered.	0
DDI-DrugBank.d224.s1.p15	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, @DRUG$, sedatives, anesthetics) should be considered.	4
DDI-DrugBank.d224.s1.p16	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, @DRUG$, anesthetics) should be considered.	4
DDI-DrugBank.d224.s1.p17	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, @DRUG$) should be considered.	4
DDI-DrugBank.d224.s1.p18	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, @DRUG$, anesthetics) should be considered.	4
DDI-DrugBank.d224.s1.p19	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, @DRUG$) should be considered.	4
DDI-DrugBank.d224.s1.p20	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, @DRUG$) should be considered.	0
DDI-DrugBank.d224.s2.p0	@DRUG$ have been reported to blunt the hypotensive effect of systemic @DRUG$.	0
DDI-DrugBank.d224.s6.p0	An additive hypotensive effect has been reported with the combination of systemic @DRUG$ and @DRUG$ therapy.	0
DDI-DrugBank.d225.s12.p0	All subjects received @DRUG$ alone and following treatment with 100 mg of @DRUG$ as a single daily oral dose for seven days.	0
DDI-DrugBank.d225.s13.p0	The mean percentage increase in the @DRUG$ AUC after @DRUG$ administration was 56.9% (range: 35 to 81).	0
DDI-DrugBank.d225.s3.p0	In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than @DRUG$ and does not interact with salicylate or dicumarol.	0
DDI-DrugBank.d225.s3.p1	In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than tolbutamide and does not interact with @DRUG$ or dicumarol.	0
DDI-DrugBank.d225.s3.p2	In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than tolbutamide and does not interact with salicylate or @DRUG$.	0
DDI-DrugBank.d225.s3.p3	In vitro binding studies with human serum proteins indicate that glipizide binds differently than @DRUG$ and does not interact with @DRUG$ or dicumarol.	0
DDI-DrugBank.d225.s3.p4	In vitro binding studies with human serum proteins indicate that glipizide binds differently than @DRUG$ and does not interact with salicylate or @DRUG$.	0
DDI-DrugBank.d225.s3.p5	In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with @DRUG$ or @DRUG$.	0
DDI-DrugBank.d225.s6.p0	These drugs include the @DRUG$ and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p1	These drugs include the @DRUG$ and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p2	These drugs include the @DRUG$ and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p3	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p4	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p5	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p6	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p7	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p8	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p9	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	4
DDI-DrugBank.d225.s6.p10	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p11	These drugs include the thiazides and other @DRUG$, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p12	These drugs include the thiazides and other @DRUG$, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p13	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p14	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p15	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p16	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p17	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p18	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p19	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	4
DDI-DrugBank.d225.s6.p20	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p21	These drugs include the thiazides and other diuretics, @DRUG$, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p22	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p23	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p24	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p25	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p26	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p27	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p28	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	1
DDI-DrugBank.d225.s6.p29	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p30	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p31	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p32	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p33	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p34	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p35	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p36	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	1
DDI-DrugBank.d225.s6.p37	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p38	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p39	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p40	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p41	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p42	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p43	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	1
DDI-DrugBank.d225.s6.p44	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p45	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p46	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p47	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p48	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p49	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	1
DDI-DrugBank.d225.s6.p50	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p51	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p52	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p53	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p54	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	1
DDI-DrugBank.d225.s6.p55	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p56	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p57	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p58	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	4
DDI-DrugBank.d225.s6.p59	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p60	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d225.s6.p61	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, @DRUG$, and isoniazid.	4
DDI-DrugBank.d225.s6.p62	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p63	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, @DRUG$, and isoniazid.	1
DDI-DrugBank.d225.s6.p64	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d225.s6.p65	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and @DRUG$.	4
DDI-DrugBank.d225.s9.p0	A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported.	0
DDI-DrugBank.d226.s0.p0	Intravenous @DRUG$ (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p1	Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p2	Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p3	Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p4	Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p5	Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p6	Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p7	Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p8	Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p9	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	2
DDI-DrugBank.d226.s0.p10	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p11	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s0.p12	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	2
DDI-DrugBank.d226.s0.p13	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	2
DDI-DrugBank.d226.s0.p14	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and @DRUG$, without any change in the adverse reaction profile.	0
DDI-DrugBank.d226.s1.p0	@DRUG$ and @DRUG$ use may be rarely associated with ventricular fibrillation when combined with Adenocard.	0
DDI-DrugBank.d226.s1.p1	@DRUG$ and verapamil use may be rarely associated with ventricular fibrillation when combined with @DRUG$.	1
DDI-DrugBank.d226.s1.p2	Digoxin and @DRUG$ use may be rarely associated with ventricular fibrillation when combined with @DRUG$.	0
DDI-DrugBank.d226.s3.p0	The use of @DRUG$ in patients receiving @DRUG$ may be rarely associated with ventricular fibrillation.	4
DDI-DrugBank.d226.s4.p0	The effects of @DRUG$ are antagonized by @DRUG$ such as caffeine and theophylline.	2
DDI-DrugBank.d226.s4.p1	The effects of @DRUG$ are antagonized by methylxanthines such as @DRUG$ and theophylline.	2
DDI-DrugBank.d226.s4.p2	The effects of @DRUG$ are antagonized by methylxanthines such as caffeine and @DRUG$.	2
DDI-DrugBank.d226.s4.p3	The effects of adenosine are antagonized by @DRUG$ such as @DRUG$ and theophylline.	2
DDI-DrugBank.d226.s4.p4	The effects of adenosine are antagonized by @DRUG$ such as caffeine and @DRUG$.	2
DDI-DrugBank.d226.s4.p5	The effects of adenosine are antagonized by methylxanthines such as @DRUG$ and @DRUG$.	2
DDI-DrugBank.d226.s5.p0	In the presence of these @DRUG$, larger doses of @DRUG$ may be required or adenosine may not be effective.	0
DDI-DrugBank.d226.s5.p1	In the presence of these @DRUG$, larger doses of adenosine may be required or @DRUG$ may not be effective.	0
DDI-DrugBank.d226.s5.p2	In the presence of these methylxanthines, larger doses of @DRUG$ may be required or @DRUG$ may not be effective.	0
DDI-DrugBank.d226.s6.p0	@DRUG$ effects are potentiated by @DRUG$.	4
DDI-DrugBank.d226.s7.p0	Thus, smaller doses of @DRUG$ may be effective in the presence of @DRUG$.	3
DDI-DrugBank.d226.s9.p0	As the primary effect of @DRUG$ is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of @DRUG$.	3
DDI-DrugBank.d227.s0.p0	@DRUG$ potentiates the muscle relaxant effect of all @DRUG$, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.	4
DDI-DrugBank.d227.s0.p1	@DRUG$ potentiates the muscle relaxant effect of all muscle relaxants, most notably @DRUG$, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.	2
DDI-DrugBank.d227.s0.p2	Isoflurane potentiates the muscle relaxant effect of all @DRUG$, most notably @DRUG$, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.	2
DDI-DrugBank.d228.s0.p0	Oral doses of @DRUG$ (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of @DRUG$ (by approximately 40%) given to healthy volunteers in moderate doses.	0
DDI-DrugBank.d228.s1.p0	Similarly, @DRUG$ decreased the rate of elimination of @DRUG$ (by approximately 50%) by the same mechanism.	0
DDI-DrugBank.d228.s2.p0	Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, carbamazepine, cimetidine, ketoconazole), though this has not been studied	3
DDI-DrugBank.d228.s2.p1	Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, cimetidine, ketoconazole), though this has not been studied	3
DDI-DrugBank.d228.s2.p2	Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, @DRUG$, ketoconazole), though this has not been studied	4
DDI-DrugBank.d228.s2.p3	Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, @DRUG$), though this has not been studied	3
DDI-DrugBank.d228.s2.p4	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, @DRUG$, cimetidine, ketoconazole), though this has not been studied	4
DDI-DrugBank.d228.s2.p5	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, carbamazepine, @DRUG$, ketoconazole), though this has not been studied	4
DDI-DrugBank.d228.s2.p6	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, carbamazepine, cimetidine, @DRUG$), though this has not been studied	3
DDI-DrugBank.d228.s2.p7	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, @DRUG$, ketoconazole), though this has not been studied	4
DDI-DrugBank.d228.s2.p8	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, cimetidine, @DRUG$), though this has not been studied	3
DDI-DrugBank.d228.s2.p9	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, @DRUG$, @DRUG$), though this has not been studied	3
DDI-DrugBank.d229.s0.p0	Drug Interaction During Pregnancy: @DRUG$ and @DRUG$ were studied following subcutaneous injections in pregnant mice.	2
DDI-DrugBank.d229.s3.p0	The addition of 540 mg/kg/day of @DRUG$ (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of @DRUG$ (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.	0
DDI-DrugBank.d23.s0.p0	@DRUG$ may augment the activity of other @DRUG$.	3
DDI-DrugBank.d231.s0.p0	@DRUG$ may increase the ototoxic potential of @DRUG$, especially in the presence of impaired renal function.	0
DDI-DrugBank.d231.s14.p0	There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when @DRUG$ was used in conjunction with @DRUG$.	0
DDI-DrugBank.d231.s17.p0	Patients receiving both @DRUG$ and @DRUG$ should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.	4
DDI-DrugBank.d231.s17.p1	Patients receiving both @DRUG$ and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of @DRUG$ is achieved.	4
DDI-DrugBank.d231.s17.p2	Patients receiving both indomethacin and @DRUG$ should be observed closely to determine if the desired diuretic and/or antihypertensive effect of @DRUG$ is achieved.	4
DDI-DrugBank.d231.s2.p0	@DRUG$ should not be used concomitantly with @DRUG$ because of the possibility of ototoxicity.	0
DDI-DrugBank.d231.s3.p0	Patients receiving high doses of @DRUG$ concomitantly with @DRUG$, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.	0
DDI-DrugBank.d231.s3.p1	Patients receiving high doses of @DRUG$ concomitantly with furosemide, as in rheumatic disease, may experience @DRUG$ toxicity at lower doses because of competitive renal excretory sites.	0
DDI-DrugBank.d231.s3.p2	Patients receiving high doses of salicylates concomitantly with @DRUG$, as in rheumatic disease, may experience @DRUG$ toxicity at lower doses because of competitive renal excretory sites.	0
DDI-DrugBank.d231.s4.p0	@DRUG$ has a tendency to antagonize the skeletal muscle relaxing effect of @DRUG$ and may potentiate the action of succinylcholine.	4
DDI-DrugBank.d231.s4.p1	@DRUG$ has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of @DRUG$.	4
DDI-DrugBank.d231.s4.p2	Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of @DRUG$ and may potentiate the action of @DRUG$.	4
DDI-DrugBank.d231.s5.p0	@DRUG$ generally should not be given with @DRUG$ because they reduce lithiums renal clearance and add a high risk of lithium toxicity.	0
DDI-DrugBank.d231.s5.p1	@DRUG$ generally should not be given with diuretics because they reduce @DRUG$s renal clearance and add a high risk of lithium toxicity.	0
DDI-DrugBank.d231.s5.p2	@DRUG$ generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of @DRUG$ toxicity.	0
DDI-DrugBank.d231.s5.p3	Lithium generally should not be given with @DRUG$ because they reduce @DRUG$s renal clearance and add a high risk of lithium toxicity.	0
DDI-DrugBank.d231.s5.p4	Lithium generally should not be given with @DRUG$ because they reduce lithiums renal clearance and add a high risk of @DRUG$ toxicity.	0
DDI-DrugBank.d231.s5.p5	Lithium generally should not be given with diuretics because they reduce @DRUG$s renal clearance and add a high risk of @DRUG$ toxicity.	0
DDI-DrugBank.d231.s6.p0	@DRUG$ may add to or potentiate the therapeutic effect of other @DRUG$.	0
DDI-DrugBank.d231.s7.p0	Potentiation occurs with @DRUG-DRUG$.	0
DDI-DrugBank.d231.s8.p0	@DRUG$ may decrease arterial responsiveness to @DRUG$.	0
DDI-DrugBank.d232.s0.p0	After multiple dosing, @DRUG$ (@DRUG$  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.	0
DDI-DrugBank.d232.s0.p1	After multiple dosing, @DRUG$ (AVONEX  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	0
DDI-DrugBank.d232.s0.p2	After multiple dosing, interferon beta-1a (@DRUG$  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	0
DDI-DrugBank.d232.s1.p0	The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	0
DDI-DrugBank.d232.s1.p1	The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	0
DDI-DrugBank.d232.s1.p2	The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	0
DDI-DrugBank.d232.s1.p3	The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	0
DDI-DrugBank.d232.s1.p4	The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	0
DDI-DrugBank.d232.s1.p5	The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	0
DDI-DrugBank.d232.s2.p0	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	2
DDI-DrugBank.d232.s2.p1	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	0
DDI-DrugBank.d232.s2.p2	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	0
DDI-DrugBank.d232.s2.p3	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	2
DDI-DrugBank.d232.s2.p4	Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	0
DDI-DrugBank.d232.s2.p5	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	2
DDI-DrugBank.d232.s2.p6	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	2
DDI-DrugBank.d232.s2.p7	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	2
DDI-DrugBank.d232.s2.p8	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	2
DDI-DrugBank.d232.s2.p9	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	0
DDI-DrugBank.d232.s2.p10	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	2
DDI-DrugBank.d232.s2.p11	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	0
DDI-DrugBank.d232.s2.p12	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	2
DDI-DrugBank.d232.s2.p13	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	0
DDI-DrugBank.d232.s2.p14	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or @DRUG$.	2
DDI-DrugBank.d233.s0.p0	Use with @DRUG$: The principal pathway for detoxification of @DRUG$ is inhibited by allopurinol.	0
DDI-DrugBank.d233.s0.p1	Use with @DRUG$: The principal pathway for detoxification of azathioprine is inhibited by @DRUG$.	0
DDI-DrugBank.d233.s0.p2	Use with Allopurinol: The principal pathway for detoxification of @DRUG$ is inhibited by @DRUG$.	0
DDI-DrugBank.d233.s1.p0	Patients receiving @DRUG$ and @DRUG$ concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.	0
DDI-DrugBank.d233.s1.p1	Patients receiving @DRUG$ and allopurinol concomitantly should have a dose reduction of @DRUG$, to approximately 1/3 to 1/4 the usual dose.	0
DDI-DrugBank.d233.s1.p2	Patients receiving azathioprine and @DRUG$ concomitantly should have a dose reduction of @DRUG$, to approximately 1/3 to 1/4 the usual dose.	0
DDI-DrugBank.d233.s3.p0	Use with @DRUG$: The use of @DRUG$ to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.	0
DDI-DrugBank.d233.s3.p1	Use with @DRUG$: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on @DRUG$ has been reported to induce severe leukopenia.	0
DDI-DrugBank.d233.s3.p2	Use with Angiotensln Converting Enzyme Inhibitors: The use of @DRUG$ to control hypertension in patients on @DRUG$ has been reported to induce severe leukopenia.	0
DDI-DrugBank.d234.s0.p0	Interaction with @DRUG$ other than @DRUG$ has not been specifically studied;	0
DDI-DrugBank.d234.s1.p0	however, no deleterious interactions were seen when @DRUG$ was administered after @DRUG$, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	4
DDI-DrugBank.d234.s1.p1	however, no deleterious interactions were seen when @DRUG$ was administered after narcotics, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	4
DDI-DrugBank.d234.s1.p2	however, no deleterious interactions were seen when @DRUG$ was administered after narcotics, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	4
DDI-DrugBank.d234.s1.p3	however, no deleterious interactions were seen when ROMAZICON was administered after @DRUG$, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	4
DDI-DrugBank.d234.s1.p4	however, no deleterious interactions were seen when ROMAZICON was administered after @DRUG$, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	4
DDI-DrugBank.d234.s1.p5	however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational @DRUG$, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	4
DDI-DrugBank.d234.s12.p0	Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	0
DDI-DrugBank.d234.s12.p1	Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	0
DDI-DrugBank.d234.s12.p2	Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	0
DDI-DrugBank.d234.s12.p3	Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	0
DDI-DrugBank.d234.s12.p4	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	0
DDI-DrugBank.d234.s12.p5	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	0
DDI-DrugBank.d234.s12.p6	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	0
DDI-DrugBank.d234.s12.p7	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	0
DDI-DrugBank.d234.s12.p8	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	0
DDI-DrugBank.d234.s12.p9	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	0
DDI-DrugBank.d234.s2.p0	Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the benzodiazepine effect by flumazenil.	0
DDI-DrugBank.d234.s2.p1	Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the @DRUG$ effect by flumazenil.	0
DDI-DrugBank.d234.s2.p2	Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by @DRUG$.	0
DDI-DrugBank.d234.s2.p3	Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the @DRUG$ effect by flumazenil.	0
DDI-DrugBank.d234.s2.p4	Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the benzodiazepine effect by @DRUG$.	0
DDI-DrugBank.d234.s2.p5	Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the @DRUG$ effect by @DRUG$.	0
DDI-DrugBank.d234.s6.p0	The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as @DRUG$, triazolopyridazines and others, are also blocked by @DRUG$.	2
DDI-DrugBank.d234.s7.p0	The pharmacokinetics of @DRUG$ are unaltered in the presence of @DRUG$ and vice versa.	0
DDI-DrugBank.d234.s8.p0	There is no pharmacokinetic interaction between @DRUG$ and @DRUG$.	0
DDI-DrugBank.d234.s9.p0	Use in Ambulatory Patients The effects of @DRUG$ may wear off before a @DRUG$ is completely cleared from the body.	4
DDI-DrugBank.d235.s4.p0	Example inhibitors include @DRUG$, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p1	Example inhibitors include @DRUG$, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p2	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p3	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p4	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p5	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p6	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p7	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p8	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p9	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p10	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p11	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p12	Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p13	Example inhibitors include azole antifungals, @DRUG$, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p14	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p15	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p16	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p17	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p18	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p19	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p20	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p21	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p22	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p23	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p24	Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p25	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p26	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p27	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p28	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p29	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p30	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p31	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p32	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p33	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p34	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p35	Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p36	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p37	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p38	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p39	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p40	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p41	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p42	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p43	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p44	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p45	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p46	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p47	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p48	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p49	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p50	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p51	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p52	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p53	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p54	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p55	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p56	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p57	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p58	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p59	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p60	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p61	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p62	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p63	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p64	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p65	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p66	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p67	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p68	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p69	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p70	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p71	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p72	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p73	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p74	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p75	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p76	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p77	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p78	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p79	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p80	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p81	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, @DRUG$, protease inhibitors, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p82	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p83	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p84	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p85	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, @DRUG$, quinidine, and verapamil.	0
DDI-DrugBank.d235.s4.p86	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p87	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p88	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, @DRUG$, and verapamil.	0
DDI-DrugBank.d235.s4.p89	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and @DRUG$.	0
DDI-DrugBank.d235.s4.p90	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d236.s0.p0	@DRUG$: @DRUG$ (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p1	@DRUG$: Gastrointestinal acidifying agents (@DRUG$, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p2	@DRUG$: Gastrointestinal acidifying agents (guanethidine, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p3	@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p4	@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p5	@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	2
DDI-DrugBank.d236.s0.p6	Acidifying agents: @DRUG$ (@DRUG$, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p7	Acidifying agents: @DRUG$ (guanethidine, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p8	Acidifying agents: @DRUG$ (guanethidine, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p9	Acidifying agents: @DRUG$ (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p10	Acidifying agents: @DRUG$ (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	2
DDI-DrugBank.d236.s0.p11	Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p12	Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p13	Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p14	Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	2
DDI-DrugBank.d236.s0.p15	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, @DRUG$, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p16	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, @DRUG$, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	2
DDI-DrugBank.d236.s0.p17	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	2
DDI-DrugBank.d236.s0.p18	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, @DRUG$, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	0
DDI-DrugBank.d236.s0.p19	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	2
DDI-DrugBank.d236.s0.p20	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of @DRUG$.	2
DDI-DrugBank.d236.s1.p0	@DRUG$ (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	2
DDI-DrugBank.d236.s1.p1	@DRUG$ (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	2
DDI-DrugBank.d236.s1.p2	@DRUG$ (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	2
DDI-DrugBank.d236.s1.p3	Urinary acidifying agents (@DRUG$, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	2
DDI-DrugBank.d236.s1.p4	Urinary acidifying agents (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	2
DDI-DrugBank.d236.s1.p5	Urinary acidifying agents (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	2
DDI-DrugBank.d236.s15.p0	@DRUG$: @DRUG$ may antagonize the hypotensive effects of antihypertensives.	0
DDI-DrugBank.d236.s15.p1	@DRUG$: Amphetamines may antagonize the hypotensive effects of @DRUG$.	0
DDI-DrugBank.d236.s15.p2	Antihypertensives: @DRUG$ may antagonize the hypotensive effects of @DRUG$.	0
DDI-DrugBank.d236.s17.p0	@DRUG$: @DRUG$ may delay intestinal absorption of ethosuximide.	0
DDI-DrugBank.d236.s17.p1	@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$.	0
DDI-DrugBank.d236.s17.p2	Ethosuximide: @DRUG$ may delay intestinal absorption of @DRUG$.	0
DDI-DrugBank.d236.s18.p0	@DRUG$: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.	0
DDI-DrugBank.d236.s18.p1	@DRUG$: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$.	0
DDI-DrugBank.d236.s18.p2	Haloperidol: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$.	0
DDI-DrugBank.d236.s19.p0	@DRUG$: The stimulatory effects of @DRUG$ may be inhibited by lithium carbonate.	4
DDI-DrugBank.d236.s19.p1	@DRUG$: The stimulatory effects of amphetamines may be inhibited by @DRUG$.	4
DDI-DrugBank.d236.s19.p2	Lithium carbonate: The stimulatory effects of @DRUG$ may be inhibited by @DRUG$.	4
DDI-DrugBank.d236.s20.p0	@DRUG$: @DRUG$ potentiate the analgesic effect of meperidine.	3
DDI-DrugBank.d236.s20.p1	@DRUG$: Amphetamines potentiate the analgesic effect of @DRUG$.	0
DDI-DrugBank.d236.s20.p2	Meperidine: @DRUG$ potentiate the analgesic effect of @DRUG$.	3
DDI-DrugBank.d236.s21.p0	@DRUG$ therapy: Urinary excretion of @DRUG$ is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.	0
DDI-DrugBank.d236.s21.p1	@DRUG$ therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by @DRUG$ used in methenamine therapy.	0
DDI-DrugBank.d236.s21.p2	@DRUG$ therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in @DRUG$ therapy.	0
DDI-DrugBank.d236.s21.p3	Methenamine therapy: Urinary excretion of @DRUG$ is increased, and efficacy is reduced, by @DRUG$ used in methenamine therapy.	0
DDI-DrugBank.d236.s21.p4	Methenamine therapy: Urinary excretion of @DRUG$ is increased, and efficacy is reduced, by acidifying agents used in @DRUG$ therapy.	0
DDI-DrugBank.d236.s21.p5	Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by @DRUG$ used in @DRUG$ therapy.	0
DDI-DrugBank.d236.s22.p0	@DRUG$: @DRUG$ enhance the adrenergic effect of norepinephrine.	0
DDI-DrugBank.d236.s22.p1	@DRUG$: Amphetamines enhance the adrenergic effect of @DRUG$.	0
DDI-DrugBank.d236.s22.p2	Norepinephrine: @DRUG$ enhance the adrenergic effect of @DRUG$.	0
DDI-DrugBank.d236.s25.p0	@DRUG$: @DRUG$ may delay intestinal absorption of phenytoin;	0
DDI-DrugBank.d236.s25.p1	@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	0
DDI-DrugBank.d236.s25.p2	Phenytoin: @DRUG$ may delay intestinal absorption of @DRUG$;	0
DDI-DrugBank.d236.s28.p0	@DRUG$: @DRUG$ inhibit the hypotensive effect of veratrum alkaloids.	0
DDI-DrugBank.d236.s28.p1	@DRUG$: Amphetamines inhibit the hypotensive effect of @DRUG$.	0
DDI-DrugBank.d236.s28.p2	Veratrum alkaloids: @DRUG$ inhibit the hypotensive effect of @DRUG$.	0
DDI-DrugBank.d236.s3.p0	@DRUG$: @DRUG$ are inhibited by amphetamines.	0
DDI-DrugBank.d236.s3.p1	@DRUG$: Adrenergic blockers are inhibited by @DRUG$.	0
DDI-DrugBank.d236.s3.p2	Adrenergic blockers: @DRUG$ are inhibited by @DRUG$.	0
DDI-DrugBank.d236.s4.p0	Alkalinizing agents: Gastrointestinal alkalinizing agents (@DRUG$, etc.) increase absorption of @DRUG$.	4
DDI-DrugBank.d236.s5.p0	Urinary alkalinizing agents (@DRUG$, some @DRUG$) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.	2
DDI-DrugBank.d236.s5.p1	Urinary alkalinizing agents (@DRUG$, some thiazides) increase the concentration of the non-ionized species of the @DRUG$ molecule, thereby decreasing urinary excretion.	2
DDI-DrugBank.d236.s5.p2	Urinary alkalinizing agents (acetazolamide, some @DRUG$) increase the concentration of the non-ionized species of the @DRUG$ molecule, thereby decreasing urinary excretion.	2
DDI-DrugBank.d236.s7.p0	@DRUG$, @DRUG$: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;	4
DDI-DrugBank.d236.s7.p1	@DRUG$, tricyclic: @DRUG$ may enhance the activity of tricyclic or sympathomimetic agents;	4
DDI-DrugBank.d236.s7.p2	@DRUG$, tricyclic: Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	4
DDI-DrugBank.d236.s7.p3	@DRUG$, tricyclic: Amphetamines may enhance the activity of tricyclic or @DRUG$;	4
DDI-DrugBank.d236.s7.p4	Antidepressants, @DRUG$: @DRUG$ may enhance the activity of tricyclic or sympathomimetic agents;	4
DDI-DrugBank.d236.s7.p5	Antidepressants, @DRUG$: Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	4
DDI-DrugBank.d236.s7.p6	Antidepressants, @DRUG$: Amphetamines may enhance the activity of tricyclic or @DRUG$;	4
DDI-DrugBank.d236.s7.p7	Antidepressants, tricyclic: @DRUG$ may enhance the activity of @DRUG$ or sympathomimetic agents;	4
DDI-DrugBank.d236.s7.p8	Antidepressants, tricyclic: @DRUG$ may enhance the activity of tricyclic or @DRUG$;	4
DDI-DrugBank.d236.s7.p9	Antidepressants, tricyclic: Amphetamines may enhance the activity of @DRUG$ or @DRUG$;	4
DDI-DrugBank.d236.s8.p0	@DRUG$ with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	2
DDI-DrugBank.d236.s8.p1	@DRUG$ with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	2
DDI-DrugBank.d236.s8.p2	@DRUG$ with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	2
DDI-DrugBank.d236.s8.p3	@DRUG$ with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	2
DDI-DrugBank.d236.s8.p4	d-amphetamine with @DRUG$ or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	2
DDI-DrugBank.d236.s8.p5	d-amphetamine with @DRUG$ or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	2
DDI-DrugBank.d236.s8.p6	d-amphetamine with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	2
DDI-DrugBank.d236.s8.p7	d-amphetamine with desipramine or @DRUG$ and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	2
DDI-DrugBank.d236.s8.p8	d-amphetamine with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	2
DDI-DrugBank.d236.s8.p9	d-amphetamine with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of @DRUG$ in the brain;	2
DDI-DrugBank.d237.s10.p0	@DRUG$: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.	0
DDI-DrugBank.d237.s10.p1	@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with ranitidine.	0
DDI-DrugBank.d237.s10.p2	@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.	0
DDI-DrugBank.d237.s10.p3	@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with @DRUG$.	0
DDI-DrugBank.d237.s10.p4	H2 Receptor Antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with ranitidine.	0
DDI-DrugBank.d237.s10.p5	H2 Receptor Antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.	0
DDI-DrugBank.d237.s10.p6	H2 Receptor Antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with @DRUG$.	0
DDI-DrugBank.d237.s10.p7	H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.	0
DDI-DrugBank.d237.s10.p8	H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with @DRUG$.	0
DDI-DrugBank.d237.s10.p9	H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with @DRUG$.	0
DDI-DrugBank.d237.s11.p0	The gastrointestinal absorption of @DRUG$ and @DRUG$ is accelerated when they are coadministered with cisapride.	4
DDI-DrugBank.d237.s11.p1	The gastrointestinal absorption of @DRUG$ and ranitidine is accelerated when they are coadministered with @DRUG$.	4
DDI-DrugBank.d237.s11.p2	The gastrointestinal absorption of cimetidine and @DRUG$ is accelerated when they are coadministered with @DRUG$.	4
DDI-DrugBank.d237.s15.p0	@DRUG$ (such as @DRUG$);	0
DDI-DrugBank.d237.s17.p0	certain @DRUG$ (such as @DRUG$);	3
DDI-DrugBank.d237.s18.p0	@DRUG$, @DRUG$, sparfloxacin, and terodiline.	3
DDI-DrugBank.d237.s18.p1	@DRUG$, bepridil, @DRUG$, and terodiline.	0
DDI-DrugBank.d237.s18.p2	@DRUG$, bepridil, sparfloxacin, and @DRUG$.	3
DDI-DrugBank.d237.s18.p3	astemizole, @DRUG$, @DRUG$, and terodiline.	0
DDI-DrugBank.d237.s18.p4	astemizole, @DRUG$, sparfloxacin, and @DRUG$.	0
DDI-DrugBank.d237.s18.p5	astemizole, bepridil, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d237.s2.p0	@DRUG$: In vitro and/or in vivo data show that @DRUG$, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p1	@DRUG$: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p2	@DRUG$: In vitro and/or in vivo data show that clarithromycin, erythromycin, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p3	@DRUG$: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p4	@DRUG$: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p5	Antibiotics: In vitro and/or in vivo data show that @DRUG$, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p6	Antibiotics: In vitro and/or in vivo data show that @DRUG$, erythromycin, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p7	Antibiotics: In vitro and/or in vivo data show that @DRUG$, erythromycin, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p8	Antibiotics: In vitro and/or in vivo data show that @DRUG$, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p9	Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p10	Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p11	Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p12	Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and @DRUG$ markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p13	Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s2.p14	Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s5.p0	It is advisable to check coagulation time within the first few days after the start and discontinuation of @DRUG$ therapy, with an appropriate adjustment of the @DRUG$ dose, if necessary.	0
DDI-DrugBank.d237.s6.p0	@DRUG$: In vitro data indicate that @DRUG$ inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s6.p1	@DRUG$: In vitro data indicate that nefazodone inhibits the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s6.p2	@DRUG$: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s6.p3	Antidepressants: In vitro data indicate that @DRUG$ inhibits the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s6.p4	Antidepressants: In vitro data indicate that @DRUG$ inhibits the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s6.p5	Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of @DRUG$, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p0	@DRUG$: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p1	@DRUG$: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p2	@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p3	@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p4	@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p5	Antifungals: In vitro and/or in vivo data indicate that @DRUG$, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p6	Antifungals: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p7	Antifungals: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p8	Antifungals: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p9	Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p10	Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p11	Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p12	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p13	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s7.p14	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	0
DDI-DrugBank.d237.s8.p0	Human pharmacokinetic data indicate that oral @DRUG$ markedly inhibits the metabolism of @DRUG$, resulting in a mean eight-fold increase in AUC of cisapride.	0
DDI-DrugBank.d237.s8.p1	Human pharmacokinetic data indicate that oral @DRUG$ markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of @DRUG$.	0
DDI-DrugBank.d237.s8.p2	Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of @DRUG$, resulting in a mean eight-fold increase in AUC of @DRUG$.	0
DDI-DrugBank.d238.s10.p0	Poor metabolizers have higher than expected lasma concentrations of @DRUG$ (@DRUG$) when given usual doses.	0
DDI-DrugBank.d238.s15.p0	@DRUG$) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).	0
DDI-DrugBank.d238.s15.p1	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	0
DDI-DrugBank.d238.s15.p2	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and flecainide).	3
DDI-DrugBank.d238.s15.p3	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	3
DDI-DrugBank.d238.s15.p4	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	3
DDI-DrugBank.d238.s15.p5	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	0
DDI-DrugBank.d238.s15.p6	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the @DRUG$ propafenone and flecainide).	0
DDI-DrugBank.d238.s15.p7	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	0
DDI-DrugBank.d238.s15.p8	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	0
DDI-DrugBank.d238.s15.p9	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the @DRUG$ propafenone and flecainide).	0
DDI-DrugBank.d238.s15.p10	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	0
DDI-DrugBank.d238.s15.p11	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).	0
DDI-DrugBank.d238.s15.p12	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ @DRUG$ and flecainide).	3
DDI-DrugBank.d238.s15.p13	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and @DRUG$).	3
DDI-DrugBank.d238.s15.p14	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and @DRUG$).	3
DDI-DrugBank.d238.s16.p0	While all the @DRUG$ (@DRUG$), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p1	While all the @DRUG$ (SSRIs), e.g., @DRUG$, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p2	While all the @DRUG$ (SSRIs), e.g., fluoxetine, @DRUG$, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p3	While all the @DRUG$ (SSRIs), e.g., fluoxetine, sertraline, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p4	While all the @DRUG$ (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p5	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., @DRUG$, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p6	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, @DRUG$, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p7	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, sertraline, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p8	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, sertraline, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p9	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, @DRUG$, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p10	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, sertraline, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p11	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, sertraline, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p12	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, @DRUG$, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p13	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, @DRUG$, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s16.p14	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, @DRUG$, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	4
DDI-DrugBank.d238.s17.p0	@DRUG$ has also been shown to inhibit P450 1A2, an isoform also involved in @DRUG$metabolism.	0
DDI-DrugBank.d238.s18.p0	The extent to which @DRUG$-@DRUG$interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.	2
DDI-DrugBank.d238.s18.p1	The extent to which @DRUG$-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	2
DDI-DrugBank.d238.s18.p2	The extent to which SSRI-@DRUG$interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	2
DDI-DrugBank.d238.s2.p0	@DRUG$ should not be used with @DRUG$.	4
DDI-DrugBank.d238.s21.p0	Concomitant use of agents in the @DRUG$ (which includes @DRUG$) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.	4
DDI-DrugBank.d238.s21.p1	Concomitant use of agents in the @DRUG$ (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	4
DDI-DrugBank.d238.s21.p2	Concomitant use of agents in the tricyclic antidepressant class (which includes @DRUG$) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	4
DDI-DrugBank.d238.s3.p0	Close supervision and careful adjustment of dosage are required when @DRUG$ is administered with @DRUG$ or sympathomimetic drugs.	0
DDI-DrugBank.d238.s3.p1	Close supervision and careful adjustment of dosage are required when @DRUG$ is administered with anticholinergic or @DRUG$.	0
DDI-DrugBank.d238.s3.p2	Close supervision and careful adjustment of dosage are required when Anafranil is administered with @DRUG$ or @DRUG$.	0
DDI-DrugBank.d238.s6.p0	plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p1	plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p2	plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p3	plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p4	plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p5	plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	0
DDI-DrugBank.d238.s6.p6	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p7	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p8	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p9	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p10	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	0
DDI-DrugBank.d238.s6.p11	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	3
DDI-DrugBank.d238.s6.p12	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	3
DDI-DrugBank.d238.s6.p13	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p14	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	0
DDI-DrugBank.d238.s6.p15	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	3
DDI-DrugBank.d238.s6.p16	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p17	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	0
DDI-DrugBank.d238.s6.p18	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, @DRUG$), and such an effect may be anticipated with CMI as well.	0
DDI-DrugBank.d238.s6.p19	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	0
DDI-DrugBank.d238.s6.p20	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with @DRUG$ as well.	0
DDI-DrugBank.d238.s7.p0	Administration of @DRUG$ has been reported to increase the plasma levels of @DRUG$, if given concomitantly.	0
DDI-DrugBank.d239.s2.p0	The co-administration of @DRUG$ with IV @DRUG$ such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p1	The co-administration of @DRUG$ with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p2	The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p3	The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p4	The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p5	The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	0
DDI-DrugBank.d239.s2.p6	The co-administration of Natrecor with IV @DRUG$ such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p7	The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p8	The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p9	The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p10	The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	0
DDI-DrugBank.d239.s2.p11	The co-administration of Natrecor with IV vasodilators such as @DRUG$, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p12	The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p13	The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p14	The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	0
DDI-DrugBank.d239.s2.p15	The co-administration of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p16	The co-administration of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p17	The co-administration of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	0
DDI-DrugBank.d239.s2.p18	The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	0
DDI-DrugBank.d239.s2.p19	The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	0
DDI-DrugBank.d239.s2.p20	The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	0
DDI-DrugBank.d240.s0.p0	@DRUG$ may interact with @DRUG$ or other CNS depressants, causing increased sedative effects.	4
DDI-DrugBank.d240.s0.p1	@DRUG$ may interact with alcohol or other @DRUG$, causing increased sedative effects.	4
DDI-DrugBank.d240.s0.p2	Ethopropazine may interact with @DRUG$ or other @DRUG$, causing increased sedative effects.	4
DDI-DrugBank.d240.s2.p0	@DRUG$ can interact with @DRUG$, increasing the metabolism of chlorpromazine.	0
DDI-DrugBank.d240.s2.p1	@DRUG$ can interact with chlorpromazine, increasing the metabolism of @DRUG$.	0
DDI-DrugBank.d240.s2.p2	Ethopropazine can interact with @DRUG$, increasing the metabolism of @DRUG$.	0
DDI-DrugBank.d241.s0.p0	Additional reductions in blood pressure may occur when @DRUG$ is administered with @DRUG$, antihypertensive agents, or other vasodilators.	4
DDI-DrugBank.d241.s0.p1	Additional reductions in blood pressure may occur when @DRUG$ is administered with diuretics, @DRUG$, or other vasodilators.	4
DDI-DrugBank.d241.s0.p2	Additional reductions in blood pressure may occur when @DRUG$ is administered with diuretics, antihypertensive agents, or other @DRUG$.	4
DDI-DrugBank.d241.s0.p3	Additional reductions in blood pressure may occur when FLOLAN is administered with @DRUG$, @DRUG$, or other vasodilators.	4
DDI-DrugBank.d241.s0.p4	Additional reductions in blood pressure may occur when FLOLAN is administered with @DRUG$, antihypertensive agents, or other @DRUG$.	4
DDI-DrugBank.d241.s0.p5	Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, @DRUG$, or other @DRUG$.	4
DDI-DrugBank.d241.s1.p0	When other @DRUG$ or @DRUG$ are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.	0
DDI-DrugBank.d241.s1.p1	When other @DRUG$ or anticoagulants are used concomitantly, there is the potential for @DRUG$ to increase the risk of bleeding.	0
DDI-DrugBank.d241.s1.p2	When other antiplatelet agents or @DRUG$ are used concomitantly, there is the potential for @DRUG$ to increase the risk of bleeding.	0
DDI-DrugBank.d241.s3.p0	In clinical trials, @DRUG$ was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p1	In clinical trials, @DRUG$ was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p2	In clinical trials, @DRUG$ was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p3	In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p4	In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p5	In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p6	In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p7	In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p8	In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p9	In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p10	In clinical trials, FLOLAN was used with @DRUG$, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p11	In clinical trials, FLOLAN was used with @DRUG$, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p12	In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p13	In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p14	In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p15	In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p16	In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p17	In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p18	In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p19	In clinical trials, FLOLAN was used with digoxin, @DRUG$, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p20	In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p21	In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p22	In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p23	In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p24	In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p25	In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p26	In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p27	In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p28	In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p29	In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p30	In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p31	In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p32	In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p33	In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p34	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p35	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p36	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p37	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p38	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p39	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p40	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p41	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p42	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p43	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p44	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p45	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p46	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p47	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p48	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p49	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p50	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p51	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p52	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p53	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s3.p54	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	0
DDI-DrugBank.d241.s5.p0	However, patients on @DRUG$ may show elevations of @DRUG$ concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.	0
DDI-DrugBank.d241.s5.p1	However, patients on @DRUG$ may show elevations of digoxin concentrations after initiation of therapy with @DRUG$, which may be clinically significant in patients prone to digoxin toxicity.	0
DDI-DrugBank.d241.s5.p2	However, patients on @DRUG$ may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to @DRUG$ toxicity.	0
DDI-DrugBank.d241.s5.p3	However, patients on digoxin may show elevations of @DRUG$ concentrations after initiation of therapy with @DRUG$, which may be clinically significant in patients prone to digoxin toxicity.	0
DDI-DrugBank.d241.s5.p4	However, patients on digoxin may show elevations of @DRUG$ concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to @DRUG$ toxicity.	0
DDI-DrugBank.d241.s5.p5	However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with @DRUG$, which may be clinically significant in patients prone to @DRUG$ toxicity.	0
DDI-DrugBank.d244.s0.p0	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p1	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p2	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p3	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p4	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p5	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p6	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	3
DDI-DrugBank.d244.s0.p7	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	3
DDI-DrugBank.d244.s0.p8	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p9	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p10	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p11	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p12	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p13	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	3
DDI-DrugBank.d244.s0.p14	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	3
DDI-DrugBank.d244.s0.p15	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p16	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p17	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p18	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p19	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	3
DDI-DrugBank.d244.s0.p20	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	3
DDI-DrugBank.d244.s0.p21	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p22	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p23	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p24	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	3
DDI-DrugBank.d244.s0.p25	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	3
DDI-DrugBank.d244.s0.p26	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p27	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p28	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	3
DDI-DrugBank.d244.s0.p29	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	3
DDI-DrugBank.d244.s0.p30	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., @DRUG$), tacrolimus, vancomycin.	3
DDI-DrugBank.d244.s0.p31	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), @DRUG$, vancomycin.	3
DDI-DrugBank.d244.s0.p32	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	3
DDI-DrugBank.d244.s0.p33	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), @DRUG$, vancomycin.	3
DDI-DrugBank.d244.s0.p34	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, @DRUG$.	3
DDI-DrugBank.d244.s0.p35	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, @DRUG$.	3
DDI-DrugBank.d245.s0.p0	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p1	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p2	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p3	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p4	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p5	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p6	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p7	The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d245.s0.p8	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p9	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p10	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p11	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p12	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p13	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p14	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d245.s0.p15	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p16	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p17	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p18	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p19	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p20	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d245.s0.p21	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p22	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p23	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p24	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p25	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d245.s0.p26	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p27	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p28	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p29	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d245.s0.p30	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p31	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p32	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d245.s0.p33	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, @DRUG$, and beta adrenergic blocking agents.	3
DDI-DrugBank.d245.s0.p34	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.	3
DDI-DrugBank.d245.s0.p35	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.	3
DDI-DrugBank.d245.s4.p0	These drugs include the @DRUG$ and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p1	These drugs include the @DRUG$ and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p2	These drugs include the @DRUG$ and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p3	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p4	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p5	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p6	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p7	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p8	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	4
DDI-DrugBank.d245.s4.p9	These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d245.s4.p10	These drugs include the thiazides and other @DRUG$, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p11	These drugs include the thiazides and other @DRUG$, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p12	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p13	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p14	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p15	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p16	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p17	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	4
DDI-DrugBank.d245.s4.p18	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d245.s4.p19	These drugs include the thiazides and other diuretics, @DRUG$, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p20	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p21	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p22	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p23	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p24	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p25	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	1
DDI-DrugBank.d245.s4.p26	These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d245.s4.p27	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p28	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p29	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p30	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p31	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p32	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	1
DDI-DrugBank.d245.s4.p33	These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d245.s4.p34	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p35	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p36	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p37	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p38	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	1
DDI-DrugBank.d245.s4.p39	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d245.s4.p40	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p41	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p42	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p43	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	1
DDI-DrugBank.d245.s4.p44	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d245.s4.p45	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p46	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p47	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	4
DDI-DrugBank.d245.s4.p48	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d245.s4.p49	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, @DRUG$, calcium channel blocking drugs, and isoniazid.	1
DDI-DrugBank.d245.s4.p50	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, @DRUG$, and isoniazid.	4
DDI-DrugBank.d245.s4.p51	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d245.s4.p52	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, @DRUG$, and isoniazid.	1
DDI-DrugBank.d245.s4.p53	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and @DRUG$.	1
DDI-DrugBank.d245.s4.p54	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and @DRUG$.	4
DDI-DrugBank.d245.s7.p0	Since animal studies suggest that the action of @DRUG$ may be prolonged by therapy with @DRUG$, barbiturates should be employed with caution.	0
DDI-DrugBank.d245.s7.p1	Since animal studies suggest that the action of @DRUG$ may be prolonged by therapy with chlorpropamide, @DRUG$ should be employed with caution.	0
DDI-DrugBank.d245.s7.p2	Since animal studies suggest that the action of barbiturates may be prolonged by therapy with @DRUG$, @DRUG$ should be employed with caution.	0
DDI-DrugBank.d245.s8.p0	In some patients, a @DRUG$-like reaction may be produced by the ingestion of @DRUG$.	0
DDI-DrugBank.d245.s9.p0	A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported.	0
DDI-DrugBank.d246.s1.p0	When used concurrently with such drugs, the dose of @DRUG$ should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of @DRUG$.	0
DDI-DrugBank.d246.s10.p0	The pharmacokinetics of a 1-mg dose of @DRUG$ administered as @DRUG$ were not affected by the coadministration of cimetidine (300 mg QID).	0
DDI-DrugBank.d246.s10.p1	The pharmacokinetics of a 1-mg dose of @DRUG$ administered as STADOL NS were not affected by the coadministration of @DRUG$ (300 mg QID).	0
DDI-DrugBank.d246.s10.p2	The pharmacokinetics of a 1-mg dose of butorphanol administered as @DRUG$ were not affected by the coadministration of @DRUG$ (300 mg QID).	0
DDI-DrugBank.d246.s11.p0	Conversely, the administration of @DRUG$ (1 mg @DRUG$ QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.	0
DDI-DrugBank.d246.s11.p1	Conversely, the administration of @DRUG$ (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of @DRUG$.	0
DDI-DrugBank.d246.s11.p2	Conversely, the administration of STADOL NS (1 mg @DRUG$ QID) did not alter the pharmacokinetics of a 300-mg dose of @DRUG$.	0
DDI-DrugBank.d246.s12.p0	It is not known if the effects of @DRUG$ are altered by concomitant medications that affect hepatic metabolism of drugs (@DRUG$, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.	0
DDI-DrugBank.d246.s14.p0	Therefore, a slower onset can be anticipated if @DRUG$ is administered concomitantly with, or immediately following, a @DRUG$.	0
DDI-DrugBank.d246.s15.p0	No information is available about the use of @DRUG$ concurrently with @DRUG$.	0
DDI-DrugBank.d246.s2.p0	In healthy volunteers, the pharmacokinetics of a 1-mg dose of @DRUG$ administered as @DRUG$ were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.	0
DDI-DrugBank.d246.s2.p1	In healthy volunteers, the pharmacokinetics of a 1-mg dose of @DRUG$ administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of @DRUG$.	0
DDI-DrugBank.d246.s2.p2	In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as @DRUG$ were not affected by the coadministration of a single 6-mg subcutaneous dose of @DRUG$.	0
DDI-DrugBank.d246.s3.p0	However, in another study in healthy volunteers, the pharmacokinetics of @DRUG$ were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of @DRUG$ was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.	0
DDI-DrugBank.d246.s3.p1	However, in another study in healthy volunteers, the pharmacokinetics of @DRUG$ were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of @DRUG$ nasal spray.	0
DDI-DrugBank.d246.s3.p2	However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of @DRUG$ was administered 1 minute after a 20-mg dose of @DRUG$ nasal spray.	0
DDI-DrugBank.d246.s5.p0	When the @DRUG$ was administered 30 minutes after the @DRUG$ nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.	0
DDI-DrugBank.d246.s5.p1	When the @DRUG$ was administered 30 minutes after the sumatriptan nasal spray, the AUC of @DRUG$ increased 11% and Cmax decreased 18%.	0
DDI-DrugBank.d246.s5.p2	When the STADOL NS was administered 30 minutes after the @DRUG$ nasal spray, the AUC of @DRUG$ increased 11% and Cmax decreased 18%.	0
DDI-DrugBank.d246.s6.p0	In neither case were the pharmacokinetics of @DRUG$ affected by coadministration with @DRUG$.	0
DDI-DrugBank.d247.s1.p0	All @DRUG$ should be used cautiously in patients taking @DRUG$.	1
DDI-DrugBank.d247.s2.p0	@DRUG$ should not be administered concomitantly with other @DRUG$ (such as isoproterenol) because of possible additive effects and increased toxicity.	0
DDI-DrugBank.d247.s2.p1	@DRUG$ should not be administered concomitantly with other sympathomimetic drugs (such as @DRUG$) because of possible additive effects and increased toxicity.	0
DDI-DrugBank.d247.s2.p2	Epinephrine should not be administered concomitantly with other @DRUG$ (such as @DRUG$) because of possible additive effects and increased toxicity.	4
DDI-DrugBank.d247.s5.p0	Administration of @DRUG$ to patients receiving @DRUG$ or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..	3
DDI-DrugBank.d247.s5.p1	Administration of @DRUG$ to patients receiving cyclopropane or @DRUG$ such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..	3
DDI-DrugBank.d247.s5.p2	Administration of @DRUG$ to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as @DRUG$ which sensitize the myocardium, may induce cardiac arrhythmia..	3
DDI-DrugBank.d247.s5.p3	Administration of epinephrine to patients receiving @DRUG$ or @DRUG$ such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..	3
DDI-DrugBank.d247.s5.p4	Administration of epinephrine to patients receiving @DRUG$ or halogenated hydrocarbon general anesthetics such as @DRUG$ which sensitize the myocardium, may induce cardiac arrhythmia..	4
DDI-DrugBank.d247.s5.p5	Administration of epinephrine to patients receiving cyclopropane or @DRUG$ such as @DRUG$ which sensitize the myocardium, may induce cardiac arrhythmia..	3
DDI-DrugBank.d247.s7.p0	@DRUG$ also should be used cautiously with other drugs (e.g., @DRUG$, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.	3
DDI-DrugBank.d247.s7.p1	@DRUG$ also should be used cautiously with other drugs (e.g., digitalis, @DRUG$) that sensitize the myocardium to the actions of sympathomimetic drugs.	3
DDI-DrugBank.d247.s7.p2	@DRUG$ also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of @DRUG$.	3
DDI-DrugBank.d247.s7.p3	Epinephrine also should be used cautiously with other drugs (e.g., @DRUG$, @DRUG$) that sensitize the myocardium to the actions of sympathomimetic drugs.	3
DDI-DrugBank.d247.s7.p4	Epinephrine also should be used cautiously with other drugs (e.g., @DRUG$, glycosides) that sensitize the myocardium to the actions of @DRUG$.	3
DDI-DrugBank.d247.s7.p5	Epinephrine also should be used cautiously with other drugs (e.g., digitalis, @DRUG$) that sensitize the myocardium to the actions of @DRUG$.	3
DDI-DrugBank.d247.s8.p0	@DRUG$ may decrease vascular response to pressor drugs such as @DRUG$.	4
DDI-DrugBank.d247.s9.p0	@DRUG$ may antagonize the neuron blockade produced by @DRUG$ resulting in decreased antihypertensive effect and requiring increased dosage of the latter.	0
DDI-DrugBank.d248.s0.p0	May interact @DRUG$ (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	3
DDI-DrugBank.d248.s0.p1	May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	3
DDI-DrugBank.d248.s0.p2	May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	0
DDI-DrugBank.d248.s0.p3	May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	3
DDI-DrugBank.d248.s0.p4	May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	3
DDI-DrugBank.d248.s0.p5	May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	3
DDI-DrugBank.d248.s0.p6	May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	3
DDI-DrugBank.d248.s0.p7	May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	3
DDI-DrugBank.d248.s0.p8	May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	3
DDI-DrugBank.d248.s0.p9	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	3
DDI-DrugBank.d248.s0.p10	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	3
DDI-DrugBank.d248.s0.p11	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	3
DDI-DrugBank.d248.s0.p12	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), @DRUG$ (increased effect of corticosteroids).	3
DDI-DrugBank.d248.s0.p13	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of @DRUG$).	3
DDI-DrugBank.d248.s0.p14	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of @DRUG$).	3
DDI-DrugBank.d249.s0.p0	@DRUG$: Concomitant administration of @DRUG$ and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s0.p1	@DRUG$: Concomitant administration of diclofenac and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s0.p2	@DRUG$: Concomitant administration of diclofenac and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s0.p3	@DRUG$: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s0.p4	Aspirin: Concomitant administration of @DRUG$ and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s0.p5	Aspirin: Concomitant administration of @DRUG$ and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s0.p6	Aspirin: Concomitant administration of @DRUG$ and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s0.p7	Aspirin: Concomitant administration of diclofenac and @DRUG$ is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s0.p8	Aspirin: Concomitant administration of diclofenac and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s0.p9	Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	0
DDI-DrugBank.d249.s1.p0	@DRUG$: While studies have not shown @DRUG$ to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.	0
DDI-DrugBank.d249.s1.p1	@DRUG$: While studies have not shown diclofenac to interact with @DRUG$, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.	0
DDI-DrugBank.d249.s1.p2	@DRUG$: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other @DRUG$.	0
DDI-DrugBank.d249.s1.p3	Anticoagulants: While studies have not shown @DRUG$ to interact with @DRUG$, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.	0
DDI-DrugBank.d249.s1.p4	Anticoagulants: While studies have not shown @DRUG$ to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other @DRUG$.	0
DDI-DrugBank.d249.s1.p5	Anticoagulants: While studies have not shown diclofenac to interact with @DRUG$, caution should be exercised, nonetheless, since interactions have been seen with other @DRUG$.	0
DDI-DrugBank.d249.s11.p0	There are rare reports, however, from marketing experiences, of changes in effects of @DRUG$ or oral @DRUG$ in the presence of diclofenac that necessitated changes in the doses of such agents.	0
DDI-DrugBank.d249.s11.p1	There are rare reports, however, from marketing experiences, of changes in effects of @DRUG$ or oral hypoglycemic agents in the presence of @DRUG$ that necessitated changes in the doses of such agents.	0
DDI-DrugBank.d249.s11.p2	There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral @DRUG$ in the presence of @DRUG$ that necessitated changes in the doses of such agents.	0
DDI-DrugBank.d249.s13.p0	A direct causal relationship has not been established, but physicians should consider the possibility that @DRUG$ may alter a diabetic patient s response to @DRUG$ or oral hypoglycemic agents.	3
DDI-DrugBank.d249.s13.p1	A direct causal relationship has not been established, but physicians should consider the possibility that @DRUG$ may alter a diabetic patient s response to insulin or oral @DRUG$.	0
DDI-DrugBank.d249.s13.p2	A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to @DRUG$ or oral @DRUG$.	0
DDI-DrugBank.d249.s14.p0	@DRUG$: @DRUG$ and other NSAIDs can inhibit the activity of diuretics.	3
DDI-DrugBank.d249.s14.p1	@DRUG$: Diclofenac and other @DRUG$ can inhibit the activity of diuretics.	3
DDI-DrugBank.d249.s14.p2	@DRUG$: Diclofenac and other NSAIDs can inhibit the activity of @DRUG$.	3
DDI-DrugBank.d249.s14.p3	Diuretics: @DRUG$ and other @DRUG$ can inhibit the activity of diuretics.	1
DDI-DrugBank.d249.s14.p4	Diuretics: @DRUG$ and other NSAIDs can inhibit the activity of @DRUG$.	2
DDI-DrugBank.d249.s14.p5	Diuretics: Diclofenac and other @DRUG$ can inhibit the activity of @DRUG$.	3
DDI-DrugBank.d249.s16.p0	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, @DRUG$, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p1	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, @DRUG$, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p2	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p3	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p4	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p5	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p6	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	0
DDI-DrugBank.d249.s16.p7	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, @DRUG$, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p8	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p9	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p10	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p11	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p12	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	0
DDI-DrugBank.d249.s16.p13	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p14	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p15	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p16	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p17	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	0
DDI-DrugBank.d249.s16.p18	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p19	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p20	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p21	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	0
DDI-DrugBank.d249.s16.p22	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p23	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p24	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	0
DDI-DrugBank.d249.s16.p25	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, @DRUG$, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	0
DDI-DrugBank.d249.s16.p26	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	0
DDI-DrugBank.d249.s16.p27	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of @DRUG$.	0
DDI-DrugBank.d249.s17.p0	@DRUG$ toxicity has been reported to have occurred in a patient on chronic @DRUG$ treatment following the initiation of diclofenac therapy.	0
DDI-DrugBank.d249.s17.p1	@DRUG$ toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of @DRUG$ therapy.	0
DDI-DrugBank.d249.s17.p2	Phenobarbital toxicity has been reported to have occurred in a patient on chronic @DRUG$ treatment following the initiation of @DRUG$ therapy.	0
DDI-DrugBank.d249.s18.p0	Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.	0
DDI-DrugBank.d249.s18.p1	Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or warfarin.	0
DDI-DrugBank.d249.s18.p2	Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or warfarin.	0
DDI-DrugBank.d249.s18.p3	Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or @DRUG$.	0
DDI-DrugBank.d249.s18.p4	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or warfarin.	0
DDI-DrugBank.d249.s18.p5	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or warfarin.	0
DDI-DrugBank.d249.s18.p6	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or @DRUG$.	0
DDI-DrugBank.d249.s18.p7	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$, @DRUG$ (10% decrease in binding), or warfarin.	0
DDI-DrugBank.d249.s18.p8	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or @DRUG$.	0
DDI-DrugBank.d249.s18.p9	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or @DRUG$.	0
DDI-DrugBank.d249.s19.p0	@DRUG$, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p1	@DRUG$, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p2	@DRUG$, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p3	@DRUG$, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p4	@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p5	@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p6	@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p7	@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	0
DDI-DrugBank.d249.s19.p8	Benzylpenicillin, @DRUG$, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p9	Benzylpenicillin, @DRUG$, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p10	Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p11	Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p12	Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	2
DDI-DrugBank.d249.s19.p13	Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p14	Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	0
DDI-DrugBank.d249.s19.p15	Benzylpenicillin, ampicillin, @DRUG$, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p16	Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p17	Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p18	Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p19	Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p20	Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	0
DDI-DrugBank.d249.s19.p21	Benzylpenicillin, ampicillin, oxacillin, @DRUG$, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p22	Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p23	Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p24	Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p25	Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	0
DDI-DrugBank.d249.s19.p26	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p27	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p28	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p29	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	0
DDI-DrugBank.d249.s19.p30	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p31	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p32	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	0
DDI-DrugBank.d249.s19.p33	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	0
DDI-DrugBank.d249.s19.p34	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	0
DDI-DrugBank.d249.s19.p35	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of @DRUG$ in human serum.	0
DDI-DrugBank.d249.s2.p0	Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all @DRUG$, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	0
DDI-DrugBank.d249.s2.p1	Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	0
DDI-DrugBank.d249.s2.p2	Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	0
DDI-DrugBank.d249.s2.p3	Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	0
DDI-DrugBank.d249.s2.p4	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all @DRUG$, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	0
DDI-DrugBank.d249.s2.p5	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all @DRUG$, including diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	0
DDI-DrugBank.d249.s2.p6	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all @DRUG$, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	0
DDI-DrugBank.d249.s2.p7	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	0
DDI-DrugBank.d249.s2.p8	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	0
DDI-DrugBank.d249.s2.p9	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	0
DDI-DrugBank.d249.s3.p0	@DRUG$, @DRUG$, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s3.p1	@DRUG$, Methotrexate, @DRUG$: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s3.p2	@DRUG$, Methotrexate, Cyclosporine: @DRUG$, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s3.p3	@DRUG$, Methotrexate, Cyclosporine: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s3.p4	Digoxin, @DRUG$, @DRUG$: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s3.p5	Digoxin, @DRUG$, Cyclosporine: @DRUG$, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s3.p6	Digoxin, @DRUG$, Cyclosporine: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s3.p7	Digoxin, Methotrexate, @DRUG$: @DRUG$, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s3.p8	Digoxin, Methotrexate, @DRUG$: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s3.p9	Digoxin, Methotrexate, Cyclosporine: @DRUG$, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	0
DDI-DrugBank.d249.s4.p0	Ingestion of @DRUG$ may increase serum concentrations of @DRUG$ and methotrexate and increase cyclosporine s nephrotoxicity.	0
DDI-DrugBank.d249.s4.p1	Ingestion of @DRUG$ may increase serum concentrations of digoxin and @DRUG$ and increase cyclosporine s nephrotoxicity.	0
DDI-DrugBank.d249.s4.p2	Ingestion of @DRUG$ may increase serum concentrations of digoxin and methotrexate and increase @DRUG$ s nephrotoxicity.	0
DDI-DrugBank.d249.s4.p3	Ingestion of diclofenac may increase serum concentrations of @DRUG$ and @DRUG$ and increase cyclosporine s nephrotoxicity.	0
DDI-DrugBank.d249.s4.p4	Ingestion of diclofenac may increase serum concentrations of @DRUG$ and methotrexate and increase @DRUG$ s nephrotoxicity.	0
DDI-DrugBank.d249.s4.p5	Ingestion of diclofenac may increase serum concentrations of digoxin and @DRUG$ and increase @DRUG$ s nephrotoxicity.	0
DDI-DrugBank.d249.s5.p0	Patients who begin taking @DRUG$ or who increase their @DRUG$ dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p1	Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p2	Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other NSAID while taking @DRUG$, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p3	Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other NSAID while taking digoxin, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p4	Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p5	Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other @DRUG$ while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p6	Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking @DRUG$, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p7	Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking digoxin, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p8	Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p9	Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking @DRUG$, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p10	Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p11	Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p12	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking @DRUG$, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p13	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking @DRUG$, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s5.p14	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, @DRUG$, or @DRUG$ may develop toxicity characteristics for these drugs.	0
DDI-DrugBank.d249.s8.p0	@DRUG$: @DRUG$ decreases lithium renal clearance and increases lithium plasma levels.	0
DDI-DrugBank.d249.s8.p1	@DRUG$: Diclofenac decreases @DRUG$ renal clearance and increases lithium plasma levels.	0
DDI-DrugBank.d249.s8.p2	@DRUG$: Diclofenac decreases lithium renal clearance and increases @DRUG$ plasma levels.	0
DDI-DrugBank.d249.s8.p3	Lithium: @DRUG$ decreases @DRUG$ renal clearance and increases lithium plasma levels.	0
DDI-DrugBank.d249.s8.p4	Lithium: @DRUG$ decreases lithium renal clearance and increases @DRUG$ plasma levels.	0
DDI-DrugBank.d249.s8.p5	Lithium: Diclofenac decreases @DRUG$ renal clearance and increases @DRUG$ plasma levels.	0
DDI-DrugBank.d249.s9.p0	In patients taking @DRUG$ and @DRUG$ concomitantly, lithium toxicity may develop.	0
DDI-DrugBank.d249.s9.p1	In patients taking @DRUG$ and lithium concomitantly, @DRUG$ toxicity may develop.	0
DDI-DrugBank.d249.s9.p2	In patients taking diclofenac and @DRUG$ concomitantly, @DRUG$ toxicity may develop.	0
DDI-DrugBank.d25.s0.p0	@DRUG$ may accentuate the electrolyte loss associated with @DRUG$ therapy.	0
DDI-DrugBank.d250.s2.p0	@DRUG$ (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p1	@DRUG$ (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p2	@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p3	@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p4	@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p5	@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	3
DDI-DrugBank.d250.s2.p6	Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, @DRUG$, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p7	Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p8	Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p9	Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p10	Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	3
DDI-DrugBank.d250.s2.p11	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p12	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p13	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p14	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	3
DDI-DrugBank.d250.s2.p15	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p16	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p17	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	3
DDI-DrugBank.d250.s2.p18	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	3
DDI-DrugBank.d250.s2.p19	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	3
DDI-DrugBank.d250.s2.p20	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	3
DDI-DrugBank.d251.s0.p0	Antiacid, @DRUG$, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p1	Antiacid, @DRUG$, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p2	Antiacid, @DRUG$, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p3	Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p4	Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p5	Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p6	Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p7	Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p8	Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	1
DDI-DrugBank.d251.s0.p9	Antiacid, clarithromycin, @DRUG$, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p10	Antiacid, clarithromycin, @DRUG$, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p11	Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p12	Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p13	Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p14	Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p15	Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p16	Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	1
DDI-DrugBank.d251.s0.p17	Antiacid, clarithromycin, Didanosine, @DRUG$, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p18	Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p19	Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p20	Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p21	Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p22	Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p23	Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	1
DDI-DrugBank.d251.s0.p24	Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p25	Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p26	Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p27	Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p28	Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p29	Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	1
DDI-DrugBank.d251.s0.p30	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p31	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p32	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p33	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p34	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	1
DDI-DrugBank.d251.s0.p35	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p36	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p37	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p38	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	1
DDI-DrugBank.d251.s0.p39	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, @DRUG$, Rifampin, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p40	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p41	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, @DRUG$.	1
DDI-DrugBank.d251.s0.p42	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, @DRUG$, Ritanovir, Saquinavir.	1
DDI-DrugBank.d251.s0.p43	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, @DRUG$.	1
DDI-DrugBank.d251.s0.p44	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, @DRUG$.	1
DDI-DrugBank.d252.s0.p0	Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and epinephrine may occur.	4
DDI-DrugBank.d252.s0.p1	Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and @DRUG$ may occur.	4
DDI-DrugBank.d252.s0.p2	Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and @DRUG$ may occur.	4
DDI-DrugBank.d252.s1.p0	Close observation of the patient is recommended when a @DRUG$ is administered to patients receiving catecholamine-depleting drugs such as @DRUG$, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.	4
DDI-DrugBank.d252.s2.p0	Patients receiving @DRUG$ along with either oral or intravenous @DRUG$ should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.	0
DDI-DrugBank.d252.s5.p0	@DRUG$ and @DRUG$ may have additive hypotensite effects due to the inhibition of each other s metabolism.	4
DDI-DrugBank.d253.s0.p0	@DRUG$: concurrent use may blunt the response to @DRUG$.	4
DDI-DrugBank.d253.s1.p0	@DRUG$ should be withdrawn at least 48 hours before conducting an @DRUG$-mediated stress test.	4
DDI-DrugBank.d253.s2.p0	@DRUG$ (such as @DRUG$, lidocaine, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.	4
DDI-DrugBank.d253.s2.p1	@DRUG$ (such as flecainide, @DRUG$, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.	4
DDI-DrugBank.d253.s2.p2	@DRUG$ (such as flecainide, lidocaine, or @DRUG$): concurrent use with arbutamine may have a proarrhythmic effect.	4
DDI-DrugBank.d253.s2.p3	@DRUG$ (such as flecainide, lidocaine, or quinidine): concurrent use with @DRUG$ may have a proarrhythmic effect.	4
DDI-DrugBank.d253.s2.p4	Antiarrhythmic agents, class I (such as @DRUG$, @DRUG$, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.	4
DDI-DrugBank.d253.s2.p5	Antiarrhythmic agents, class I (such as @DRUG$, lidocaine, or @DRUG$): concurrent use with arbutamine may have a proarrhythmic effect.	0
DDI-DrugBank.d253.s2.p6	Antiarrhythmic agents, class I (such as @DRUG$, lidocaine, or quinidine): concurrent use with @DRUG$ may have a proarrhythmic effect.	0
DDI-DrugBank.d253.s2.p7	Antiarrhythmic agents, class I (such as flecainide, @DRUG$, or @DRUG$): concurrent use with arbutamine may have a proarrhythmic effect.	0
DDI-DrugBank.d253.s2.p8	Antiarrhythmic agents, class I (such as flecainide, @DRUG$, or quinidine): concurrent use with @DRUG$ may have a proarrhythmic effect.	0
DDI-DrugBank.d253.s2.p9	Antiarrhythmic agents, class I (such as flecainide, lidocaine, or @DRUG$): concurrent use with @DRUG$ may have a proarrhythmic effect.	0
DDI-DrugBank.d253.s3.p0	@DRUG$ (@DRUG$), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p1	@DRUG$ (tricyclic), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p2	@DRUG$ (tricyclic), atropine or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p3	@DRUG$ (tricyclic), atropine or other anticholinergic agents, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p4	@DRUG$ (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p5	Antidepressants (@DRUG$), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p6	Antidepressants (@DRUG$), atropine or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p7	Antidepressants (@DRUG$), atropine or other anticholinergic agents, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p8	Antidepressants (@DRUG$), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p9	Antidepressants (tricyclic), @DRUG$ or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p10	Antidepressants (tricyclic), @DRUG$ or other anticholinergic agents, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p11	Antidepressants (tricyclic), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p12	Antidepressants (tricyclic), atropine or other @DRUG$, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p13	Antidepressants (tricyclic), atropine or other @DRUG$, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d253.s3.p14	Antidepressants (tricyclic), atropine or other anticholinergic agents, or @DRUG$: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	4
DDI-DrugBank.d254.s0.p0	Other @DRUG$ (e.g. @DRUG$, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p1	Other @DRUG$ (e.g. barbiturates, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p2	Other @DRUG$ (e.g. barbiturates, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p3	Other @DRUG$ (e.g. barbiturates, tranquilizers, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p4	Other @DRUG$ (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.	4
DDI-DrugBank.d254.s0.p5	Other CNS depressant drugs (e.g. @DRUG$, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p6	Other CNS depressant drugs (e.g. @DRUG$, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p7	Other CNS depressant drugs (e.g. @DRUG$, tranquilizers, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p8	Other CNS depressant drugs (e.g. @DRUG$, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.	4
DDI-DrugBank.d254.s0.p9	Other CNS depressant drugs (e.g. barbiturates, @DRUG$, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p10	Other CNS depressant drugs (e.g. barbiturates, @DRUG$, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p11	Other CNS depressant drugs (e.g. barbiturates, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.	4
DDI-DrugBank.d254.s0.p12	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, @DRUG$ and general @DRUG$) have additive or potentiating effects with INAPSINE.	4
DDI-DrugBank.d254.s0.p13	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with @DRUG$.	4
DDI-DrugBank.d254.s0.p14	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general @DRUG$) have additive or potentiating effects with @DRUG$.	4
DDI-DrugBank.d254.s2.p0	Following the administration of @DRUG$, the dose of other @DRUG$ should be reduced.	0
DDI-DrugBank.d256.s0.p0	@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	3
DDI-DrugBank.d256.s2.p0	Antagonism has been demonstrated between @DRUG$ and @DRUG$ in vitro.	0
DDI-DrugBank.d257.s3.p0	Although no interaction between @DRUG$ and @DRUG$ has been observed, it is not recommended for use with MAO inhibitors.	0
DDI-DrugBank.d257.s3.p1	Although no interaction between @DRUG$ and Levo-Dromoran has been observed, it is not recommended for use with @DRUG$.	0
DDI-DrugBank.d257.s3.p2	Although no interaction between MAO inhibitors and @DRUG$ has been observed, it is not recommended for use with @DRUG$.	0
DDI-DrugBank.d257.s4.p0	Most cases of serious or fatal adverse events involving @DRUG$ reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of @DRUG$ with other drugs affecting respiration.	0
DDI-DrugBank.d257.s6.p0	Interactions with @DRUG$: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p1	Interactions with @DRUG$: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p2	Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p3	Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p4	Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p5	Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p6	Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p7	Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	1
DDI-DrugBank.d257.s6.p8	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p9	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p10	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p11	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p12	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p13	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p14	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	1
DDI-DrugBank.d257.s6.p15	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p16	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p17	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p18	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p19	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p20	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	1
DDI-DrugBank.d257.s6.p21	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p22	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p23	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p24	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p25	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	1
DDI-DrugBank.d257.s6.p26	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p27	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p28	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p29	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	1
DDI-DrugBank.d257.s6.p30	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p31	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p32	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	1
DDI-DrugBank.d257.s6.p33	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	1
DDI-DrugBank.d257.s6.p34	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	1
DDI-DrugBank.d257.s6.p35	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as @DRUG$.	1
DDI-DrugBank.d257.s7.p0	In @DRUG$-dependent patients, @DRUG$ may precipitate withdrawal symptoms.	0
DDI-DrugBank.d258.s0.p0	@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	0
DDI-DrugBank.d258.s0.p1	@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, @DRUG$, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	0
DDI-DrugBank.d258.s0.p2	@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers.	0
DDI-DrugBank.d258.s0.p3	Loratadine (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, @DRUG$, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	0
DDI-DrugBank.d258.s0.p4	Loratadine (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, cimetidine, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers.	0
DDI-DrugBank.d258.s0.p5	Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, @DRUG$, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers.	0
DDI-DrugBank.d258.s1.p0	Although increased plasma concentrations (AUC 0-24 hrs) of @DRUG$ and/or @DRUG$ were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	0
DDI-DrugBank.d258.s1.p1	Although increased plasma concentrations (AUC 0-24 hrs) of @DRUG$ and/or descarboethoxyloratadine were observed following coadministration of @DRUG$ with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	0
DDI-DrugBank.d258.s1.p2	Although increased plasma concentrations (AUC 0-24 hrs) of @DRUG$ and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	0
DDI-DrugBank.d258.s1.p3	Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or @DRUG$ were observed following coadministration of @DRUG$ with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	0
DDI-DrugBank.d258.s1.p4	Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or @DRUG$ were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	0
DDI-DrugBank.d258.s1.p5	Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of @DRUG$ with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	0
DDI-DrugBank.d258.s3.p0	No effects on plasma concentrations of @DRUG$ or @DRUG$ were observed.	0
DDI-DrugBank.d258.s4.p0	Plasma concentrations (AUC 0-24 hrs) of @DRUG$ decreased 15% with coadministration of @DRUG$ relative to that observed with erythromycin alone.	0
DDI-DrugBank.d258.s4.p1	Plasma concentrations (AUC 0-24 hrs) of @DRUG$ decreased 15% with coadministration of loratadine relative to that observed with @DRUG$ alone.	0
DDI-DrugBank.d258.s4.p2	Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of @DRUG$ relative to that observed with @DRUG$ alone.	0
DDI-DrugBank.d258.s7.p0	TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of @DRUG$ and @DRUG$ After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers	0
DDI-DrugBank.d258.s7.p1	TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of @DRUG$ and Descarboethoxyloratadine After 10 Days of Coadministration (@DRUG$ 10 mg) in Normal Volunteers	0
DDI-DrugBank.d258.s7.p2	TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and @DRUG$ After 10 Days of Coadministration (@DRUG$ 10 mg) in Normal Volunteers	0
DDI-DrugBank.d258.s8.p0	@DRUG$ @DRUG$	0
DDI-DrugBank.d26.s0.p0	Patients receiving other @DRUG$s, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p1	Patients receiving other @DRUG$s, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p2	Patients receiving other @DRUG$s, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p3	Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p4	Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p5	Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p6	Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p7	Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p8	Patients receiving other narcotic analgesics, general @DRUG$, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p9	Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p10	Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p11	Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p12	Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p13	Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p14	Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p15	Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p16	Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p17	Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p18	Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p19	Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p20	Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p21	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p22	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p23	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p24	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p25	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p26	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p27	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p28	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p29	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p30	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p31	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p32	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p33	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p34	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	4
DDI-DrugBank.d26.s0.p35	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with @DRUG$ may exhibit an additive CNS depression.	4
DDI-DrugBank.d260.s3.p0	Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p1	Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p2	Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p3	Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p4	Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p5	Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p6	Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p7	Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p8	Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	3
DDI-DrugBank.d260.s3.p9	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p10	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p11	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p12	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p13	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p14	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p15	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p16	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	3
DDI-DrugBank.d260.s3.p17	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p18	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p19	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p20	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p21	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p22	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p23	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	3
DDI-DrugBank.d260.s3.p24	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p25	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p26	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p27	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p28	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p29	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	3
DDI-DrugBank.d260.s3.p30	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p31	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p32	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p33	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p34	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	3
DDI-DrugBank.d260.s3.p35	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p36	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p37	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p38	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	3
DDI-DrugBank.d260.s3.p39	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p40	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p41	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	3
DDI-DrugBank.d260.s3.p42	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	3
DDI-DrugBank.d260.s3.p43	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and @DRUG$] is contraindicated.	3
DDI-DrugBank.d260.s3.p44	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and @DRUG$] is contraindicated.	3
DDI-DrugBank.d261.s0.p0	@DRUG$, a @DRUG$, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	0
DDI-DrugBank.d261.s0.p1	@DRUG$, a bacteriostatic antibiotic, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.	0
DDI-DrugBank.d261.s0.p2	Tetracycline, a @DRUG$, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.	0
DDI-DrugBank.d262.s0.p0	The concomitant use of @DRUG$ or other @DRUG$ may have an additive effect.	4
DDI-DrugBank.d263.s0.p0	@DRUG$: There is no significant pharmacokinetic interaction between @DRUG$ and zalcitabine which has been confirmed clinically.	0
DDI-DrugBank.d263.s0.p1	@DRUG$: There is no significant pharmacokinetic interaction between ZDV and @DRUG$ which has been confirmed clinically.	0
DDI-DrugBank.d263.s0.p2	Zidovudine: There is no significant pharmacokinetic interaction between @DRUG$ and @DRUG$ which has been confirmed clinically.	0
DDI-DrugBank.d263.s10.p0	@DRUG$: The combination of @DRUG$, saquinavir, and ZDV has been studied (as triple combination) in adults.	4
DDI-DrugBank.d263.s10.p1	@DRUG$: The combination of HIVID, @DRUG$, and ZDV has been studied (as triple combination) in adults.	0
DDI-DrugBank.d263.s10.p2	@DRUG$: The combination of HIVID, saquinavir, and @DRUG$ has been studied (as triple combination) in adults.	0
DDI-DrugBank.d263.s10.p3	Saquinavir: The combination of @DRUG$, @DRUG$, and ZDV has been studied (as triple combination) in adults.	4
DDI-DrugBank.d263.s10.p4	Saquinavir: The combination of @DRUG$, saquinavir, and @DRUG$ has been studied (as triple combination) in adults.	1
DDI-DrugBank.d263.s10.p5	Saquinavir: The combination of HIVID, @DRUG$, and @DRUG$ has been studied (as triple combination) in adults.	0
DDI-DrugBank.d263.s13.p0	Drugs that have been associated with peripheral neuropathy include @DRUG$, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p1	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p2	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p3	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p4	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p5	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p6	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p7	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p8	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p9	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p10	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p11	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p12	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p13	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	2
DDI-DrugBank.d263.s13.p14	Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	2
DDI-DrugBank.d263.s13.p15	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p16	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p17	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p18	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p19	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p20	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p21	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p22	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p23	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p24	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p25	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p26	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p27	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p28	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p29	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p30	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p31	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p32	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p33	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p34	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p35	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p36	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p37	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p38	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p39	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p40	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p41	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p42	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p43	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p44	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p45	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p46	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p47	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p48	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p49	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p50	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p51	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p52	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p53	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p54	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p55	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p56	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p57	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p58	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p59	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p60	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p61	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p62	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p63	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	2
DDI-DrugBank.d263.s13.p64	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	2
DDI-DrugBank.d263.s13.p65	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p66	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p67	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p68	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p69	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p70	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p71	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p72	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p73	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p74	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p75	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p76	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p77	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p78	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p79	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p80	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p81	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p82	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p83	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p84	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p85	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p86	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p87	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p88	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p89	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p90	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p91	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p92	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p93	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p94	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p95	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p96	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p97	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	2
DDI-DrugBank.d263.s13.p98	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	2
DDI-DrugBank.d263.s13.p99	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p100	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p101	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p102	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p103	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p104	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p105	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p106	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p107	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p108	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p109	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p110	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, @DRUG$, phenytoin, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p111	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	2
DDI-DrugBank.d263.s13.p112	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	2
DDI-DrugBank.d263.s13.p113	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	2
DDI-DrugBank.d263.s13.p114	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, @DRUG$, ribavirin, and vincristine.	0
DDI-DrugBank.d263.s13.p115	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p116	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p117	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, @DRUG$, and vincristine.	0
DDI-DrugBank.d263.s13.p118	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and @DRUG$.	0
DDI-DrugBank.d263.s13.p119	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d263.s15.p0	Intravenous @DRUG$: Treatment with @DRUG$ should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.	0
DDI-DrugBank.d263.s16.p0	Death due to fulminant pancreatitis possibly related to intravenous @DRUG$ and @DRUG$ has been reported.	0
DDI-DrugBank.d263.s17.p0	If intravenous @DRUG$ is required to treat Pneumocystis carinii pneumonia, treatment with @DRUG$ should be interrupted.	0
DDI-DrugBank.d263.s2.p0	In the same study it was shown that @DRUG$ and @DRUG$ had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.	3
DDI-DrugBank.d263.s2.p1	In the same study it was shown that @DRUG$ and stavudine had no significant effect on the intracellular phosphorylation of @DRUG$ in peripheral blood mononuclear cells.	3
DDI-DrugBank.d263.s2.p2	In the same study it was shown that didanosine and @DRUG$ had no significant effect on the intracellular phosphorylation of @DRUG$ in peripheral blood mononuclear cells.	3
DDI-DrugBank.d263.s21.p0	Patients receiving these drugs in combination with @DRUG$ should be monitored for signs of toxicity and the dose of @DRUG$ reduced if warranted.	0
DDI-DrugBank.d263.s22.p0	@DRUG$/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p1	@DRUG$/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p2	@DRUG$/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p3	@DRUG$/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p4	@DRUG$/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	4
DDI-DrugBank.d263.s22.p5	@DRUG$/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	4
DDI-DrugBank.d263.s22.p6	Magnesium/@DRUG$-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p7	Magnesium/@DRUG$-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p8	Magnesium/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p9	Magnesium/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	4
DDI-DrugBank.d263.s22.p10	Magnesium/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	4
DDI-DrugBank.d263.s22.p11	Magnesium/Aluminum-containing @DRUG$: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p12	Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p13	Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	4
DDI-DrugBank.d263.s22.p14	Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	4
DDI-DrugBank.d263.s22.p15	Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	4
DDI-DrugBank.d263.s22.p16	Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	4
DDI-DrugBank.d263.s22.p17	Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	4
DDI-DrugBank.d263.s22.p18	Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/@DRUG$-containing antacid products.	4
DDI-DrugBank.d263.s22.p19	Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing @DRUG$.	4
DDI-DrugBank.d263.s22.p20	Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing @DRUG$.	4
DDI-DrugBank.d263.s23.p0	The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with @DRUG$/aluminum-containing antacids.	0
DDI-DrugBank.d263.s23.p1	The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with magnesium/@DRUG$-containing antacids.	0
DDI-DrugBank.d263.s23.p2	The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with magnesium/aluminum-containing @DRUG$.	0
DDI-DrugBank.d263.s23.p3	The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with @DRUG$/@DRUG$-containing antacids.	0
DDI-DrugBank.d263.s23.p4	The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with @DRUG$/aluminum-containing @DRUG$.	0
DDI-DrugBank.d263.s23.p5	The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/@DRUG$-containing @DRUG$.	0
DDI-DrugBank.d263.s24.p0	@DRUG$: Bioavailability is mildly reduced (approximately 10%) when @DRUG$ and metoclopramide are coadministered.	0
DDI-DrugBank.d263.s24.p1	@DRUG$: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and @DRUG$ are coadministered.	0
DDI-DrugBank.d263.s24.p2	Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when @DRUG$ and @DRUG$ are coadministered.	0
DDI-DrugBank.d263.s25.p0	@DRUG$: @DRUG$ caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.	3
DDI-DrugBank.d263.s25.p1	@DRUG$: Doxorubicin caused a decrease in @DRUG$ phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.	3
DDI-DrugBank.d263.s25.p2	Doxorubicin: @DRUG$ caused a decrease in @DRUG$ phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.	3
DDI-DrugBank.d263.s3.p0	@DRUG$: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that @DRUG$ significantly inhibited zalcitabine phosphorylation in a dose dependent manner.	3
DDI-DrugBank.d263.s3.p1	@DRUG$: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited @DRUG$ phosphorylation in a dose dependent manner.	3
DDI-DrugBank.d263.s3.p2	Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that @DRUG$ significantly inhibited @DRUG$ phosphorylation in a dose dependent manner.	3
DDI-DrugBank.d263.s6.p0	however, it is considered to be unlikely that this decrease of phosphorylated @DRUG$ concentration is of clinical significance, as @DRUG$ is a more efficient substrate for deoxycytidine kinase than zalcitabine.	0
DDI-DrugBank.d263.s6.p1	however, it is considered to be unlikely that this decrease of phosphorylated @DRUG$ concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than @DRUG$.	0
DDI-DrugBank.d263.s6.p2	however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as @DRUG$ is a more efficient substrate for deoxycytidine kinase than @DRUG$.	0
DDI-DrugBank.d265.s8.p0	@DRUG$ and related drugs may decrease arterial responsiveness to @DRUG$.	0
DDI-DrugBank.d266.s0.p0	In vitro studies have shown @DRUG$ can displace @DRUG$s, such as warfarin, from their protein-binding sites.	0
DDI-DrugBank.d266.s0.p1	In vitro studies have shown @DRUG$ can displace coumarin anticoagulants, such as @DRUG$, from their protein-binding sites.	0
DDI-DrugBank.d266.s0.p2	In vitro studies have shown CASODEX can displace @DRUG$s, such as @DRUG$, from their protein-binding sites.	0
DDI-DrugBank.d266.s1.p0	It is recommended that if @DRUG$ is started in patients already receiving @DRUG$, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.	0
DDI-DrugBank.d266.s1.p1	It is recommended that if @DRUG$ is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the @DRUG$ dose may be necessary.	0
DDI-DrugBank.d266.s1.p2	It is recommended that if CASODEX is started in patients already receiving @DRUG$, prothrombin times should be closely monitored and adjustment of the @DRUG$ dose may be necessary.	0
DDI-DrugBank.d267.s0.p0	Prior administration of @DRUG$ has no clinically important effect on the neuromuscular blocking action of @DRUG$.	0
DDI-DrugBank.d267.s1.p0	The use of @DRUG$ before @DRUG$ to attenuate some of the side effects of succinylcholine has not been studied.	4
DDI-DrugBank.d267.s1.p1	The use of @DRUG$ before succinylcholine to attenuate some of the side effects of @DRUG$ has not been studied.	4
DDI-DrugBank.d267.s1.p2	The use of NUROMAX before @DRUG$ to attenuate some of the side effects of @DRUG$ has not been studied.	4
DDI-DrugBank.d267.s5.p0	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p1	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p2	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p3	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p4	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p5	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p6	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p7	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p8	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p9	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p10	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p11	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p12	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p13	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p14	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p15	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p16	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p17	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p18	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p19	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p20	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p21	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p22	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p23	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p24	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p25	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p26	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p27	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p28	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p29	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p30	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p31	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p32	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p33	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p34	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p35	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p36	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p37	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p38	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p39	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p40	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p41	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p42	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p43	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p44	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p45	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p46	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p47	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p48	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p49	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p50	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p51	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p52	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p53	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p54	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p55	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p56	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p57	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p58	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p59	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p60	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p61	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p62	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p63	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p64	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p65	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p66	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p67	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p68	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p69	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p70	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p71	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p72	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p73	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p74	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p75	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p76	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p77	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p78	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p79	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p80	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p81	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p82	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p83	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p84	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p85	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p86	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p87	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p88	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p89	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p90	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p91	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p92	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p93	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p94	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p95	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, @DRUG$, local anesthetics, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p96	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p97	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p98	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p99	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local @DRUG$, procainamide, and quinidine.	3
DDI-DrugBank.d267.s5.p100	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p101	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p102	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, @DRUG$, and quinidine.	3
DDI-DrugBank.d267.s5.p103	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and @DRUG$.	3
DDI-DrugBank.d267.s5.p104	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and @DRUG$.	3
DDI-DrugBank.d267.s6.p0	As with some other @DRUG$, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.	3
DDI-DrugBank.d267.s6.p1	As with some other @DRUG$, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving @DRUG$ or carbamazepine.	3
DDI-DrugBank.d267.s6.p2	As with some other @DRUG$, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or @DRUG$.	3
DDI-DrugBank.d267.s6.p3	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving @DRUG$ or carbamazepine.	3
DDI-DrugBank.d267.s6.p4	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving phenytoin or @DRUG$.	3
DDI-DrugBank.d267.s6.p5	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving @DRUG$ or @DRUG$.	3
DDI-DrugBank.d269.s1.p0	poor metabolizers of @DRUG$: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p1	poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p2	poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p3	poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p4	poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	4
DDI-DrugBank.d269.s1.p5	poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	0
DDI-DrugBank.d269.s1.p6	poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p7	poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p8	poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p9	poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	4
DDI-DrugBank.d269.s1.p10	poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	0
DDI-DrugBank.d269.s1.p11	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p12	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p13	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	4
DDI-DrugBank.d269.s1.p14	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	0
DDI-DrugBank.d269.s1.p15	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p16	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p17	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	0
DDI-DrugBank.d269.s1.p18	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	0
DDI-DrugBank.d269.s1.p19	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	0
DDI-DrugBank.d269.s1.p20	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	4
DDI-DrugBank.d269.s11.p0	@DRUG$: @DRUG$ concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.	0
DDI-DrugBank.d269.s11.p1	@DRUG$: Digoxin concentrations are increased by about 15% when @DRUG$ and carvedilol are administered concomitantly.	0
DDI-DrugBank.d269.s11.p2	@DRUG$: Digoxin concentrations are increased by about 15% when digoxin and @DRUG$ are administered concomitantly.	0
DDI-DrugBank.d269.s11.p3	Digoxin: @DRUG$ concentrations are increased by about 15% when @DRUG$ and carvedilol are administered concomitantly.	0
DDI-DrugBank.d269.s11.p4	Digoxin: @DRUG$ concentrations are increased by about 15% when digoxin and @DRUG$ are administered concomitantly.	0
DDI-DrugBank.d269.s11.p5	Digoxin: Digoxin concentrations are increased by about 15% when @DRUG$ and @DRUG$ are administered concomitantly.	0
DDI-DrugBank.d269.s12.p0	Both @DRUG$ and @DRUG$ slow AV conduction.	0
DDI-DrugBank.d269.s14.p0	Inducers and Inhibitors of Hepatic Metabolism: @DRUG$ reduced plasma concentrations of @DRUG$ by about 70%.	0
DDI-DrugBank.d269.s16.p0	@DRUG$: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when @DRUG$ is co-administered with diltiazem.	0
DDI-DrugBank.d269.s16.p1	@DRUG$: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with @DRUG$.	0
DDI-DrugBank.d269.s16.p2	Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when @DRUG$ is co-administered with @DRUG$.	0
DDI-DrugBank.d269.s18.p0	@DRUG$ or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.	3
DDI-DrugBank.d269.s18.p1	@DRUG$ or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.	3
DDI-DrugBank.d269.s18.p2	@DRUG$ or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.	3
DDI-DrugBank.d269.s18.p3	@DRUG$ or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral @DRUG$.	3
DDI-DrugBank.d269.s18.p4	Insulin or Oral @DRUG$: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.	0
DDI-DrugBank.d269.s18.p5	Insulin or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.	3
DDI-DrugBank.d269.s18.p6	Insulin or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral @DRUG$.	0
DDI-DrugBank.d269.s18.p7	Insulin or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.	3
DDI-DrugBank.d269.s18.p8	Insulin or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral @DRUG$.	0
DDI-DrugBank.d269.s18.p9	Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral @DRUG$.	3
DDI-DrugBank.d269.s19.p0	Therefore, in patients taking @DRUG$ or oral @DRUG$, regular monitoring of blood glucose is recommended.	0
DDI-DrugBank.d269.s3.p0	Catecholamine-depleting Agents: Patients taking both @DRUG$ and a drug that can deplete catecholamines (e.g., @DRUG$ and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.	0
DDI-DrugBank.d269.s3.p1	Catecholamine-depleting Agents: Patients taking both @DRUG$ and a drug that can deplete catecholamines (e.g., reserpine and @DRUG$) should be observed closely for signs of hypotension and/or severe bradycardia.	0
DDI-DrugBank.d269.s3.p2	Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., @DRUG$ and @DRUG$) should be observed closely for signs of hypotension and/or severe bradycardia.	0
DDI-DrugBank.d269.s4.p0	@DRUG$: Concomitant administration of @DRUG$ with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.	4
DDI-DrugBank.d269.s4.p1	@DRUG$: Concomitant administration of clonidine with @DRUG$ may potentiate blood-pressure- and heart-rate-lowering effects.	4
DDI-DrugBank.d269.s4.p2	Clonidine: Concomitant administration of @DRUG$ with @DRUG$ may potentiate blood-pressure- and heart-rate-lowering effects.	4
DDI-DrugBank.d269.s8.p0	In about 30% of patients, the dose of @DRUG$ had to be reduced in order to maintain @DRUG$ concentrations within the therapeutic range, while in the remainder no adjustment was needed.	0
DDI-DrugBank.d27.s0.p0	No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with @DRUG$, @DRUG$, warfarin, and nifedipine.	0
DDI-DrugBank.d27.s0.p1	No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with @DRUG$, digoxin, @DRUG$, and nifedipine.	0
DDI-DrugBank.d27.s0.p2	No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with @DRUG$, digoxin, warfarin, and @DRUG$.	0
DDI-DrugBank.d27.s0.p3	No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, @DRUG$, and nifedipine.	0
DDI-DrugBank.d27.s0.p4	No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, and @DRUG$.	0
DDI-DrugBank.d27.s0.p5	No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, @DRUG$, and @DRUG$.	0
DDI-DrugBank.d27.s1.p0	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors @DRUG$, @DRUG$ and nifedipine.	0
DDI-DrugBank.d27.s1.p1	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors @DRUG$, tolbutamide and @DRUG$.	0
DDI-DrugBank.d27.s1.p2	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, @DRUG$ and @DRUG$.	0
DDI-DrugBank.d27.s4.p0	In separate studies of patients receiving maintenance doses of @DRUG$, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p1	In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p2	In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p3	In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p4	In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d27.s4.p5	In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p6	In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p7	In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p8	In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d27.s4.p9	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p10	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p11	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d27.s4.p12	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	0
DDI-DrugBank.d27.s4.p13	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d27.s4.p14	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of @DRUG$.	0
DDI-DrugBank.d27.s5.p0	The pharmacokinetics of @DRUG$ were not affected by coadministration of @DRUG$ or hydrochlorothiazide	0
DDI-DrugBank.d27.s5.p1	The pharmacokinetics of @DRUG$ were not affected by coadministration of nifedipine or @DRUG$	0
DDI-DrugBank.d27.s5.p2	The pharmacokinetics of irbesartan were not affected by coadministration of @DRUG$ or @DRUG$	0
DDI-DrugBank.d270.s11.p0	When @DRUG$ is co-administered with @DRUG$, anticoagulation levels should be monitored frequently.	3
DDI-DrugBank.d270.s24.p0	@DRUG$ and @DRUG$	0
DDI-DrugBank.d270.s37.p0	@DRUG$/@DRUG$	4
DDI-DrugBank.d270.s39.p0	A dose increase of @DRUG$/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with nevirapine.	0
DDI-DrugBank.d270.s39.p1	A dose increase of @DRUG$/ritonavir to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	0
DDI-DrugBank.d270.s39.p2	A dose increase of lopinavir/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	0
DDI-DrugBank.d270.s53.p0	@DRUG$ and @DRUG$ should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.	4
DDI-DrugBank.d270.s53.p1	@DRUG$ and rifampin should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	4
DDI-DrugBank.d270.s53.p2	Nevirapine and @DRUG$ should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	4
DDI-DrugBank.d270.s54.p0	Physicians needing to treatpatients co-infected with tuberculosis andusing a @DRUG$ containing regimen mayuse @DRUG$ instead.	2
DDI-DrugBank.d270.s58.p0	aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and @DRUG$ concurrently, and evidence of decreased plasma concentrations of methadone.	0
DDI-DrugBank.d270.s58.p1	aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and methadone concurrently, and evidence of decreased plasma concentrations of @DRUG$.	0
DDI-DrugBank.d270.s58.p2	aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and @DRUG$ concurrently, and evidence of decreased plasma concentrations of @DRUG$.	0
DDI-DrugBank.d270.s63.p0	@DRUG$, @DRUG$, lidocaine	3
DDI-DrugBank.d270.s63.p1	@DRUG$, disopyramide, @DRUG$	0
DDI-DrugBank.d270.s63.p2	Amiodarone, @DRUG$, @DRUG$	1
DDI-DrugBank.d270.s65.p0	@DRUG$, @DRUG$, ethosuximide	0
DDI-DrugBank.d270.s65.p1	@DRUG$, clonazepam, @DRUG$	4
DDI-DrugBank.d270.s65.p2	Carbamazepine, @DRUG$, @DRUG$	1
DDI-DrugBank.d270.s69.p0	@DRUG$, @DRUG$, verapamil	1
DDI-DrugBank.d270.s69.p1	@DRUG$, nifedipine, @DRUG$	0
DDI-DrugBank.d270.s69.p2	Diltiazem, @DRUG$, @DRUG$	1
DDI-DrugBank.d270.s9.p0	The in vitro interaction between @DRUG$ and the @DRUG$ warfarin is complex.	0
DDI-DrugBank.d270.s9.p1	The in vitro interaction between @DRUG$ and the antithrombotic agent @DRUG$ is complex.	0
DDI-DrugBank.d270.s9.p2	The in vitro interaction between nevirapine and the @DRUG$ @DRUG$ is complex.	3
DDI-DrugBank.d271.s0.p0	Physiological changes resulting from smoking cessation, with or without @DRUG$ replacement, may alter the pharmacokinetics of certain concomitant medications, such as @DRUG$ and theophylline.	0
DDI-DrugBank.d271.s0.p1	Physiological changes resulting from smoking cessation, with or without @DRUG$ replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic antidepressants and @DRUG$.	3
DDI-DrugBank.d271.s0.p2	Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as @DRUG$ and @DRUG$.	0
DDI-DrugBank.d272.s0.p0	The risk of using @DRUG$ in combination with other drugs has not been systematically evaluated, but @DRUG$ may potentiate the side effects of bromocriptine mesylate.	4
DDI-DrugBank.d272.s0.p1	The risk of using @DRUG$ in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of @DRUG$.	4
DDI-DrugBank.d272.s0.p2	The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but @DRUG$ may potentiate the side effects of @DRUG$.	4
DDI-DrugBank.d272.s2.p0	Compounds in these categories result in a decreased efficacy of @DRUG$: @DRUG$, haloperidol, metoclopramide, pimozide.	0
DDI-DrugBank.d272.s2.p1	Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, @DRUG$, metoclopramide, pimozide.	4
DDI-DrugBank.d272.s2.p2	Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, haloperidol, @DRUG$, pimozide.	3
DDI-DrugBank.d272.s2.p3	Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, haloperidol, metoclopramide, @DRUG$.	3
DDI-DrugBank.d272.s2.p4	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: @DRUG$, @DRUG$, metoclopramide, pimozide.	3
DDI-DrugBank.d272.s2.p5	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: @DRUG$, haloperidol, @DRUG$, pimozide.	3
DDI-DrugBank.d272.s2.p6	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: @DRUG$, haloperidol, metoclopramide, @DRUG$.	3
DDI-DrugBank.d272.s2.p7	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, @DRUG$, @DRUG$, pimozide.	3
DDI-DrugBank.d272.s2.p8	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, @DRUG$, metoclopramide, @DRUG$.	3
DDI-DrugBank.d272.s2.p9	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, @DRUG$, @DRUG$.	3
DDI-DrugBank.d272.s3.p0	Concomitant use of @DRUG$ with other @DRUG$ is not recommended.	0
DDI-DrugBank.d273.s1.p0	However, interactions may be expected, and @DRUG$ should NOT be used in combination with other @DRUG$.	0
DDI-DrugBank.d274.s0.p0	Animal studies indicate that @DRUG$ may be ineffective if the patient has recently received a @DRUG$.	0
DDI-DrugBank.d274.s2.p0	Preliminary studies indicate that the concomitant use of @DRUG$ and @DRUG$ results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.	0
DDI-DrugBank.d275.s1.p0	Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either @DRUG$ or @DRUG$ when the two agents were administered together.	0
DDI-DrugBank.d275.s2.p0	In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$ and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).	0
DDI-DrugBank.d275.s2.p1	In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$ and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$ alone (0%).	0
DDI-DrugBank.d275.s2.p2	In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$ alone (0%).	0
DDI-DrugBank.d275.s3.p0	Two percent of patients treated concurrently with @DRUG$ and @DRUG$ developed neutropenia (ANC  1 x 109/L).	2
DDI-DrugBank.d276.s0.p0	@DRUG$ containing @DRUG$, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.	4
DDI-DrugBank.d276.s0.p1	@DRUG$ containing magnesium trisilicate, when administered concomitantly with @DRUG$, reduce both the rate and extent of absorption.	4
DDI-DrugBank.d276.s0.p2	Antacids containing @DRUG$, when administered concomitantly with @DRUG$, reduce both the rate and extent of absorption.	4
DDI-DrugBank.d276.s2.p0	@DRUG$, such as @DRUG$ and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.	0
DDI-DrugBank.d276.s2.p1	@DRUG$, such as probenecid and @DRUG$, can inhibit renal tubular secretion of nitrofurantoin.	0
DDI-DrugBank.d276.s2.p2	@DRUG$, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of @DRUG$.	0
DDI-DrugBank.d276.s2.p3	Uricosuric drugs, such as @DRUG$ and @DRUG$, can inhibit renal tubular secretion of nitrofurantoin.	0
DDI-DrugBank.d276.s2.p4	Uricosuric drugs, such as @DRUG$ and sulfinpyrazone, can inhibit renal tubular secretion of @DRUG$.	0
DDI-DrugBank.d276.s2.p5	Uricosuric drugs, such as probenecid and @DRUG$, can inhibit renal tubular secretion of @DRUG$.	0
DDI-DrugBank.d277.s0.p0	In evaluating the potential for interactions among co-administered antiepilepsy drugs (@DRUG$), whether or not an @DRUG$ induces or does not induce metabolic enzymes is an important consideration.	0
DDI-DrugBank.d277.s11.p0	@DRUG$: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.	0
DDI-DrugBank.d277.s11.p1	@DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	0
DDI-DrugBank.d277.s11.p2	@DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing @DRUG$.	0
DDI-DrugBank.d277.s11.p3	Phenytoin: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	0
DDI-DrugBank.d277.s11.p4	Phenytoin: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing @DRUG$.	0
DDI-DrugBank.d277.s11.p5	Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing @DRUG$.	0
DDI-DrugBank.d277.s13.p0	@DRUG$: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p1	@DRUG$: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p2	@DRUG$: The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p3	@DRUG$: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p4	@DRUG$: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p5	Valproate: The addition of @DRUG$ to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p6	Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p7	Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p8	Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p9	Valproate: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p10	Valproate: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p11	Valproate: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p12	Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p13	Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s13.p14	Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	0
DDI-DrugBank.d277.s15.p0	Interaction of @DRUG$ with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.	0
DDI-DrugBank.d277.s15.p1	Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.	0
DDI-DrugBank.d277.s15.p2	Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics.	0
DDI-DrugBank.d277.s15.p3	Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.	0
DDI-DrugBank.d277.s15.p4	Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.	0
DDI-DrugBank.d277.s15.p5	Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics.	0
DDI-DrugBank.d277.s15.p6	Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.	0
DDI-DrugBank.d277.s15.p7	Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics.	0
DDI-DrugBank.d277.s15.p8	Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.	0
DDI-DrugBank.d277.s15.p9	Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking @DRUG$ chronically had no effect on @DRUG$ pharmacokinetics.	0
DDI-DrugBank.d277.s16.p0	@DRUG$: A single 10 mg dose of @DRUG$ did not affect the pharmacokinetics of theophylline at steady state.	0
DDI-DrugBank.d277.s16.p1	@DRUG$: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of @DRUG$ at steady state.	0
DDI-DrugBank.d277.s16.p2	Theophylline: A single 10 mg dose of @DRUG$ did not affect the pharmacokinetics of @DRUG$ at steady state.	0
DDI-DrugBank.d277.s17.p0	@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or S-warfarin with the addition of tiagabine given as a single dose.	0
DDI-DrugBank.d277.s17.p1	@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or @DRUG$ with the addition of tiagabine given as a single dose.	0
DDI-DrugBank.d277.s17.p2	@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of @DRUG$ given as a single dose.	0
DDI-DrugBank.d277.s17.p3	Warfarin: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or @DRUG$ with the addition of tiagabine given as a single dose.	0
DDI-DrugBank.d277.s17.p4	Warfarin: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or S-warfarin with the addition of @DRUG$ given as a single dose.	0
DDI-DrugBank.d277.s17.p5	Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or @DRUG$ with the addition of @DRUG$ given as a single dose.	0
DDI-DrugBank.d277.s2.p0	@DRUG$ and @DRUG$ are not.	4
DDI-DrugBank.d277.s21.p0	The pharmacokinetics of @DRUG$ were not affected by multiple-dose administration of @DRUG$.	0
DDI-DrugBank.d277.s24.p0	Oral @DRUG$: Multiple dose administration of @DRUG$ (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.	0
DDI-DrugBank.d277.s24.p1	Oral @DRUG$: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral @DRUG$ in healthy women of childbearing age.	0
DDI-DrugBank.d277.s24.p2	Oral Contraceptives: Multiple dose administration of @DRUG$ (8 mg/day monotherapy) did not alter the pharmacokinetics of oral @DRUG$ in healthy women of childbearing age.	0
DDI-DrugBank.d277.s26.p0	This indicates that @DRUG$ does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of @DRUG$.	3
DDI-DrugBank.d277.s27.p0	Interaction of @DRUG$ with Highly Protein Bound Drugs: In vitro data showed that @DRUG$ is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.	0
DDI-DrugBank.d277.s5.p0	Effects of @DRUG$ on other Antiepilepsy Drugs (@DRUG$) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	0
DDI-DrugBank.d277.s5.p1	Effects of @DRUG$ on other Antiepilepsy Drugs (AEDs) : @DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	0
DDI-DrugBank.d277.s5.p2	Effects of @DRUG$ on other Antiepilepsy Drugs (AEDs) : Phenytoin: @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	0
DDI-DrugBank.d277.s5.p3	Effects of @DRUG$ on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	0
DDI-DrugBank.d277.s5.p4	Effects of GABITRIL on other Antiepilepsy Drugs (@DRUG$) : @DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	0
DDI-DrugBank.d277.s5.p5	Effects of GABITRIL on other Antiepilepsy Drugs (@DRUG$) : Phenytoin: @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	0
DDI-DrugBank.d277.s5.p6	Effects of GABITRIL on other Antiepilepsy Drugs (@DRUG$) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	0
DDI-DrugBank.d277.s5.p7	Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : @DRUG$: @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	0
DDI-DrugBank.d277.s5.p8	Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : @DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	0
DDI-DrugBank.d277.s5.p9	Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: @DRUG$ had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	0
DDI-DrugBank.d277.s6.p0	@DRUG$: @DRUG$ had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.	0
DDI-DrugBank.d277.s6.p1	@DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ or its epoxide metabolite in patients with epilepsy.	0
DDI-DrugBank.d277.s6.p2	Carbamazepine: @DRUG$ had no effect on the steady-state plasma concentrations of @DRUG$ or its epoxide metabolite in patients with epilepsy.	0
DDI-DrugBank.d277.s7.p0	@DRUG$: @DRUG$ causes a slight decrease (about 10%) in steady-state valproate concentrations.	0
DDI-DrugBank.d277.s7.p1	@DRUG$: Tiagabine causes a slight decrease (about 10%) in steady-state @DRUG$ concentrations.	0
DDI-DrugBank.d277.s7.p2	Valproate: @DRUG$ causes a slight decrease (about 10%) in steady-state @DRUG$ concentrations.	0
DDI-DrugBank.d277.s9.p0	The addition of @DRUG$ in a limited number of patients in three well-controlled studies caused no systematic changes in @DRUG$ or primidone concentrations when compared to placebo.	0
DDI-DrugBank.d277.s9.p1	The addition of @DRUG$ in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or @DRUG$ concentrations when compared to placebo.	0
DDI-DrugBank.d277.s9.p2	The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in @DRUG$ or @DRUG$ concentrations when compared to placebo.	0
DDI-DrugBank.d278.s0.p0	@DRUG$ dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of @DRUG$ or the level of platelet aggregation in healthy adults.	0
DDI-DrugBank.d279.s10.p0	It would be expected that @DRUG$ use during therapy with @DRUG$ would worsen the incidence or severity of diarrhea, but this has not been studied.	4
DDI-DrugBank.d279.s3.p0	Lymphocytopenia has been reported in patients receiving @DRUG$, and it is possible that the administration of @DRUG$ as antiemetic prophylaxis may have enhanced the likelihood of this effect.	0
DDI-DrugBank.d279.s8.p0	The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when @DRUG$ was administered on the same day as @DRUG$ than when these drugs were given on separate days (1.3%, 1/80 patients).	0
DDI-DrugBank.d28.s1.p0	Results from existing clinical trials suggest no significant interactions between @DRUG$  and other therapies commonly used in MS patients, including the concurrent use of @DRUG$ for up to 28 days.	0
DDI-DrugBank.d28.s2.p0	@DRUG$  has not been formally evaluated in combination with @DRUG$.	4
DDI-DrugBank.d282.s0.p0	@DRUG$ should not be administered concurrently with D2-antagonists, such as @DRUG$, butyrophenones, thioxanthines, or metoclopramide.	1
DDI-DrugBank.d282.s0.p1	@DRUG$ should not be administered concurrently with D2-antagonists, such as phenothiazines, @DRUG$, thioxanthines, or metoclopramide.	1
DDI-DrugBank.d282.s0.p2	@DRUG$ should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, @DRUG$, or metoclopramide.	4
DDI-DrugBank.d282.s0.p3	@DRUG$ should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or @DRUG$.	4
DDI-DrugBank.d282.s0.p4	DOSTINEX should not be administered concurrently with D2-antagonists, such as @DRUG$, @DRUG$, thioxanthines, or metoclopramide.	1
DDI-DrugBank.d282.s0.p5	DOSTINEX should not be administered concurrently with D2-antagonists, such as @DRUG$, butyrophenones, @DRUG$, or metoclopramide.	1
DDI-DrugBank.d282.s0.p6	DOSTINEX should not be administered concurrently with D2-antagonists, such as @DRUG$, butyrophenones, thioxanthines, or @DRUG$.	1
DDI-DrugBank.d282.s0.p7	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, @DRUG$, @DRUG$, or metoclopramide.	1
DDI-DrugBank.d282.s0.p8	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, @DRUG$, thioxanthines, or @DRUG$.	1
DDI-DrugBank.d282.s0.p9	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, @DRUG$, or @DRUG$.	4
DDI-DrugBank.d283.s0.p0	Oral @DRUG$ CAUTION SHOULD BE EXERCISED WHEN @DRUG$ ARE GIVEN IN CONJUNCTION WITH TRICOR.	0
DDI-DrugBank.d283.s0.p1	Oral @DRUG$ CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH @DRUG$.	0
DDI-DrugBank.d283.s0.p2	Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN @DRUG$ ARE GIVEN IN CONJUNCTION WITH @DRUG$.	0
DDI-DrugBank.d283.s12.p0	Therefore, @DRUG$ should be taken at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption .	4
DDI-DrugBank.d283.s13.p0	Concomitant administration of @DRUG$ (equivalent to 145mg @DRUG$) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	0
DDI-DrugBank.d283.s13.p1	Concomitant administration of @DRUG$ (equivalent to 145mg TRICOR) with @DRUG$ (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	0
DDI-DrugBank.d283.s13.p2	Concomitant administration of @DRUG$ (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	0
DDI-DrugBank.d283.s13.p3	Concomitant administration of fenofibrate (equivalent to 145mg @DRUG$) with @DRUG$ (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	0
DDI-DrugBank.d283.s13.p4	Concomitant administration of fenofibrate (equivalent to 145mg @DRUG$) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	0
DDI-DrugBank.d283.s13.p5	Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with @DRUG$ (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	0
DDI-DrugBank.d283.s15.p0	Concomitant administration of @DRUG$ (equivalent to 145 mg @DRUG$) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.	0
DDI-DrugBank.d283.s15.p1	Concomitant administration of @DRUG$ (equivalent to 145 mg TRICOR) with @DRUG$ (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.	0
DDI-DrugBank.d283.s15.p2	Concomitant administration of @DRUG$ (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in @DRUG$ AUC values in 22 healthy males.	0
DDI-DrugBank.d283.s15.p3	Concomitant administration of fenofibrate (equivalent to 145 mg @DRUG$) with @DRUG$ (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.	0
DDI-DrugBank.d283.s15.p4	Concomitant administration of fenofibrate (equivalent to 145 mg @DRUG$) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in @DRUG$ AUC values in 22 healthy males.	0
DDI-DrugBank.d283.s15.p5	Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with @DRUG$ (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in @DRUG$ AUC values in 22 healthy males.	0
DDI-DrugBank.d283.s17.p0	The pharmacokinetics of @DRUG$ were not significantly affected by @DRUG$	0
DDI-DrugBank.d283.s4.p0	@DRUG$: Since @DRUG$ may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.	4
DDI-DrugBank.d283.s4.p1	@DRUG$: Since bile acid sequestrants may bind other drugs given concurrently, patients should take @DRUG$ at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.	4
DDI-DrugBank.d283.s4.p2	@DRUG$: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption.	4
DDI-DrugBank.d283.s4.p3	Resins: Since @DRUG$ may bind other drugs given concurrently, patients should take @DRUG$ at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.	4
DDI-DrugBank.d283.s4.p4	Resins: Since @DRUG$ may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption.	4
DDI-DrugBank.d283.s4.p5	Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take @DRUG$ at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption.	4
DDI-DrugBank.d283.s5.p0	@DRUG$: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.	0
DDI-DrugBank.d283.s5.p1	@DRUG$: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including TRICOR, there is a risk that an interaction will lead to deterioration.	0
DDI-DrugBank.d283.s5.p2	@DRUG$: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including @DRUG$, there is a risk that an interaction will lead to deterioration.	0
DDI-DrugBank.d283.s5.p3	Cyclosporine: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including TRICOR, there is a risk that an interaction will lead to deterioration.	0
DDI-DrugBank.d283.s5.p4	Cyclosporine: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including @DRUG$, there is a risk that an interaction will lead to deterioration.	0
DDI-DrugBank.d283.s5.p5	Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including @DRUG$, there is a risk that an interaction will lead to deterioration.	0
DDI-DrugBank.d283.s6.p0	The benefits and risks of using @DRUG$ with @DRUG$ and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed	0
DDI-DrugBank.d283.s8.p0	Drug-drug interactions In vitro studies using human liver microsomes indicate that @DRUG$ and @DRUG$ are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.	0
DDI-DrugBank.d284.s0.p0	If additional @DRUG$ are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of @DRUG$ may be potentiated.	4
DDI-DrugBank.d284.s1.p0	When @DRUG$, a potent inhibitor of CYP2D6, was co-administered with @DRUG$ at steady-state, exposure to either drug was not altered.	0
DDI-DrugBank.d284.s10.p0	In a 12-month controlled trial that included a 50 mcg once daily @DRUG$ dose, 30 of the 528 @DRUG$ -treated subjects received concomitant theophylline at study entry.	0
DDI-DrugBank.d284.s10.p1	In a 12-month controlled trial that included a 50 mcg once daily @DRUG$ dose, 30 of the 528 BROVANA -treated subjects received concomitant @DRUG$ at study entry.	0
DDI-DrugBank.d284.s10.p2	In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 @DRUG$ -treated subjects received concomitant @DRUG$ at study entry.	0
DDI-DrugBank.d284.s12.p0	@DRUG$ (@DRUG$) and BROVANA may interfere with the effect of each other when administered concurrently.	4
DDI-DrugBank.d284.s12.p1	@DRUG$ (beta-blockers) and @DRUG$ may interfere with the effect of each other when administered concurrently.	4
DDI-DrugBank.d284.s12.p2	Beta-adrenergic receptor antagonists (@DRUG$) and @DRUG$ may interfere with the effect of each other when administered concurrently.	4
DDI-DrugBank.d284.s13.p0	@DRUG$ not only block the therapeutic effects of @DRUG$, but may produce severe bronchospasm in COPD patients.	4
DDI-DrugBank.d284.s4.p0	The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.	3
DDI-DrugBank.d284.s4.p1	The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as loop or @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.	3
DDI-DrugBank.d284.s4.p2	The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as loop or thiazide diuretics) can be acutely worsened by @DRUG$, especially when the recommended dose of the beta-agonist is exceeded.	0
DDI-DrugBank.d284.s4.p3	The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the @DRUG$ is exceeded.	0
DDI-DrugBank.d284.s4.p4	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG-DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.	0
DDI-DrugBank.d284.s4.p5	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG$) can be acutely worsened by @DRUG$, especially when the recommended dose of the beta-agonist is exceeded.	0
DDI-DrugBank.d284.s4.p6	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the @DRUG$ is exceeded.	0
DDI-DrugBank.d284.s4.p7	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or @DRUG$) can be acutely worsened by @DRUG$, especially when the recommended dose of the beta-agonist is exceeded.	0
DDI-DrugBank.d284.s4.p8	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the @DRUG$ is exceeded.	0
DDI-DrugBank.d284.s4.p9	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by @DRUG$, especially when the recommended dose of the @DRUG$ is exceeded.	0
DDI-DrugBank.d284.s8.p0	The concurrent use of intravenously or orally administered @DRUG$ (e.g., @DRUG$, theophylline) by patients receiving BROVANA has not been completely evaluated.	4
DDI-DrugBank.d284.s8.p1	The concurrent use of intravenously or orally administered @DRUG$ (e.g., aminophylline, @DRUG$) by patients receiving BROVANA has not been completely evaluated.	4
DDI-DrugBank.d284.s8.p2	The concurrent use of intravenously or orally administered @DRUG$ (e.g., aminophylline, theophylline) by patients receiving @DRUG$ has not been completely evaluated.	4
DDI-DrugBank.d284.s8.p3	The concurrent use of intravenously or orally administered methylxanthines (e.g., @DRUG$, @DRUG$) by patients receiving BROVANA has not been completely evaluated.	4
DDI-DrugBank.d284.s8.p4	The concurrent use of intravenously or orally administered methylxanthines (e.g., @DRUG$, theophylline) by patients receiving @DRUG$ has not been completely evaluated.	4
DDI-DrugBank.d284.s8.p5	The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, @DRUG$) by patients receiving @DRUG$ has not been completely evaluated.	4
DDI-DrugBank.d284.s9.p0	In two combined 12-week placebo controlled trials that included @DRUG$ doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 @DRUG$ -treated subjects received concomitant theophylline at study entry.	0
DDI-DrugBank.d284.s9.p1	In two combined 12-week placebo controlled trials that included @DRUG$ doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant @DRUG$ at study entry.	0
DDI-DrugBank.d284.s9.p2	In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 @DRUG$ -treated subjects received concomitant @DRUG$ at study entry.	0
DDI-DrugBank.d285.s1.p0	A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p1	A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, ampicillin, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p2	A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with @DRUG$, ampicillin, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p3	A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, @DRUG$, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p4	A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and @DRUG$ (72)	3
DDI-DrugBank.d285.s1.p5	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, @DRUG$ and possibly with griseofulvin, ampicillin, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p6	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with @DRUG$, ampicillin, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p7	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, @DRUG$, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p8	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, ampicillin, and @DRUG$ (72)	3
DDI-DrugBank.d285.s1.p9	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with @DRUG$, ampicillin, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p10	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, @DRUG$, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p11	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, ampicillin, and @DRUG$ (72)	3
DDI-DrugBank.d285.s1.p12	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with @DRUG$, @DRUG$, and tetracyclines (72)	3
DDI-DrugBank.d285.s1.p13	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with @DRUG$, ampicillin, and @DRUG$ (72)	3
DDI-DrugBank.d285.s1.p14	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, @DRUG$, and @DRUG$ (72)	3
DDI-DrugBank.d286.s1.p0	It may increase excretion of @DRUG$, @DRUG$, and ASA and may also increase the toxicity of salicylates.	0
DDI-DrugBank.d286.s1.p1	It may increase excretion of @DRUG$, lithium, and @DRUG$ and may also increase the toxicity of salicylates.	0
DDI-DrugBank.d286.s1.p2	It may increase excretion of @DRUG$, lithium, and ASA and may also increase the toxicity of @DRUG$.	0
DDI-DrugBank.d286.s1.p3	It may increase excretion of barbiturates, @DRUG$, and @DRUG$ and may also increase the toxicity of salicylates.	0
DDI-DrugBank.d286.s1.p4	It may increase excretion of barbiturates, @DRUG$, and ASA and may also increase the toxicity of @DRUG$.	0
DDI-DrugBank.d286.s1.p5	It may increase excretion of barbiturates, lithium, and @DRUG$ and may also increase the toxicity of @DRUG$.	0
DDI-DrugBank.d287.s0.p0	@DRUG$ should be administered with caution to patients taking @DRUG$, because of the possibility of conduction disturbances.	0
DDI-DrugBank.d288.s0.p0	In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).	2
DDI-DrugBank.d288.s0.p1	In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).	2
DDI-DrugBank.d288.s0.p2	In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).	2
DDI-DrugBank.d288.s0.p3	In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, @DRUG$ before cisplatin).	2
DDI-DrugBank.d288.s0.p4	In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).	2
DDI-DrugBank.d288.s0.p5	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).	2
DDI-DrugBank.d288.s0.p6	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).	0
DDI-DrugBank.d288.s0.p7	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, @DRUG$ before cisplatin).	2
DDI-DrugBank.d288.s0.p8	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).	0
DDI-DrugBank.d288.s0.p9	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).	2
DDI-DrugBank.d288.s0.p10	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, @DRUG$ before cisplatin).	2
DDI-DrugBank.d288.s0.p11	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).	2
DDI-DrugBank.d288.s0.p12	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, @DRUG$ before cisplatin).	2
DDI-DrugBank.d288.s0.p13	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before @DRUG$).	0
DDI-DrugBank.d288.s0.p14	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, @DRUG$ before @DRUG$).	2
DDI-DrugBank.d288.s11.p0	Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, @DRUG$ for injection concentrate and @DRUG$ for injection concentrate) should not be treated with TAXOL.	2
DDI-DrugBank.d288.s11.p1	Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, @DRUG$ for injection concentrate and teniposide for injection concentrate) should not be treated with @DRUG$.	2
DDI-DrugBank.d288.s11.p2	Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and @DRUG$ for injection concentrate) should not be treated with @DRUG$.	2
DDI-DrugBank.d288.s12.p0	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).	0
DDI-DrugBank.d288.s12.p1	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).	0
DDI-DrugBank.d288.s12.p2	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and @DRUG$ (such as cimetidine or ranitidine).	0
DDI-DrugBank.d288.s12.p3	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as @DRUG$ or ranitidine).	0
DDI-DrugBank.d288.s12.p4	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).	0
DDI-DrugBank.d288.s12.p5	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).	0
DDI-DrugBank.d288.s12.p6	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and @DRUG$ (such as cimetidine or ranitidine).	0
DDI-DrugBank.d288.s12.p7	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as @DRUG$ or ranitidine).	0
DDI-DrugBank.d288.s12.p8	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).	0
DDI-DrugBank.d288.s12.p9	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and @DRUG$ (such as cimetidine or ranitidine).	0
DDI-DrugBank.d288.s12.p10	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and H2 antagonists (such as @DRUG$ or ranitidine).	0
DDI-DrugBank.d288.s12.p11	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).	0
DDI-DrugBank.d288.s12.p12	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and @DRUG$ (such as @DRUG$ or ranitidine).	0
DDI-DrugBank.d288.s12.p13	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and @DRUG$ (such as cimetidine or @DRUG$).	0
DDI-DrugBank.d288.s12.p14	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as @DRUG$ or @DRUG$).	1
DDI-DrugBank.d288.s14.p0	However, severe reactions, such as hypotension requiring treatment, dyspnea requiring @DRUG$, angioedema, or generalized urticaria require immediate discontinuation of @DRUG$ and aggressive symptomatic therapy.	3
DDI-DrugBank.d288.s4.p0	Potential interactions between @DRUG$, a substrate of CYP3A4, and @DRUG$ (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p1	Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p2	Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (ritonavir, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p3	Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p4	Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p5	Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (@DRUG$, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p6	Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (ritonavir, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p7	Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (ritonavir, saquinavir, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p8	Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (ritonavir, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p9	Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p10	Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p11	Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p12	Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, @DRUG$, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p13	Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, @DRUG$, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s4.p14	Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, @DRUG$, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	0
DDI-DrugBank.d288.s5.p0	Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite @DRUG$) may be increased when paclitaxel and doxorubicin are used in combination.	0
DDI-DrugBank.d288.s5.p1	Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite doxorubicinol) may be increased when @DRUG$ and doxorubicin are used in combination.	0
DDI-DrugBank.d288.s5.p2	Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite doxorubicinol) may be increased when paclitaxel and @DRUG$ are used in combination.	0
DDI-DrugBank.d288.s5.p3	Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite @DRUG$) may be increased when @DRUG$ and doxorubicin are used in combination.	0
DDI-DrugBank.d288.s5.p4	Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite @DRUG$) may be increased when paclitaxel and @DRUG$ are used in combination.	0
DDI-DrugBank.d288.s5.p5	Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when @DRUG$ and @DRUG$ are used in combination.	0
DDI-DrugBank.d289.s10.p0	Specific interaction studies have demonstrated the following: @DRUG$: During the first day of concomitant administration, trough concentrations of @DRUG$ were increased by about 30-fold.	0
DDI-DrugBank.d289.s11.p0	Steady-state @DRUG$ plasma concentrations were 3- to 4-fold higher than in the absence of @DRUG$.	0
DDI-DrugBank.d289.s12.p0	The concomitant administration of @DRUG$ and @DRUG$ is contraindicated.	0
DDI-DrugBank.d289.s16.p0	Caution should be exercised if @DRUG$ and @DRUG$ are used together.	0
DDI-DrugBank.d289.s17.p0	@DRUG$: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with @DRUG$.	0
DDI-DrugBank.d289.s18.p0	Therefore, the concomitant administration of @DRUG$ and @DRUG$ is contraindicated, and alternative hypoglycemic agents should be considered.	3
DDI-DrugBank.d289.s18.p1	Therefore, the concomitant administration of @DRUG$ and glyburide is contraindicated, and alternative @DRUG$ should be considered.	0
DDI-DrugBank.d289.s18.p2	Therefore, the concomitant administration of TRACLEER and @DRUG$ is contraindicated, and alternative @DRUG$ should be considered.	0
DDI-DrugBank.d289.s19.p0	Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ by approximately 40%.	0
DDI-DrugBank.d289.s24.p0	No dose adjustment of @DRUG$ is necessary, but increased effects of @DRUG$ should be considered.	0
DDI-DrugBank.d289.s27.p0	@DRUG$ is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.	0
DDI-DrugBank.d289.s27.p1	@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and atorvastatin.	0
DDI-DrugBank.d289.s27.p2	@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.	0
DDI-DrugBank.d289.s27.p3	Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as @DRUG$ and atorvastatin.	0
DDI-DrugBank.d289.s27.p4	Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.	0
DDI-DrugBank.d289.s27.p5	Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and @DRUG$.	0
DDI-DrugBank.d289.s29.p0	Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after @DRUG$ is initiated to see whether the statin dose needs adjustment.	0
DDI-DrugBank.d289.s29.p1	Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after TRACLEER is initiated to see whether the @DRUG$ dose needs adjustment.	0
DDI-DrugBank.d289.s29.p2	Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after @DRUG$ is initiated to see whether the @DRUG$ dose needs adjustment.	0
DDI-DrugBank.d289.s32.p0	@DRUG$, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p1	@DRUG$, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p2	@DRUG$, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p3	@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p4	@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p5	@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p6	@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	0
DDI-DrugBank.d289.s32.p7	Digoxin, @DRUG$ and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p8	Digoxin, @DRUG$ and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p9	Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p10	Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p11	Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p12	Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	0
DDI-DrugBank.d289.s32.p13	Digoxin, Nimodipine and @DRUG$: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p14	Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p15	Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p16	Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p17	Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	0
DDI-DrugBank.d289.s32.p18	Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p19	Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p20	Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p21	Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	0
DDI-DrugBank.d289.s32.p22	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p23	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p24	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	0
DDI-DrugBank.d289.s32.p25	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and @DRUG$ has no significant effect on plasma levels of bosentan.	0
DDI-DrugBank.d289.s32.p26	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of @DRUG$.	0
DDI-DrugBank.d289.s32.p27	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of @DRUG$.	0
DDI-DrugBank.d289.s6.p0	@DRUG$, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p1	@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p2	@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p3	@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p4	@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p5	@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p6	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p7	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p8	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p9	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p10	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p11	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p12	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p13	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p14	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p15	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p16	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p17	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p18	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p19	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	0
DDI-DrugBank.d289.s6.p20	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and @DRUG$ levels of 14% and 31%, respectively.	0
DDI-DrugBank.d29.s12.p0	Therefore, @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, @DRUG$, iron salts and digoxin).	4
DDI-DrugBank.d29.s12.p1	Therefore, @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, @DRUG$ salts and digoxin).	4
DDI-DrugBank.d29.s12.p2	Therefore, @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and @DRUG$).	4
DDI-DrugBank.d29.s12.p3	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, @DRUG$, @DRUG$ salts and digoxin).	4
DDI-DrugBank.d29.s12.p4	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, @DRUG$, iron salts and @DRUG$).	4
DDI-DrugBank.d29.s12.p5	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, @DRUG$ salts and @DRUG$).	4
DDI-DrugBank.d29.s14.p0	Concomitant administration of @DRUG$ with @DRUG$ is contraindicated.	0
DDI-DrugBank.d29.s3.p0	Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with @DRUG$, warfarin, quinidine, clarithromycin or amoxicillin.	0
DDI-DrugBank.d29.s3.p1	Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, @DRUG$, quinidine, clarithromycin or amoxicillin.	0
DDI-DrugBank.d29.s3.p2	Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, warfarin, @DRUG$, clarithromycin or amoxicillin.	0
DDI-DrugBank.d29.s3.p3	Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, warfarin, quinidine, @DRUG$ or amoxicillin.	0
DDI-DrugBank.d29.s3.p4	Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or @DRUG$.	0
DDI-DrugBank.d29.s3.p5	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, @DRUG$, quinidine, clarithromycin or amoxicillin.	0
DDI-DrugBank.d29.s3.p6	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, warfarin, @DRUG$, clarithromycin or amoxicillin.	0
DDI-DrugBank.d29.s3.p7	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, warfarin, quinidine, @DRUG$ or amoxicillin.	0
DDI-DrugBank.d29.s3.p8	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, warfarin, quinidine, clarithromycin or @DRUG$.	0
DDI-DrugBank.d29.s3.p9	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, @DRUG$, @DRUG$, clarithromycin or amoxicillin.	0
DDI-DrugBank.d29.s3.p10	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, @DRUG$, quinidine, @DRUG$ or amoxicillin.	0
DDI-DrugBank.d29.s3.p11	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, @DRUG$, quinidine, clarithromycin or @DRUG$.	0
DDI-DrugBank.d29.s3.p12	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, @DRUG$, @DRUG$ or amoxicillin.	0
DDI-DrugBank.d29.s3.p13	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, @DRUG$, clarithromycin or @DRUG$.	0
DDI-DrugBank.d29.s3.p14	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, @DRUG$ or @DRUG$.	0
DDI-DrugBank.d29.s6.p0	Patients treated with @DRUG$ and @DRUG$ concomitantly may need to be monitored for increases in INR and prothrombin time.	0
DDI-DrugBank.d29.s8.p0	Coadministration of @DRUG$ 30 mg and @DRUG$, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.	0
DDI-DrugBank.d29.s8.p1	Coadministration of @DRUG$ 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of @DRUG$.	0
DDI-DrugBank.d29.s8.p2	Coadministration of esomeprazole 30 mg and @DRUG$, a CYP2C19 substrate, resulted in a 45% decrease in clearance of @DRUG$.	0
DDI-DrugBank.d290.s1.p0	Standard therapy includes @DRUG$, such as @DRUG$ and gentamicin;	3
DDI-DrugBank.d290.s1.p1	Standard therapy includes @DRUG$, such as penicillin and @DRUG$;	0
DDI-DrugBank.d290.s1.p2	Standard therapy includes antibiotics, such as @DRUG$ and @DRUG$;	4
DDI-DrugBank.d290.s2.p0	@DRUG$, such as @DRUG$ and isoproterenol;	4
DDI-DrugBank.d290.s2.p1	@DRUG$, such as dopamine and @DRUG$;	1
DDI-DrugBank.d290.s2.p2	vasopressors, such as @DRUG$ and @DRUG$;	0
DDI-DrugBank.d290.s4.p0	and @DRUG$, such as @DRUG$.	4
DDI-DrugBank.d290.s5.p0	@DRUG$: The potential for pharmacokinetic drug-drug interactions between @DRUG$ and other agents has not been formally studied.	0
DDI-DrugBank.d291.s1.p0	For this reason, the dose of the @DRUG$ should be reduced by 30 - 50% at the start of treatment with @DRUG$ or Bezalip retard and then titrated according to the blood clotting parameters	3
DDI-DrugBank.d291.s1.p1	For this reason, the dose of the @DRUG$ should be reduced by 30 - 50% at the start of treatment with Bezalip or @DRUG$ retard and then titrated according to the blood clotting parameters	3
DDI-DrugBank.d291.s1.p2	For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with @DRUG$ or @DRUG$ retard and then titrated according to the blood clotting parameters	3
DDI-DrugBank.d291.s11.p0	- @DRUG$ or @DRUG$ (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.	3
DDI-DrugBank.d291.s11.p1	- @DRUG$ or MAO-inhibitors (with hepatotoxic potential) must not be administered together with @DRUG$ or Bezalip retard.	4
DDI-DrugBank.d291.s11.p2	- @DRUG$ or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or @DRUG$.	4
DDI-DrugBank.d291.s11.p3	- Perhexiline hydrogen maleate or @DRUG$ (with hepatotoxic potential) must not be administered together with @DRUG$ or Bezalip retard.	0
DDI-DrugBank.d291.s11.p4	- Perhexiline hydrogen maleate or @DRUG$ (with hepatotoxic potential) must not be administered together with Bezalip or @DRUG$.	0
DDI-DrugBank.d291.s11.p5	- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with @DRUG$ or @DRUG$.	0
DDI-DrugBank.d291.s3.p0	- The action of @DRUG$ and @DRUG$ may be enhanced by Bezalip or Bezalip retard.	3
DDI-DrugBank.d291.s3.p1	- The action of @DRUG$ and insulin may be enhanced by @DRUG$ or Bezalip retard.	3
DDI-DrugBank.d291.s3.p2	- The action of @DRUG$ and insulin may be enhanced by Bezalip or @DRUG$.	3
DDI-DrugBank.d291.s3.p3	- The action of sulphonylureas and @DRUG$ may be enhanced by @DRUG$ or Bezalip retard.	3
DDI-DrugBank.d291.s3.p4	- The action of sulphonylureas and @DRUG$ may be enhanced by Bezalip or @DRUG$.	3
DDI-DrugBank.d291.s3.p5	- The action of sulphonylureas and insulin may be enhanced by @DRUG$ or @DRUG$.	3
DDI-DrugBank.d291.s6.p0	- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving @DRUG$ therapy and concomitant @DRUG$.	0
DDI-DrugBank.d291.s9.p0	- When @DRUG$ or @DRUG$ is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	0
DDI-DrugBank.d291.s9.p1	- When @DRUG$ or Bezalip retard is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	4
DDI-DrugBank.d291.s9.p2	- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	0
DDI-DrugBank.d291.s9.p3	- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	0
DDI-DrugBank.d291.s9.p4	- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	0
DDI-DrugBank.d291.s9.p5	- When Bezalip or @DRUG$ is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	4
DDI-DrugBank.d291.s9.p6	- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	0
DDI-DrugBank.d291.s9.p7	- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	0
DDI-DrugBank.d291.s9.p8	- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	0
DDI-DrugBank.d291.s9.p9	- When Bezalip or Bezalip retard is used concurrently with @DRUG$ (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	3
DDI-DrugBank.d291.s9.p10	- When Bezalip or Bezalip retard is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	4
DDI-DrugBank.d291.s9.p11	- When Bezalip or Bezalip retard is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	4
DDI-DrugBank.d291.s9.p12	- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	0
DDI-DrugBank.d291.s9.p13	- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	0
DDI-DrugBank.d291.s9.p14	- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or @DRUG$ is impaired	0
DDI-DrugBank.d293.s0.p0	May interact with thyroid medication (e.g., @DRUG$), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p1	May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p2	May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p3	May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p4	May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p5	May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p6	May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	4
DDI-DrugBank.d293.s0.p7	May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	4
DDI-DrugBank.d293.s0.p8	May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p9	May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p10	May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p11	May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p12	May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p13	May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	4
DDI-DrugBank.d293.s0.p14	May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	4
DDI-DrugBank.d293.s0.p15	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p16	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p17	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p18	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p19	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	4
DDI-DrugBank.d293.s0.p20	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	4
DDI-DrugBank.d293.s0.p21	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p22	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p23	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p24	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	4
DDI-DrugBank.d293.s0.p25	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	4
DDI-DrugBank.d293.s0.p26	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p27	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p28	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	4
DDI-DrugBank.d293.s0.p29	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	4
DDI-DrugBank.d293.s0.p30	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and @DRUG$ (e.g., lansoprazole, omeprazole).	4
DDI-DrugBank.d293.s0.p31	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	4
DDI-DrugBank.d293.s0.p32	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	4
DDI-DrugBank.d293.s0.p33	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., @DRUG$, omeprazole).	4
DDI-DrugBank.d293.s0.p34	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, @DRUG$).	4
DDI-DrugBank.d293.s0.p35	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, @DRUG$).	4
DDI-DrugBank.d294.s0.p0	Drug/LaboratoryTest Interactions @DRUG$ may interfere with bioassay procedures for the determination of @DRUG$ levels.	4
DDI-DrugBank.d295.s0.p0	Since @DRUG$ is primarily eliminated by the kidneys, coadministration of @DRUG$ with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.	0
DDI-DrugBank.d295.s0.p1	Since @DRUG$ is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either @DRUG$ or the coadministered drug.	0
DDI-DrugBank.d295.s0.p2	Since entecavir is primarily eliminated by the kidneys, coadministration of @DRUG$ with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either @DRUG$ or the coadministered drug.	0
DDI-DrugBank.d296.s0.p0	@DRUG$ has additive effects with @DRUG$ and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p1	@DRUG$ has additive effects with alcohol and other @DRUG$ (hypnotics, sedatives, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p2	@DRUG$ has additive effects with alcohol and other CNS depressants (@DRUG$, sedatives, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p3	@DRUG$ has additive effects with alcohol and other CNS depressants (hypnotics, @DRUG$, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p4	@DRUG$ has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, @DRUG$, etc).	4
DDI-DrugBank.d296.s0.p5	Diphenhydramine hydrochloride has additive effects with @DRUG$ and other @DRUG$ (hypnotics, sedatives, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p6	Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants (@DRUG$, sedatives, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p7	Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants (hypnotics, @DRUG$, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p8	Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants (hypnotics, sedatives, @DRUG$, etc).	4
DDI-DrugBank.d296.s0.p9	Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ (@DRUG$, sedatives, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p10	Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ (hypnotics, @DRUG$, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p11	Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ (hypnotics, sedatives, @DRUG$, etc).	4
DDI-DrugBank.d296.s0.p12	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (@DRUG$, @DRUG$, tranquilizers, etc).	4
DDI-DrugBank.d296.s0.p13	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (@DRUG$, sedatives, @DRUG$, etc).	4
DDI-DrugBank.d296.s0.p14	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, @DRUG$, @DRUG$, etc).	4
DDI-DrugBank.d296.s1.p0	@DRUG$ prolong and intensify the anticholinergic (drying) effects of @DRUG$.	4
DDI-DrugBank.d297.s1.p0	Population pharmacokinetic analyses revealed that @DRUG$, @DRUG$, corticosteroids, and TNF blocking agents did not influence abatacept clearance.	1
DDI-DrugBank.d297.s1.p1	Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, @DRUG$, and TNF blocking agents did not influence abatacept clearance.	1
DDI-DrugBank.d297.s1.p2	Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, corticosteroids, and @DRUG$ did not influence abatacept clearance.	2
DDI-DrugBank.d297.s1.p3	Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, corticosteroids, and TNF blocking agents did not influence @DRUG$ clearance.	2
DDI-DrugBank.d297.s1.p4	Population pharmacokinetic analyses revealed that MTX, @DRUG$, @DRUG$, and TNF blocking agents did not influence abatacept clearance.	1
DDI-DrugBank.d297.s1.p5	Population pharmacokinetic analyses revealed that MTX, @DRUG$, corticosteroids, and @DRUG$ did not influence abatacept clearance.	2
DDI-DrugBank.d297.s1.p6	Population pharmacokinetic analyses revealed that MTX, @DRUG$, corticosteroids, and TNF blocking agents did not influence @DRUG$ clearance.	1
DDI-DrugBank.d297.s1.p7	Population pharmacokinetic analyses revealed that MTX, NSAIDs, @DRUG$, and @DRUG$ did not influence abatacept clearance.	2
DDI-DrugBank.d297.s1.p8	Population pharmacokinetic analyses revealed that MTX, NSAIDs, @DRUG$, and TNF blocking agents did not influence @DRUG$ clearance.	2
DDI-DrugBank.d297.s1.p9	Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and @DRUG$ did not influence @DRUG$ clearance.	2
DDI-DrugBank.d297.s2.p0	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p1	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	3
DDI-DrugBank.d297.s2.p2	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	3
DDI-DrugBank.d297.s2.p3	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p4	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p5	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p6	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p7	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p8	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p9	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	2
DDI-DrugBank.d297.s2.p10	The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p11	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	3
DDI-DrugBank.d297.s2.p12	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	3
DDI-DrugBank.d297.s2.p13	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p14	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p15	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p16	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p17	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p18	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p19	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	2
DDI-DrugBank.d297.s2.p20	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p21	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	3
DDI-DrugBank.d297.s2.p22	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p23	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p24	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p25	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	3
DDI-DrugBank.d297.s2.p26	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p27	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	3
DDI-DrugBank.d297.s2.p28	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	3
DDI-DrugBank.d297.s2.p29	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p30	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p31	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p32	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p33	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	3
DDI-DrugBank.d297.s2.p34	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p35	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	3
DDI-DrugBank.d297.s2.p36	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	3
DDI-DrugBank.d297.s2.p37	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p38	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p39	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p40	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p41	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p42	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p43	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	2
DDI-DrugBank.d297.s2.p44	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p45	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p46	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p47	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p48	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p49	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	2
DDI-DrugBank.d297.s2.p50	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p51	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p52	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p53	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p54	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	2
DDI-DrugBank.d297.s2.p55	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p56	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, @DRUG$, leflunomide, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p57	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p58	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	2
DDI-DrugBank.d297.s2.p59	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p60	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, @DRUG$, sulfasalazine, and anakinra.	2
DDI-DrugBank.d297.s2.p61	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, @DRUG$, and anakinra.	2
DDI-DrugBank.d297.s2.p62	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p63	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, @DRUG$, and anakinra.	2
DDI-DrugBank.d297.s2.p64	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and @DRUG$.	2
DDI-DrugBank.d297.s2.p65	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and @DRUG$.	2
DDI-DrugBank.d297.s3.p0	Concurrent administration of a @DRUG$ with @DRUG$ has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.	0
DDI-DrugBank.d297.s3.p1	Concurrent administration of a @DRUG$ with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the @DRUG$ alone.	0
DDI-DrugBank.d297.s3.p2	Concurrent administration of a TNF antagonist with @DRUG$ has been associated with an increased risk of serious infections and no significant additional efficacy over use of the @DRUG$ alone.	0
DDI-DrugBank.d297.s4.p0	Concurrent therapy with @DRUG$ and @DRUG$ is not recommended.	0
DDI-DrugBank.d298.s0.p0	@DRUG$ may interfere with the anti-glaucoma action of @DRUG$ or pilocarpine;	3
DDI-DrugBank.d298.s0.p1	@DRUG$ may interfere with the anti-glaucoma action of carbachol or @DRUG$;	3
DDI-DrugBank.d298.s0.p2	Cyclopentolate may interfere with the anti-glaucoma action of @DRUG$ or @DRUG$;	3
DDI-DrugBank.d299.s1.p0	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or @DRUG$ (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s1.p1	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like @DRUG$ or methysergide) and AXERT within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s1.p2	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and AXERT within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s1.p3	Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s1.p4	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like @DRUG$ or methysergide) and AXERT within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s1.p5	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or @DRUG$) and AXERT within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s1.p6	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s1.p7	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or @DRUG$) and AXERT within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s1.p8	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s1.p9	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and @DRUG$ within 24 hours of each other should be avoided.	4
DDI-DrugBank.d299.s10.p0	Coadministration of @DRUG$ and the potent CYP3A4 inhibitor @DRUG$ (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.	0
DDI-DrugBank.d299.s10.p1	Coadministration of @DRUG$ and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of @DRUG$.	0
DDI-DrugBank.d299.s10.p2	Coadministration of almotriptan and the potent CYP3A4 inhibitor @DRUG$ (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of @DRUG$.	0
DDI-DrugBank.d299.s11.p0	Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p1	Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p2	Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p3	Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p4	Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p5	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, @DRUG$, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p6	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p7	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p8	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p9	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p10	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p11	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p12	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p13	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	0
DDI-DrugBank.d299.s11.p14	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when @DRUG$ is used concomitantly with these medications.	0
DDI-DrugBank.d299.s2.p0	@DRUG$: Coadministration of @DRUG$ resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.	0
DDI-DrugBank.d299.s2.p1	@DRUG$: Coadministration of moclobemide resulted in a 27% decrease in @DRUG$ clearance and an increase in Cmax of approximately 6%.	0
DDI-DrugBank.d299.s2.p2	Monoamine Oxidase Inhibitors: Coadministration of @DRUG$ resulted in a 27% decrease in @DRUG$ clearance and an increase in Cmax of approximately 6%.	0
DDI-DrugBank.d299.s4.p0	Other @DRUG$ Concomitant use of other @DRUG$ within 24 hours of treatment with AXERT is contraindicated.	0
DDI-DrugBank.d299.s4.p1	Other @DRUG$ Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with @DRUG$ is contraindicated.	0
DDI-DrugBank.d299.s4.p2	Other 5-HT1B/1D Agonists Concomitant use of other @DRUG$ within 24 hours of treatment with @DRUG$ is contraindicated.	0
DDI-DrugBank.d299.s6.p0	@DRUG$ (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p1	@DRUG$ (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p2	@DRUG$ (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p3	@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p4	@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p5	@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p6	@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	4
DDI-DrugBank.d299.s6.p7	Selective Serotonin Reuptake Inhibitors (@DRUG$): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p8	Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p9	Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p10	Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p11	Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p12	Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	4
DDI-DrugBank.d299.s6.p13	Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p14	Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p15	Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p16	Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p17	Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	4
DDI-DrugBank.d299.s6.p18	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p19	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p20	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p21	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	4
DDI-DrugBank.d299.s6.p22	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p23	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p24	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	4
DDI-DrugBank.d299.s6.p25	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	4
DDI-DrugBank.d299.s6.p26	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	4
DDI-DrugBank.d299.s6.p27	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	4
DDI-DrugBank.d299.s8.p0	@DRUG$: Coadministration of @DRUG$ and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.	0
DDI-DrugBank.d299.s8.p1	@DRUG$: Coadministration of almotriptan and @DRUG$ resulted in a 24% increase in plasma concentrations of almotriptan.	0
DDI-DrugBank.d299.s8.p2	@DRUG$: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of @DRUG$.	0
DDI-DrugBank.d299.s8.p3	Verapamil: Coadministration of @DRUG$ and @DRUG$ resulted in a 24% increase in plasma concentrations of almotriptan.	0
DDI-DrugBank.d299.s8.p4	Verapamil: Coadministration of @DRUG$ and verapamil resulted in a 24% increase in plasma concentrations of @DRUG$.	0
DDI-DrugBank.d299.s8.p5	Verapamil: Coadministration of almotriptan and @DRUG$ resulted in a 24% increase in plasma concentrations of @DRUG$.	0
DDI-DrugBank.d3.s11.p0	@DRUG$: Inhibition of renal @DRUG$ clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.	0
DDI-DrugBank.d3.s11.p1	@DRUG$: Inhibition of renal lithium clearance, leading to an increase in plasma @DRUG$ concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.	0
DDI-DrugBank.d3.s11.p2	Lithium: Inhibition of renal @DRUG$ clearance, leading to an increase in plasma @DRUG$ concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.	0
DDI-DrugBank.d3.s12.p0	The effect of @DRUG$ on plasma @DRUG$ has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.	0
DDI-DrugBank.d3.s12.p1	The effect of @DRUG$ on plasma lithium has not been studied, but cases of increased @DRUG$ plasma levels during TORADOL therapy have been reported.	0
DDI-DrugBank.d3.s12.p2	The effect of @DRUG$ on plasma lithium has not been studied, but cases of increased lithium plasma levels during @DRUG$ therapy have been reported.	0
DDI-DrugBank.d3.s12.p3	The effect of TORADOL on plasma @DRUG$ has not been studied, but cases of increased @DRUG$ plasma levels during TORADOL therapy have been reported.	0
DDI-DrugBank.d3.s12.p4	The effect of TORADOL on plasma @DRUG$ has not been studied, but cases of increased lithium plasma levels during @DRUG$ therapy have been reported.	0
DDI-DrugBank.d3.s12.p5	The effect of TORADOL on plasma lithium has not been studied, but cases of increased @DRUG$ plasma levels during @DRUG$ therapy have been reported.	0
DDI-DrugBank.d3.s14.p0	The effect of @DRUG$ on @DRUG$ clearance has not been studied.	0
DDI-DrugBank.d3.s15.p0	@DRUG$: In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and @DRUG$ that resulted in apnea.	0
DDI-DrugBank.d3.s16.p0	The concurrent use of @DRUG$ with @DRUG$ has not been formally studied.	4
DDI-DrugBank.d3.s17.p0	@DRUG$: Concomitant use of @DRUG$ may increase the risk of renal impairment, particularly in volume-depleted patients.	0
DDI-DrugBank.d3.s19.p0	@DRUG$: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).	1
DDI-DrugBank.d3.s19.p1	@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, thiothixene, alprazolam).	0
DDI-DrugBank.d3.s19.p2	@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, thiothixene, alprazolam).	1
DDI-DrugBank.d3.s19.p3	@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, @DRUG$, alprazolam).	0
DDI-DrugBank.d3.s19.p4	@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, @DRUG$).	1
DDI-DrugBank.d3.s19.p5	Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking @DRUG$ (fluoxetine, thiothixene, alprazolam).	1
DDI-DrugBank.d3.s19.p6	Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (@DRUG$, thiothixene, alprazolam).	1
DDI-DrugBank.d3.s19.p7	Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (fluoxetine, @DRUG$, alprazolam).	1
DDI-DrugBank.d3.s19.p8	Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (fluoxetine, thiothixene, @DRUG$).	1
DDI-DrugBank.d3.s19.p9	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (@DRUG$, thiothixene, alprazolam).	1
DDI-DrugBank.d3.s19.p10	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, @DRUG$, alprazolam).	0
DDI-DrugBank.d3.s19.p11	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, thiothixene, @DRUG$).	1
DDI-DrugBank.d3.s19.p12	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, @DRUG$, alprazolam).	1
DDI-DrugBank.d3.s19.p13	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, thiothixene, @DRUG$).	1
DDI-DrugBank.d3.s19.p14	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, @DRUG$, @DRUG$).	1
DDI-DrugBank.d3.s2.p0	@DRUG$ does not alter @DRUG$ protein binding.	0
DDI-DrugBank.d3.s20.p0	@DRUG$: TORADOLIV/IM has been administered concurrently with @DRUG$ in several clinical trials of postoperative pain without evidence of adverse interactions.	0
DDI-DrugBank.d3.s3.p0	In vitro studies indicate that, at therapeutic concentrations of @DRUG$ (300 m g/mL), the binding of @DRUG$ was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.	0
DDI-DrugBank.d3.s3.p1	In vitro studies indicate that, at therapeutic concentrations of @DRUG$ (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound @DRUG$ plasma levels.	0
DDI-DrugBank.d3.s3.p2	In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of @DRUG$ was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound @DRUG$ plasma levels.	0
DDI-DrugBank.d3.s4.p0	Therapeutic concentrations of @DRUG$, @DRUG$, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p1	Therapeutic concentrations of @DRUG$, warfarin, @DRUG$, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p2	Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p3	Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p4	Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p5	Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p6	Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	0
DDI-DrugBank.d3.s4.p7	Therapeutic concentrations of digoxin, @DRUG$, @DRUG$, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p8	Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p9	Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p10	Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p11	Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p12	Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	0
DDI-DrugBank.d3.s4.p13	Therapeutic concentrations of digoxin, warfarin, @DRUG$, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p14	Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p15	Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p16	Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p17	Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	0
DDI-DrugBank.d3.s4.p18	Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p19	Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p20	Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p21	Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	0
DDI-DrugBank.d3.s4.p22	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p23	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p24	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	0
DDI-DrugBank.d3.s4.p25	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, @DRUG$, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	0
DDI-DrugBank.d3.s4.p26	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	0
DDI-DrugBank.d3.s4.p27	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter @DRUG$ protein binding.	0
DDI-DrugBank.d3.s5.p0	In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg @DRUG$, causing no significant changes in pharmacokinetics or pharmacodynamics of @DRUG$.	0
DDI-DrugBank.d3.s6.p0	In another study, TORADOLIV/IM was given with two doses of 5000 U of @DRUG$ to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for @DRUG$ alone and 5.1 minutes (3.5 to 8.5 min) for placebo.	0
DDI-DrugBank.d3.s7.p0	Although these results do not indicate a significant interaction between @DRUG$ and @DRUG$ or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s7.p1	Although these results do not indicate a significant interaction between @DRUG$ and warfarin or @DRUG$, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s7.p2	Although these results do not indicate a significant interaction between @DRUG$ and warfarin or heparin, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s7.p3	Although these results do not indicate a significant interaction between @DRUG$ and warfarin or heparin, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s7.p4	Although these results do not indicate a significant interaction between TORADOL and @DRUG$ or @DRUG$, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s7.p5	Although these results do not indicate a significant interaction between TORADOL and @DRUG$ or heparin, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s7.p6	Although these results do not indicate a significant interaction between TORADOL and @DRUG$ or heparin, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s7.p7	Although these results do not indicate a significant interaction between TORADOL and warfarin or @DRUG$, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s7.p8	Although these results do not indicate a significant interaction between TORADOL and warfarin or @DRUG$, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s7.p9	Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of @DRUG$ to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	0
DDI-DrugBank.d3.s8.p0	@DRUG$: @DRUG$ IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	0
DDI-DrugBank.d3.s8.p1	@DRUG$: TORADOL IV/IM reduced the @DRUG$ response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	0
DDI-DrugBank.d3.s8.p2	@DRUG$: TORADOL IV/IM reduced the diuretic response to @DRUG$ in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	0
DDI-DrugBank.d3.s8.p3	Furosemide: @DRUG$ IV/IM reduced the @DRUG$ response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	0
DDI-DrugBank.d3.s8.p4	Furosemide: @DRUG$ IV/IM reduced the diuretic response to @DRUG$ in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	0
DDI-DrugBank.d3.s8.p5	Furosemide: TORADOL IV/IM reduced the @DRUG$ response to @DRUG$ in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	0
DDI-DrugBank.d30.s0.p0	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, @DRUG$, warfarin, cimetidine and phenobarbital.	0
DDI-DrugBank.d30.s0.p1	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, digoxin, @DRUG$, cimetidine and phenobarbital.	0
DDI-DrugBank.d30.s0.p2	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, digoxin, warfarin, @DRUG$ and phenobarbital.	0
DDI-DrugBank.d30.s0.p3	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, digoxin, warfarin, cimetidine and @DRUG$.	0
DDI-DrugBank.d30.s0.p4	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, @DRUG$, cimetidine and phenobarbital.	0
DDI-DrugBank.d30.s0.p5	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, @DRUG$ and phenobarbital.	0
DDI-DrugBank.d30.s0.p6	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, cimetidine and @DRUG$.	0
DDI-DrugBank.d30.s0.p7	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, @DRUG$, @DRUG$ and phenobarbital.	0
DDI-DrugBank.d30.s0.p8	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, @DRUG$, cimetidine and @DRUG$.	0
DDI-DrugBank.d30.s0.p9	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, @DRUG$ and @DRUG$.	0
DDI-DrugBank.d30.s3.p0	@DRUG$ did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.	0
DDI-DrugBank.d30.s3.p1	@DRUG$ did not affect the conversion of losartan to the active metabolite after intravenous administration of @DRUG$, and erythromycin had no clinically significant effect after oral administration.	0
DDI-DrugBank.d30.s3.p2	@DRUG$ did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and @DRUG$ had no clinically significant effect after oral administration.	0
DDI-DrugBank.d30.s3.p3	Ketoconazole did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of @DRUG$, and erythromycin had no clinically significant effect after oral administration.	0
DDI-DrugBank.d30.s3.p4	Ketoconazole did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of losartan, and @DRUG$ had no clinically significant effect after oral administration.	0
DDI-DrugBank.d30.s3.p5	Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of @DRUG$, and @DRUG$ had no clinically significant effect after oral administration.	0
DDI-DrugBank.d30.s4.p0	@DRUG$, an inhibitor of P450 2C9, decreased active metabolite concentration and increased @DRUG$ concentration.	0
DDI-DrugBank.d301.s14.p0	Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating @DRUG$ and @DRUG$, respectively.	0
DDI-DrugBank.d303.s0.p0	@DRUG$: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s0.p1	@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s0.p2	@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s0.p3	@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s0.p4	Metformin: In healthy subjects given single 500 mg doses of @DRUG$ and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s0.p5	Metformin: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s0.p6	Metformin: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s0.p7	Metformin: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s0.p8	Metformin: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s0.p9	Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	0
DDI-DrugBank.d303.s1.p0	No information is available about the interaction of @DRUG$ and @DRUG$ following multiple doses of either drug.	0
DDI-DrugBank.d303.s2.p0	Although not observed in this study, adverse effects could potentially arise from co-administration of @DRUG$ and @DRUG$ by inhibition of tubular secretion via organic cationic transporter systems.	0
DDI-DrugBank.d303.s3.p0	Accordingly, careful patient monitoring and dose adjustment of @DRUG$ is recommended in patients concomitantly taking @DRUG$ and metformin.	0
DDI-DrugBank.d303.s3.p1	Accordingly, careful patient monitoring and dose adjustment of @DRUG$ is recommended in patients concomitantly taking cephalexin and @DRUG$.	0
DDI-DrugBank.d303.s3.p2	Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking @DRUG$ and @DRUG$.	0
DDI-DrugBank.d303.s4.p0	@DRUG$: As with other @DRUG$, the renal excretion of cephalexin is inhibited by probenecid.	0
DDI-DrugBank.d303.s4.p1	@DRUG$: As with other b-lactams, the renal excretion of @DRUG$ is inhibited by probenecid.	0
DDI-DrugBank.d303.s4.p2	@DRUG$: As with other b-lactams, the renal excretion of cephalexin is inhibited by @DRUG$.	0
DDI-DrugBank.d303.s4.p3	Probenecid: As with other @DRUG$, the renal excretion of @DRUG$ is inhibited by probenecid.	0
DDI-DrugBank.d303.s4.p4	Probenecid: As with other @DRUG$, the renal excretion of cephalexin is inhibited by @DRUG$.	0
DDI-DrugBank.d303.s4.p5	Probenecid: As with other b-lactams, the renal excretion of @DRUG$ is inhibited by @DRUG$.	0
DDI-DrugBank.d304.s0.p0	May interact with the following: @DRUG$, @DRUG$ (use with thiazide diuretics may prevent the diuretic from working properly;	4
DDI-DrugBank.d304.s0.p1	May interact with the following: @DRUG$, colestipol (use with @DRUG$ may prevent the diuretic from working properly;	4
DDI-DrugBank.d304.s0.p2	May interact with the following: @DRUG$, colestipol (use with thiazide diuretics may prevent the @DRUG$ from working properly;	4
DDI-DrugBank.d304.s0.p3	May interact with the following: cholestyramine, @DRUG$ (use with @DRUG$ may prevent the diuretic from working properly;	4
DDI-DrugBank.d304.s0.p4	May interact with the following: cholestyramine, @DRUG$ (use with thiazide diuretics may prevent the @DRUG$ from working properly;	4
DDI-DrugBank.d304.s0.p5	May interact with the following: cholestyramine, colestipol (use with @DRUG$ may prevent the @DRUG$ from working properly;	4
DDI-DrugBank.d305.s1.p0	However, neither @DRUG$ nor @DRUG$ appears to affect Dantrium metabolism.	0
DDI-DrugBank.d305.s1.p1	However, neither @DRUG$ nor diazepam appears to affect @DRUG$ metabolism.	0
DDI-DrugBank.d305.s1.p2	However, neither phenobarbital nor @DRUG$ appears to affect @DRUG$ metabolism.	0
DDI-DrugBank.d305.s2.p0	Binding to plasma protein is not significantly altered by @DRUG$, @DRUG$, or phenylbutazone.	0
DDI-DrugBank.d305.s2.p1	Binding to plasma protein is not significantly altered by @DRUG$, diphenylhydantoin, or @DRUG$.	0
DDI-DrugBank.d305.s2.p2	Binding to plasma protein is not significantly altered by diazepam, @DRUG$, or @DRUG$.	0
DDI-DrugBank.d305.s7.p0	Administration of @DRUG$ may potentiate @DRUG$-induced neuromuscular block.	3
DDI-DrugBank.d306.s0.p0	The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p1	The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p2	The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and barbiturates, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p3	The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p4	The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the @DRUG$ rifampin.	3
DDI-DrugBank.d306.s0.p5	The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug @DRUG$.	3
DDI-DrugBank.d306.s0.p6	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ @DRUG$, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p7	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, @DRUG$, and barbiturates, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p8	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p9	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and barbiturates, and the @DRUG$ rifampin.	3
DDI-DrugBank.d306.s0.p10	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug @DRUG$.	3
DDI-DrugBank.d306.s0.p11	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, @DRUG$, and barbiturates, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p12	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p13	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the @DRUG$ rifampin.	3
DDI-DrugBank.d306.s0.p14	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the antituberculosis drug @DRUG$.	3
DDI-DrugBank.d306.s0.p15	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and @DRUG$, and the antituberculosis drug rifampin.	3
DDI-DrugBank.d306.s0.p16	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and barbiturates, and the @DRUG$ rifampin.	3
DDI-DrugBank.d306.s0.p17	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and barbiturates, and the antituberculosis drug @DRUG$.	3
DDI-DrugBank.d306.s0.p18	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the @DRUG$ rifampin.	3
DDI-DrugBank.d306.s0.p19	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug @DRUG$.	3
DDI-DrugBank.d306.s0.p20	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the @DRUG$ @DRUG$.	3
DDI-DrugBank.d307.s1.p0	In addition, several @DRUG$ s that are cytochrome P450 inducers can decrease plasma concentrations of @DRUG$ and MHD.	0
DDI-DrugBank.d307.s1.p1	In addition, several @DRUG$ s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and @DRUG$.	0
DDI-DrugBank.d307.s1.p2	In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of @DRUG$ and @DRUG$.	0
DDI-DrugBank.d307.s11.p0	@DRUG$: Potential interactions between @DRUG$ and other AEDs were assessed in clinical studies.	0
DDI-DrugBank.d307.s11.p1	@DRUG$: Potential interactions between Trileptal and other @DRUG$ were assessed in clinical studies.	0
DDI-DrugBank.d307.s11.p2	Antiepileptic drugs: Potential interactions between @DRUG$ and other @DRUG$ were assessed in clinical studies.	0
DDI-DrugBank.d307.s16.p0	Influence of @DRUG$ on @DRUG$ Concentration (Mean change, 90% Confidence Interval)	2
DDI-DrugBank.d307.s17.p0	Influence of @DRUG$ On @DRUG$ Concentration (Mean change, 90% Confidence Interval)	2
